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ABSTRACT 
Broadly neutralizing antibodies are capable of neutralizing a large number of HIV-1 strains 
and have shown to be protective against infection in non-human primate models. These 
antibodies are likely to play an important role in an effective vaccine against HIV. Eliciting 
them by vaccination has thus far been unsuccessful and their unusual features such as long 
CDHR3 lengths and high levels of somatic hypermutation make this a particularly 
challenging task. Approximately 15-30% of chronically HIV-1 infected individuals 
develop these types of antibodies but an understanding of the underlying mechanisms is 
limited. The aim of this study, therefore, was to investigate host factors associated with the 
development of broadly neutralizing antibodies in HIV-1 subtype C infected individuals. 
In particular we analysed genetic variation of the genes encoding the variable region of 
antibodies, the evolution of an HIV-1 specific antibody lineage and glycan-binding profiles 
of serum antibodies.  
 The human heavy chain variable region genes (IGHV) are the largest and most 
variable of all human immunoglobulin genes and encode the major antigen-binding region. 
These genes are divided into seven subgroups, each subgroup contains numerous genes 
and alleles. Using genomic DNA from 28 HIV-1 subtype C infected individuals we 
performed next generation sequencing using both Illumina MiSeq and Roche 454 
technologies. Included were 13 individuals who developed broadly neutralizing antibodies, 
13 who did not despite chronic HIV-1 infection and two intermediate neutralizers. We 
found no genetic differences in the IGHV genes between these two groups. However, we 
 iv 
identified 85 novel alleles and 38 alleles that had previously only been observed in 
rearranged antibody sequences. Of these alleles, eight were used by functional antibodies, 
two of which were HIV-1 specific. This study highlights the importance of a fully 
comprehensive database for inferring germline gene usage and the unmutated common 
ancestors of antibody lineages. In addition it showed that everyone has the same genetic 
potential of developing broadly neutralizing antibodies, which has positive implications for 
vaccine development.  
 A number of studies have demonstrated the importance of strain-specific antibodies 
in the development of broadly neutralizing antibodies. In addition to being the forerunners 
of broadly neutralizing antibodies, strain-specific antibodies can help shape the viral 
populations that elicit different broadly neutralizing antibody lineages. We therefore 
studied the evolution of a strain-specific HIV antibody lineage (CAP88-CH06) in an 
individual who failed to develop neutralization breadth even after 5 years of infection, to 
understand why some strain-specific antibodies remain limited to autologous viruses. 
CAP88-CH06 was previously isolated as an IgA1 antibody using the IGHV4-39 gene with 
8.8% divergence from donor CAP88 at 34 weeks post-infection, which mapped to the C3-
V4 region of gp120. IgA and IgG antibodies using the same germline IGHV were 
sequenced on an Illumina MiSeq from 5 to 121 weeks post-infection. IgA sequences 
identical to that of the fully matured antibody with 8.8% divergence were detected from 
early infection and throughout until after 2 years, well after viral escape. This was 
consistent with plasma neutralization of the C3-V4 region within CAP88. However, very 
little evidence of evolution was seen within the IgA sequences. A group of related IgG 
sequences were also identified between 11 and 34 weeks but not at other time-points. 
Interestingly, within the 11 week transcripts we identified an identical sequence as both an 
IgA and IgG isotype, which likely gave rise to these transient IgG antibodies. The lack of 
 v 
neutralization breadth in this individual could therefore be the result of both limited 
evolution of the IgA isotype and well as the disappearance of the IgG isotype. 
 The HIV envelope is surrounded by glycans, known as the glycan shield. These 
glycans contribute towards the structural integrity of the envelope and serve as protection 
against immune responses to conserved regions. However, glycans often form targets for 
broadly neutralizing antibodies. Thus we studied the glycan-binding profiles of HIV-
negative and HIV-positive individuals (including 12 individuals who develop broadly 
neutralizing antibodies and 13 who did not despite chronic infection) to determine whether 
glycan-binding was specific to individuals who develop broadly neutralizing antibodies. 
Longitudinal samples were taken yearly for three years from all 47 individuals and their 
serum IgG levels were tested on glycan microarrays. We observed fluctuations in glycan-
binding over time within the HIV-negative individuals and these were used to establish 
baseline values. The HIV-positive individuals were found to have elevated levels of 
antibodies targeting high mannose N-linked glycans, Tn-peptides and glycolipids during 
infection. Binding to Tn-peptides and glycolipids were elevated throughout infection, 
whereas high mannose N-linked glycans were elevated from 2-3 years post-infection. We 
observed no differences in these glycans between the individuals who developed broadly 
neutralizing antibodies compared to those who did not despite chronic HIV infection. This 
data suggests that the elevated levels of glycan-binding serum antibodies were a 
consequence of infection rather than specific to broadly neutralizing antibodies. Since 
glycan-binding antibodies against Tn-peptides and glycolipids were detected earlier than 
high mannose N-linked glycans and antibodies targeting these glycans were elevated 
during infection, they might warrant further investigation with respect to immunogen 
design.  
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 Collectively this study has contributed to a greater understanding of the role of 
various host factors in the development of broadly neutralizing antibodies to HIV. This 
includes showing that there were no differences in the IGHV genes between individuals 
who did and did not develop broadly neutralizing antibodies as well as providing a wealth 
of new data on human antibody genes that will have benefits beyond the field of HIV. 
Furthermore our study has reinforced the essential role of somatic hypermutation in 
developing neutralization breadth and the need for further co-evolution studies on strain-
specific lineages to understand this roadblock. Finally our study using glycan arrays has 
highlighted that glycan-binding antibodies are induced in all HIV-infected individuals even 
though only a minority go on to develop broadly neutralizing antibodies. Overall these data 
suggest that all humans have the ability to develop broadly neutralizing antibodies but a 
vaccine capable of eliciting such protective responses remains a major hurdle.   
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1. INTRODUCTION 
1.1. HIV Pandemic and Interventions 
The HIV pandemic continues to be one of the worlds major public health problems, with 
approximately 35.3 million people (3.3 million of whom are children) at the end of 2012 
living with HIV (UNAIDS, 2013). The greatest burden of disease is in sub-Saharan Africa, 
accounting for 71% (25 million) of the global infections (Figure 1). Globally, there were 
approximately 2.3 million new infections (with ~6,300 infections occurring daily) and 1.6 
million AIDS-related deaths in 2012 (UNAIDS, 2013). Although these numbers are still 
extremely high, they represent a decrease of 33% in adult HIV prevalence rates and 52% in 
new infections in children since 2001. AIDS-related deaths have also decreased by 30% 
since 2005 (UNAIDS, 2013).  
 The decreases in number of infections and AIDS-related deaths can be attributed to 
the increased rollout of antiretroviral therapy (ART) and the use of ART in the prevention 
of mother-to-child transmission (PMTCT) (Barre-Sinoussi, et al., 2013). At the end of 
2013, ~12.9 million people living with HIV were receiving ART, of whom ~11.9 million 
are from low- to middle-income countries (WHO, 2014). While this represents the bulk of 
people on ART it accounts only for 36% (32.6 million) of the individuals living with HIV 
in these areas (WHO, 2014), highlighting that much still needs to be done. Other 
prevention interventions such as male circumcision, pre-exposure prophylaxis (PrEP) and 
condom use have also had some impact on the reduced infection rate. 
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Figure 1: Estimated prevalence of HIV in adults and children worldwide in 2012 
Shown are the numbers of adults and children estimated to be living with HIV worldwide, at the 
end of 2012. The figures in brackets represent the range of estimated values. Figure taken from 
(UNAIDS, 2013). 
 
 Although many of these preventative interventions are helping to reduce the 
transmission rate, the HIV epidemic continues to grow, particularly in sub-Saharan Africa 
among high-risk populations. In addition, although ART delays disease progression it is 
not able to completely eradicate the virus from an infected individual nor can it restore 
damage caused by the infection, such as immune exhaustion and gut damage (Barre-
Sinoussi, et al., 2013). Furthermore many individuals eligible for ART choose not to take 
the treatment or are non-compliant, due to the adverse effects associated with the ART, or 
socio-economic challenges (Enriquez, et al., 2011). Nonadherence to ART is associated 
with non-suppression of viral load, which can lead to drug resistance and treatment failure.  
 Since adherence is a large problem associated with ART use and since ART does 
not eliminate the virus from an infected individual or completely reverse the pathology 
associated with HIV infection, many studies are focused on finding a vaccine for HIV. A 
vaccine would ideally prevent further HIV infections, but is still lacking despite years of 
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research in this area (discussed in more detail in Section 1.8). However there is also active 
research in the area of a cure for HIV. The two main strategies in this field of research are 
1) eradication, in which the virus is completely eliminated from the body and therapy is no 
longer required; 2) functional cure in which the virus is still present but at very low levels 
and is controlled without requiring standard treatments (Fauci, et al., 2013). Latently 
infected resting CD4 T-cells, which contain the integrated viral genome, have been 
identified as part of the HIV reservoir and is one of the sources of the viral re-emergence 
when ART is discontinued (Chun, et al., 1999). It has also been shown that early initiation 
of ART may prevent the establishment of reservoirs enabling patients to discontinue 
treatment after viral load suppression without viral rebound (Fauci, et al., 2013). Early 
treatment initiation is often impossible, especially in resource limited settings, thus other 
strategies such as the activation and elimination of latently infected cells, immuno-toxic 
therapy of the HIV reservoir, gene therapy and stem-cell transplantation are being 
researched (Cohen, 2013).  
 
1.2. HIV Diversity, Composition and Life Cycle  
1.2.1. HIV Diversity 
There are two types of the Human Immunodeficiency Virus, HIV-1 and HIV-2. HIV-2 is 
less virulent than HIV-1, with typically lower viral loads and is largely restricted to West 
Africa (Sharp, et al., 2011). Since HIV-1 is responsible for the pandemic seen throughout 
the world, the majority of the research is focused on this virus.  
 HIV-1 originated as a primate lentivirus, Simian Immunodeficiency Virus (SIV), in 
Chimpanzees (SIVcpz) but crossed the species barrier to infect humans (Sharp, et al., 
2011). HIV-1 is divided into four distinct lineages known as M, N, O and P, each of which 
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resulted from four separate cross-species transmission events. Group M was the first to be 
discovered and accounts for the majority of the pandemic viruses. The remaining groups 
are less prevalent with group O accounting for less than 1% of infections, group N 
identified in 13 cases and group P found in two individuals; all three groups (N, O and P) 
originated in West Africa (Sharp, et al., 2011). 
 Group M is further subdivided into different subtypes/clades A, B, C, D, F, G, H, J, 
K and circulating recombinant forms (CRFs) and are usually restricted to certain parts of 
the world, shown in Figure 2 (Taylor, et al., 2008). The most prevalent subtypes 
worldwide are A, B and C, with subtype C accounting for almost half of the infections 
(Buonaguro, et al., 2007). Subtype A is found in central and eastern African countries 
(including Kenya, Uganda, Tanzania and Rwanda) and eastern European countries. 
Subtype B is found in northern America, western and central Europe and Australia while 
subtype C is found in southern Africa (including South Africa) and India. 
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Figure 2: Distribution of HIV-1 clades worldwide 
Shown are the different clades spread throughout the world, coloured according to clade. This 
figure was taken from (Medscape, 2009).  
 
1.2.2. HIV-1 Genetic Composition 
HIV-1 is a retrovirus with nine open reading frames in an RNA genome, which encode 15 
proteins, shown in Figure 3 (Frankel, et al., 1998). Three of the open reading frames (gag, 
env and pol) encode structural proteins, with gag comprising a Matrix (MA), Capsid (CA), 
Nucleocapsid (NC) and p6 proteins which make up the viral capsid (Frankel, et al., 1998). 
Env encodes the surface (SU) gp120 glycoprotein and transmembrane (TM) gp41 
glycoprotein of the viral spike, while pol encodes viral polymerases: Protease (PR), 
Reverse Transcriptase (RT), Ribonuclease (RNase) and Integrase (IN) necessary for viral 
replication (Frankel, et al., 1998). The remaining open reading frames encode accessory 
proteins, three (Vif, Vpr and Nef) of which are found in the viral particle. Vif is involved 
in viral infectivity, Vpr is essential for viral nucleoprotein transport into the host nucleus 
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and Nef is involved in host receptor degradation and cell apoptosis (Frankel, et al., 1998). 
The remaining proteins (Rev, Tat and Vpu) are not found in the viral particle but are 
essential for gene regulation and viral assembly (Frankel, et al., 1998).  
 
Figure 3: HIV-1 genome 
and viral particle structure 
Shown are the 15 proteins 
encoded in the HIV-1 RNA 
genome as well as the viral 
particle comprising structural 
proteins (viral envelope spikes 
SU and TM, MA, CA, and NC), 
enzymes (PR, RT and IN), 
accessory proteins (Vif, Vpr and 
Nef) and two single stranded RNA molecules. Figure taken from (Frankel, et al., 1998). 
 
1.2.3. HIV-1 Life Cycle 
 Like many viruses, HIV-1 uses host cells for viral replication, targeting immune 
cells expressing CD4 such as dendritic cells, macrophages and CD4+ T-cells. The envelope 
spikes on the virus, comprising trimeric gp120 and gp41 glycoproteins (shown in Figure 
3), are responsible for binding and initiating entry into CD4+ T-cells. Contact is first made 
between the CD4-receptor on T-cells and the CD4-binding site on gp120, (Figure 4). This 
interaction causes the virus to undergo conformational changes opening up a secondary 
binding site for a cell surface co-receptor, either CCR5 or CXCR4, following which the 
fusion peptide on gp41 is inserted into the host cell (Engelman, et al., 2012; Barre-
Sinoussi, et al., 2013). The viral capsid then opens up to release the viral RNA, enzymes 
and accessory proteins into the host cytoplasm. Once in the cytoplasm the single stranded 
viral RNA molecules released from the capsid are reverse transcribed into double-stranded 
DNA using the viral RT. The DNA viral genome is transported into the cell nucleus as a 
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pre-integrated complex (PIC) and inserted into the host genome with the aid of viral 
proteins Vpr and IN and the host cell protein lens epithelium-derived growth factor 
(LEDGF) (Frankel, et al., 1998; Engelman, et al., 2012; Barre-Sinoussi, et al., 2013).   
 Transcription of the integrated viral genome is facilitated by the viral Tat and host 
proteins: RNA polymerase II (RNA Pol II) and positive transcription elongation factor b 
(P-TEFb) (Engelman, et al., 2012). The transcribed mRNA molecules are transported out 
of the host cell nucleus into the cytoplasm, in some cases facilitated by the viral protein 
Nef and host protein CRM1. Polyproteins Gag and Pol along with accessory viral proteins 
Vif, Vpr and Nef are translated in the host cytoplasm and assembled along with the entire 
viral genome length RNA molecules.  
 
 
Figure 4: Life cycle of HIV-1 
Shown is a simplification of the life cycle of HIV-1 in CD4 T-cells. The green boxes represent 
anti-retroviral drug regimens that target specific aspects of the life cycle. The brown boxes 
represent host proteins targeting the different steps in the viral life cycle. Figure taken from (Barre-
Sinoussi, et al., 2013). 
 
 The Env protein is synthesised as a trimeric gp160 precursor polyprotein and 
glycans are added to its surface in the endoplasmic reticulum of the infected host cell 
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(Wyatt, et al., 1998). The gp160 trimeric protein is then transported to the Golgi apparatus 
where it is cleaved by the host enzyme furin to gp120 and gp41 (Bonomelli, et al., 2011). 
The glycans, surrounding the complex, undergo modifications, which result in inefficiently 
trimmed glycans. The trimeric gp120 and gp41 complexes are then transported to the host 
cell membrane in preparation for budding (Wyatt, et al., 1998). 
 The assembled viral proteins and RNA molecules bud out of the host cell surface 
embedded with HIV envelope glycoprotein trimers (gp120 and gp41). These are released 
with the aid of host proteins Endosomal Sorting Complex Required for Transport (ESCRT) 
I and II and Actin Intergrating Protein 1 (AIP1) (Engelman, et al., 2012). In the final step 
of the HIV-1 life cycle, PR is used to cleave the Gag and Pol polyproteins into the 
structural components of the viral capsid: MA, CA, NC and viral enzymes PR, RT and IN, 
respectively. 
 Numerous host responses (highlighted in brown boxes in Figure 4) and anti-
retroviral drug regimens (highlighted in green boxes in Figure 4) target various aspects of 
the HIV-1 life cycle that interfere with viral replication. Some individuals have a natural 
protection against HIV infection as a result of an inherited CCR5 deletion resulting a non-
functional CCR5 receptor on their CD4+ T-cells and thus the inability of CCR5 dependent 
viruses to attach to CD4+ T-cells and gain entry (Liu, et al., 1996; Samson, et al., 1996). 
Once the virus has gained entry into the host cell, TRIM5α, a host restriction factor, 
prevents the uncoating of the virus, while APOBEC3G and SAMHD1 prevent the reverse 
transcription of the viral RNA genome to DNA (Barre-Sinoussi, et al., 2013). These host 
enzymes, however, are counteracted by the viral proteins Vpu, Vif and Vpx (Barre-
Sinoussi, et al., 2013). Tetherin, a host type II transmembrane protein, prevents viral 
particles from budding out of the host cell, but can be thwarted by Vpu (Engelman, et al., 
2012; Barre-Sinoussi, et al., 2013). 
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 Similarly antiretroviral drug regimens such as entry inhibitors prevent the virus 
from entering the host cell and include both CCR5 inhibitors, which block the binding of 
the virus to the CCR5 co-receptor, and fusion inhibitors which prevent the fusion of the 
virus into the host cell (Arts, et al., 2012). Nucleoside/Nucleotide Reverse Transcriptase 
Inhibitors (NRTIs) and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) are 
classes of drugs that inhibit the transcription of the viral RNA genome to DNA, while 
Integrase inhibitors prevent the integration of the viral genome into the host genome (Arts, 
et al., 2012). The Protease inhibitor class of anti-viral drugs prevents PR from cleaving the 
Gag and Pol polyproteins into the viral capsid and enzyme proteins and thus the formation 
of a mature viral particle (Arts, et al., 2012). 
 
1.3. HIV-1 Envelope Structure 
Since HIV gains entry into the host cell via the envelope trimeric spike, which is also the 
main target of the antibody response (discussed in Sections 1.5 and 1.6), many studies have 
focused on elucidating the structure of the trimer. As previously mentioned the envelope of 
HIV is composed of trimeric gp120 and gp41 glycoproteins, which are initially synthesised 
as a gp160 precursor protein and cleaved by furin in the endoplasmic reticulum and further 
processed with the addition of glycans in the Golgi complex (Wyatt, et al., 1998; 
Bonomelli, et al., 2011).  
 The trimeric structure undergoes various conformational changes prior, during and 
after fusion of the virus into host cells. The pre-fusion state of the envelope that includes a 
detailed view of the gp41 subunit was recently elucidated using a BG505 SOSIP.664 
protein bound to PGT122 and 35O22 antibodies (Pancera, et al., 2014). In the pre-fusion 
state four helices (α6 to α9) from gp41 enclose the amino- and carboxy- termini of gp120 
forming a collar, which is clasped by the insertion of a methionine residue on the α6 and a 
 11 
triple-tryptophan motif on α8 and α9 (Pancera, et al., 2014). Upon binding of the trimeric 
structure to host cell receptors the clasp is released between gp41 and gp120 allowing the 
trimer to open up and gp41 to extend and penetrate the host cell membrane and promote 
cell fusion (Figure 5). 
 
 
Figure 5: HIV-1 envelope trimer structure before and after fusing with CD4+ T-cells 
Shown are the HIV-1 envelope trimer (grey), gp120 (red) and gp41 (rainbow colours) before and 
after fusing with CD4 T-cells. Figure taken from (Pancera, et al., 2014). 
 
 Prior to the elucidation of the gp41 subunit of the trimer, the pre-fusion state of 
gp120 was resolved using three different structures. Two of which used the 
BG505.SOSIP.664 trimer bound either by a CD4 binding site antibody (PGV04) or 
PGT122, which targets the N332 supersite (discussed in more detail in Section 1.6) (Julien, 
et al., 2013; Lyumkis, et al., 2013). The third used a KNH1144.SOSIP trimer bound by 
VRC03, also a CD4 binding site antibody (Bartesaghi, et al., 2013). All three structures 
show that the gp120 trimer is held together at the apex by the V1, V2 and V3 loops and 
that the core of gp120 and the interaction between gp41 and gp120 is stabilized by the α 
helices of gp41 (Figure 6). 
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Figure 6: Reconstruction of the Env trimer structure bound by PGV04 
Shown is a reconstruction of the crystal structure of the BG505.SOSIP trimer bound by PGV04 
CD4bs bNAb (shown in grey). A) and B) Show the side and top views of the trimer structure. C) 
Shows the side view of the trimer with and without the Fab density. The V1V2 region of gp120 is 
represented in purple, the V3 region represented in green, the gp120 core in blue and gp41 in gold. 
This figure is taken from (Lyumkis, et al., 2013). 
 
 Both gp120 and gp41 are heavy glycosylated with between 25-30 N-linked 
glycosylation sites and these glycans account for half of the molecular mass of the trimer, 
known as the glycan shield (Figure 7, (Wang, 2013; Pancera, et al., 2014)). The glycan 
shield on trimeric gp120 is mostly comprised of densely packed high mannose, particularly 
Manα1-2Man terminating glycans such as Man6-9GlcNAc2, and complex N-linked glycans 
although some O-linked glycans, such as Tn-peptides, do occur (Zhu, et al., 2000; Doores, 
et al., 2010b; Go, et al., 2013). Due to the high density of the glycans on the Env trimer 
they often lack the typical glycosylation processing and tend to be inefficiently trimmed. In 
addition to protecting immunogenic sites on the virus, these glycans are also essential for 
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glycoprotein folding and are thus often conserved (Bonomelli, et al., 2011; Pancera, et al., 
2014).  
 
Figure 7: Glycan shield on 
the HIV-1 envelope trimer 
Shown are the conserved (light 
green) and variable (dark green) 
glycans and sequence variability 
(pink) on the HIV-1 Env trimer in 
both the pre-fusion and CD4-
bound conformations. Figure 
taken from (Pancera, et al., 2014). 
 
 
 
 
1.4. HIV-1 Pathogenesis  
HIV is transmitted through bodily fluids such as blood, semen, pre-seminal fluid, vaginal 
fluids, rectal fluids, breast milk and sharing of contaminated needles (intravenous drug 
use). It targets cells expressing CD4 such as macrophages, dendritic cells and CD4+ T-
cells. Macrophages and dendritic cells are usually the first cells to be infected at the point 
of viral entry, followed by CD4+ T-cells, which carry the burden of infection (Parham, 
2009).  
 Disease progression is directly proportional to the level of virus and CD4+ T-cells 
in plasma. The onset of infection is associated with high viral loads in the peripheral blood 
(shown in red in Figure 8) and rapid decline of CD4+ T-cells (shown in blue in Figure 8) 
and is often but not always associated with flu-like symptoms (An, et al., 2010). This rapid 
increase in viral load and decrease in CD4+ T-cells is known as the acute phase and can 
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last approximately 6-12 weeks. During the acute phase the immune system responds by 
producing antibodies against the virus (described in more detail in Section 1.5) as well as a 
cytotoxic T-cell response, which results in a decrease in viral load and increase in CD4+ T-
cells.  
 Although these immune responses decrease the viral load in plasma they are unable 
to clear the virus and patients enter into a chronic phase of infection, which is associated 
with a steady state of viral replication (known as a set-point) and a gradual decline in CD4+ 
T-cells if ARVs are not introduced (An, et al., 2010). The reason why viral load is not 
completely suppressed is partly explained through the highly error prone rate of the viral 
reverse transcriptase (described in Section 1.2.3) which introduces nucleotide 
polymorphisms into the viral genome. Thus while infection is usually triggered by a single 
virus the accumulation of polymorphisms during infection gives rise to different viral 
strains or quasi-species within an infected individual (Parham, 2009).  
 During chronic HIV infection most patients are in a state of clinical latency in 
which no symptoms of the viral infection are apparent. Chronic phase can last years before 
the onset of AIDS, associated with a CD4+ T-cell count below 200 cells/mm3 (healthy 
individuals have CD4+ T-cell counts above 1000 cells/mm3) and an increased viral load 
(An, et al., 2010). Some individuals, termed long-term non-progressors never progress to 
AIDS and others do not become infected despite exposure to the virus in some cases 
because of a mutation in their CCR5 co-receptor (discussed in Section 1.2.3). Subtype C 
infection has been associated with rapid disease progression with CD4+ T-cells below 350 
cells/mm3 within 2 years of infection (Mlisana, et al., 2014). The majority of individuals 
without ARV treatment, however, will progress to AIDS. The current recommendation for 
the initiation of ARV treatment in South Africa is when an individuals' CD4+ T-cell count 
reaches below 500 cells/mm3. In addition, all HIV-positive pregnant women are initiated 
 15 
onto treatment regardless of CD4+ T-cell count because of the significant efficacy of 
reducing infections from mother to child (South African Department of Health: 
www.doh.gov.za).  
   
 
Figure 8: HIV viral load and CD4 count during infection 
Shown are the typical viral loads (red) and CD4+ T-cell count (blue) observed in an individual 
during primary infection, clinical latency and AIDS. Figure taken from (An, et al., 2010). 
 
 Due to the declining number of CD4+ T-cells the patient is unable to mount an 
effective immune response to HIV as well as to other potential pathogens that one 
encounters daily. Thus AIDS is associated with increased susceptibility to opportunistic 
infections including parasitic, bacterial, the most common of which is TB (Mycobacterium 
tuberculosis), fungal and other viral infections. In addition cancers associated with 
different viruses such as Kaposi's sarcoma, Non-Hodgkin's lymphoma and EBV-positive 
Burkitt's lymphoma are increased in AIDS patients (Parham, 2009). Typically an 
opportunistic infection overwhelms the patient leading to death. 
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 In addition to the loss of CD4+ T-cells during HIV infection a wide range of B-cell 
dysfunctions have also been reported. One of the defects associated with HIV infection is 
the presence of B-cell populations not normally observed in healthy individuals, such as 
immature transitional B-cells, activated mature B-cells, exhausted tissue-like memory B-
cells and short-lived plasmablasts (Figure 9, (Moir, et al., 2009). In contrast resting 
memory B-cells are decreased in HIV-infected individuals compared to HIV-negative 
individuals. The hyperactivation of B-cells due to chronic HIV leads to 
hypergammaglobulinaemia (over expression of IgG antibodies), increased polyclonal B-
cell activation, increased differentiation into plasmablasts, increased autoreactivity and B-
cell malignancies. The hyperactivated B-cells are not HIV-specific and tend to overwhelm 
the HIV-specific response. 
 
 
Figure 9: B-cell dysfunction and subpopulations associated with HIV-1 infection  
Shown are different B-cell populations that are affected by HIV infection. Figure taken from (Moir, 
et al., 2009). 
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1.5. Antibody Responses to HIV-1 
During HIV-1 infection antibodies targeting various regions of HIV can be detected. Only 
antibodies targeting the envelope (gp120 and gp41 glycoproteins) are able to bind and 
neutralize HIV and will be discussed here. Binding antibody responses are first detected 
from ~12 days post-infection which bind gp41, however these responses have no impact 
on viral load (Figure 10, (Tomaras, et al., 2008)). Autologous strain-specific neutralizing 
antibodies are detected from 4-14 weeks after infection and persist throughout infection 
and typically target gp120 (Gray, et al., 2007; Euler, et al., 2012; West, et al., 2014). 
Although neutralization by these antibodies is limited to a single virus they exert enough 
pressure on the virus to drive viral escape. In approximately 15-30% of HIV-1 infected 
individuals broadly neutralizing antibodies (bNAbs) develop, which are able to neutralize 
numerous subtypes of the virus and are detected from 2-3 years post-infection (Gray, et al., 
2011b; West, et al., 2014; Moore, et al., 2015).  
 
 
Figure 10: Anti-HIV-1 antibody response during infection 
Shown is the CD4+ T-cell count (blue), viral load (orange), non-neutralizing antibody responses 
(green), autologous neutralizing antibody responses (purple) and broadly neutralizing antibody 
responses (red) during HIV-1 infection. Figure adapted from (Euler, et al., 2012). 
 
 18 
 BNAbs are the main focus of vaccine development since such antibodies have been 
shown to be protective in non-human primates (Moldt, et al., 2012; Barouch, et al., 2013; 
Ko, et al., 2014; Saunders, et al., 2015). However, thus far envelope vaccines have been 
unable to elicit such antibodies (discussed in more detail in Section 1.8), partly because the 
mechanisms underlying their emergence remain unknown. BNAbs have unusual features 
in that they tend to have unusually long CDRH3 regions, high levels of somatic 
hypermutation and are frequently polyreactive (Table 1, (West, et al., 2014)).  
 
Table 1: Comparison of non-broadly- and broadly neutralizing antibody features 
 Non-bNAbs bNAbs 
Neutralization breadth 1 - 10% 40 - 90% 
Level of somatic hypermutation  1 - 12% 12 - 32% 
CDRH3 length ~16 amino acids 26 - 39 amino acids 
Detected during infection weeks - months ≥ 2 years 
Data taken from (West, et al., 2014; Zolla-Pazner, 2014). 
 
 To date over 100 bNAbs targeting 5 epitopes on the HIV-1 envelope have been 
isolated from a number of HIV-1 infected individuals. Typically these are IgG antibodies 
usually IgG1 although some have been isolated as IgG3 (CATNAP, 2014). In general most 
bNAbs neutralize >70% of viruses with 10E8, an MPER directed antibody, showing the 
highest breadth of 98% (Huang, et al., 2012). BNAbs show a wide range of potencies with 
IC80 values of 0.0001 to 100 µg/ml (Doria-Rose, et al., 2015). Despite their ability to 
potently neutralize numerous HIV strains and show protection against infection, these 
antibodies are not able to slow disease progression or reduce viraemia since viral escape 
against these targets readily occurs (Gray, et al., 2011b; Moore, et al., 2015). 
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1.6. Broadly-Neutralizing Antibody Targets 
There are five main bNAb epitopes on the HIV envelope (Figure 11). These five sites are 
defined as the V2 site, N332 supersite, CD4-binding site, gp120-gp41 interface and the 
membrane proximal external region (MPER) (Wibmer, et al., 2015). The V2 (highlighted 
in red in Figure 11) is at the apex of the trimer involving all three gp120 glycoproteins, 
which are protected by densely packed glycans (McLellan, et al., 2011; Bartesaghi, et al., 
2013; Julien, et al., 2013; Lyumkis, et al., 2013). Neutralization of this region usually 
involves antibodies with very long CDRH3s, which are able to get around the variable 
loops and/or penetrate the glycan shield (Walker, et al., 2009; McLellan, et al., 2011; 
Doria-Rose, et al., 2014). Due to the presence of many glycans at this site neutralization is 
often dependent on glycan-binding, such as PG9 and PG16, which bind glycans at the 
N160 region (Walker, et al., 2009; McLellan, et al., 2011). However neutralization at this 
site does occur without glycan-binding as seen in CAP256.VRC26 (Doria-Rose, et al., 
2014). 
 
Figure 11: Broadly neutralizing antibody 
targets on the HIV-1 envelope trimer  
Shown is the gp120 region of the HIV-1 Env 
trimer (cyan) with the variable loops labelled 
(V1-V5), gp41 region (grey) and the five main 
bNAb targets: V2 region (red), V3 and V4 
regions (orange and yellow), CD4-binding site 
(CD4bs) (green) and the gp41-gp120 interface 
(brown, purple and blue for 8ANC195, 35022 
and PGT151, respectively). The region where 
the MPER joins the trimer is shown. Figure 
taken from (Wibmer, et al., 2015).  
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 The N332 supersite involves many glycans covering the V2, V3 and V4 regions 
(red, orange and yellow in Figure 11). The key glycans involved in the N332 supersite are 
at positions: N137, N156, N295, N301, N332, N339, N386 and N392 (Kong, et al., 2013). 
Many of the bNAbs targeting this region also have long CDRH3s, such as PGT121 and 
PGT128 which target glycans at N301 and N332 (Walker, et al., 2011). 2G12, the first 
bNAb identified as having a glycan dependent specificity, binds glycans at N295, N332, 
N339 and N392 (Calarese, et al., 2003). Other examples of bNAbs that target the N332 
supersite are PGT130 and PGT135 (Walker, et al., 2011; Kong, et al., 2013; Doores, et al., 
2015). 
 The CD4-binding site (highlighted in green in Figure 11), which is the site at which 
the virus contacts CD4+ T-cells to gain entry into the cell, usually does not involve glycans 
(Wibmer, et al., 2015). bNAbs targeting this site tend to use the germline heavy chain 
variable genes IGHV1-2 and IGHV1-46, although some use IGHV1-3 and IGHV4-59 
(West, et al., 2012). Examples of bNAbs targeting the CD4-binding site are VRC01-03, 
NIH45-46, b12, 8ANC131 and CH103. 
 The gp120-gp41 interface (highlighted in purple, brown and blue in Figure 11) is a 
newly identified target. This site is found just below the CD4-binding site and involves 
numerous glycans at positions: N88, N230, N234, N241, N276, N611, N625 and N637 
(Scharf, et al., 2014). Three bNAbs associated with this epitope are 8ANC195 (epitope 
highlighted in purple in Figure 11), 35O22 (epitope highlighted in brown in Figure 11) and 
PGT151 (epitope highlighted in blue in Figure 11), (Falkowska, et al., 2014; Huang, et al., 
2014). 
 The MPER (highlighted in grey in Figure 11) is a α-helical linear region within 
gp41 that links the transmembrane domain to the ectodomain (Wibmer, et al., 2015). 
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Examples of bNAbs that bind the MPER are 2F5, Z13e1, 4E10 and 10E8 (Buchacher, et 
al., 1994; Zwick, et al., 2001; Binley, et al., 2004; Huang, et al., 2012).   
 
1.7. Glycan Targets and Microarrays 
Since many of the bNAbs targets involve glycans on the HIV envelope studies have 
focused on the types of glycans that are bound by these antibodies. As previously 
mentioned the HIV envelope is comprised of densely packed N-linked high mannose 
glycans such as Man6-9GlcNAc2, as well as complex N-linked glycans and O-linked 
glycans, such as Tn-peptides (Doores, et al., 2010b; Go, et al., 2013). Glycan-binding 
bNAbs 2G12, PGT125-131 and PGT135, which target the N332 supersite, bind high 
mannose N-linked glycans such as Man7-9 (Scanlan, et al., 2002; Walker, et al., 2011). 
PGT121-123, also targeting the N332 supersite, bind complex type glycans, such as α2-6 
sialyated (A2), monoantennary N-glycan (N2) and complex-type asialyl biantennary 
glycan (NA2) (Mouquet, et al., 2012). PG9 and PG16, which target the V2 site, bind both 
high mannose and complex sialylated N-linked glycans (Amin, et al., 2013; Shivatare, et 
al., 2013).  
 Glycan microarrays, which contain various glycans spotted onto glass slides, have 
been particularly useful in determining the types of glycans bound by bNAbs. The glycan 
specificities of PGTs 125-131 and PGT135 were determined using the mammalian printed 
glycan array version 5.0, created by the Consortium for Functional Glycomics (Walker, et 
al., 2011; CFG, 2014), while the glycan specificities of PGT121-123 and PG9 and PG16 
were determined using custom glycan arrays (Mouquet, et al., 2012; Shivatare, et al., 
2013). Glycan arrays have also been useful in determining glycan responses in serum of 
non-human primates after Ad5hr-SIV vaccination and SIV infection as well as potential 
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HIV vaccine responses in rabbits (Astronomo, et al., 2008; Dunlop, et al., 2010; Campbell, 
et al., 2013).  
 
1.8. Antibody Development 
1.8.1. Germline Immunoglobulin Genes 
Human antibodies are made up of two identical heavy and light chains which are encoded 
at three different immunoglobulin gene loci: one for the heavy chain and two for the 
different light chains (κ and λ) (Lefranc, et al., 2009). The heavy chain is encoded on 
chromosome 14 at 14q32.33, the κ light chain is encoded at 2p11.2 on chromosome 2 and 
the λ light chain is encoded at 22q11.2 on chromosome 22. Each human immunoglobulin 
gene locus contains a variable (V), joining (J) and constant (C) region, with the heavy 
chain having an additional diversity (D) region (Figure 12). 
 
Figure 12: Germline heavy and light chain immunoglobulin gene loci 
Shown are the three loci encoding the different human immunoglobulin gene segments that make 
up the heavy and light (λ and κ) chains. Figure taken from (Parham, 2009). 
 
 The human germline immunoglobulin gene loci are highly variable with each gene 
region (V, D, J and C) having multiple functional genes, open-reading frames (ORF) and 
pseudogenes with only functional genes being involved in antibody production. Most of 
these genes have multiple alleles, including functional and non-functional alleles, which 
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differ by either a single nucleotide polymorphism (SNP) or by multiple SNPs, which can 
be either synonymous or nonsynonymous, or frameshift mutations caused by indels that 
contribute diversity to the immunoglobulin gene repertoire (Table 2). Furthermore, whole 
IGHV genes have been reported as duplicated or deleted from the germline repertoire of 
some individuals resulting in varied gene copy numbers (Watson, et al., 2012; Watson, et 
al., 2013).  
 
Table 2: Germline immunoglobulin gene diversity 
Loci 
V D J C 
Sub-
groups Genes Alleles 
Sub-
groups Genes Alleles Genes Alleles Genes Alleles 
λ 11 33 70       7 7 5 12 
κ 7 42 70       5 9 1 5 
Heavy 7 48 239 7 23 30 6 13 5 49 
Numbers represent only human functional genes and alleles. Information obtained from (IMGT, 
2014). 
  The five different human heavy chain constant region genes (µ, δ, γ, α and ε, 
which encode IgM, IgD, IgG, IgA and IgE, respectively) are responsible for determining 
the isotype of the antibody (Lefranc, et al., 2009). The IgG and IgA isotypes are further 
divided into different subtypes IgG1-IgG4 and IgA1 and IgA2. All of the genes in both the 
heavy and light immunoglobulin gene loci are termed the germline immunoglobulin gene 
repertoire. The large number of genes and high level of variability in the germline 
repertoire is necessary to enable immune system to respond to a wide range of antigenic 
stimuli. Diversity is further achieved through somatic recombination of the variable, 
diversity, joining and constant regions of the heavy and light chains. 
 
1.8.2. Early B-cell Development and V(D)J Recombination 
B-cells are responsible for antibody development and secretion. During the embryonic 
stage B-cells arise in the fetal liver and in the bone marrow in adults (Tobon, et al., 2013). 
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B-cells start off as hematopoietic precursor cells that become progenitor B-cells (pro-B-
cells, Figure 13) involving somatic recombination of a single variable (V), diversity (D) 
and joining (J) regions of the heavy chain immunoglobulin genes found on chromosome 14 
(Pieper, et al., 2013; Tobon, et al., 2013).  
 The VDJ recombination of the heavy chain follows two steps, the first step 
involves the joining of a single D gene to a J gene which is then followed by the joining of 
the DJ segment to a single V gene (Janeway, et al., 2001). This process occurs at the 
recombination signal sequences (RSS) on either side of the different V, D and J segments 
and is mediated by the recombination activating gene proteins 1 and 2 (RAG1/2) (Van 
Gent, et al., 2001). The DNA of the intervening V, D and J segments are excised and the 
recombined ends joined with the aid of several proteins, KU70, KU80, DNA protein 
kinase (DNA-PKCS), DNA ligase IV and XRCC4. During the ligation phase of the 
recombination, terminal deoxynucleotidyl transferase adds nucleotides between the 
recombined segments, creating additional diversity in the VDJ exon (Market, et al., 2003). 
 Following the recombination of the heavy chain in the pro-B-cell, another round of 
somatic recombination occurs in the light chain using the same process as that of the heavy 
chain, resulting in a precursor B-cell (pre-B-cell, Figure 13 (Pieper, et al., 2013; Tobon, et 
al., 2013)). An immature B-cell expresses a membrane bound IgM antibody (Figure 13B, 
(Pieper, et al., 2013; Tobon, et al., 2013)). The V(D)J region of an antibody is collectively 
known as the variable region and is the region that binds antigens. This region is further 
subdivided into three complementarity determining regions (CDR, CDRH (for heavy 
chains) and CDRL (for light chains)), which are flanked by four framework regions (FR) 
(Parham, 2009). The complementarity determining regions are highly variable while the 
framework regions tend to be more conserved. The first two complementarity determining 
regions are encoded entirely by the variable region genes, while the CDR3 is created 
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through the recombination of the variable, diversity and joining regions and thus includes 
part of the variable region, and all of the diversity (heavy chain only) and part of the 
joining regions. The CDR3 on the heavy chain (CDRH3) is the largest and most variable, 
often showing high levels of SHM and a wide range in length. It is also often involved in 
antigen binding (Wu, et al., 1993). 
 Before leaving the bone marrow the immature B-cell goes through a checkpoint 
testing for autoreactivity (Gonzalez, et al., 2011). If the B-cell receptor (BCR, created 
through V(D)J recombination) binds a self-antigen the B-cell is either deleted through 
apoptosis, or the BCR is edited by the assembly of a different light chain to the heavy 
chain or silenced in a constant state of unresponsiveness, known as anergy (Cambier, et al., 
2007; Gonzalez, et al., 2011). If the B-cell does not bind a self-antigen it migrates out of 
the bone marrow into the spleen where it develops into a mature antigen naive B-cell 
expressing both IgM and IgD cell surface antigens (Tobon, et al., 2013). In the spleen 
mature B-cells undergo a second round of autoreactivity testing (Gonzalez, et al., 2011). 
 The rearrangement of the heavy and light chain V(D)J segments and the addition of 
nucleotides between the recombined segments creates a vast repertoire of B-cells 
(approximately 1013) each expressing a unique membrane bound BCR enabling the 
adaptive immune response to recognise a wide range of antigens (Pieper, et al., 2013). The 
affinity of the BCR to the antigen is further enhanced through somatic hypermutation 
(SHM), a process known as affinity maturation. In addition, different immune responses to 
a particular antigen are enabled through class-switch recombination (CSR or class-
switching) of the constant regions.  
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Figure 13: Early B-cell development and VDJ recombination  
A) Early B-cell development. Shown are the different stages of B-cell development within the bone 
marrow. Figure taken from (Parham, 2005). B) VDJ recombination. Shown are the steps involved 
in somatic recombination of the V, (D) and J segments in the heavy and light chain 
immunoglobulin genes during B-cell development. Figure taken from (Janeway, et al., 2001). 
 
1.8.3. Antibody Maturation 
Mature B-cells expressing cell surface IgM and IgD become activated following 
engagement with T helper follicular (TFH) cells (Pone, et al., 2010). In the case of HIV 
infection the loss of CD4 T helper has a profound effect on B cell activation which impacts 
on the quality of the antibody response (Binley, et al., 2000). The activated B-cell then 
differentiates into short lived plasmablasts secreting IgM and/or low levels of IgD or 
proliferate and undergo affinity maturation and CSR (Pone, et al., 2010). Affinity 
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maturation occurs in the dark zone of the germinal centre of lymph nodes through SHM, in 
this state the mature B-cells are known as centroblasts (Figure 14, (Klein, et al., 2008)). 
SHM is a process by which single nucleotide polymorphisms are introduced into the 
variable region of the antibody structure (the part created through V(D)J recombination in 
both heavy and light chains) mediated by activation-induced deaminase (AID) (Klein, et 
al., 2008). Further antibody diversity can be achieved through a process known as gene 
conversion. Gene conversion involves a non-reciprocal homologous recombination of an 
upstream variable gene to the recombined VDJ segment from one chromosome to another 
(Lavinder, et al., 2014). This process, like SHM, is also mediated by AID. 
 Following SHM the centroblasts enter the light zone of the germinal centre as a 
centrocyte and undergo a process of selection, which is mediated by TH-cells and follicular 
dendritic cells (Figure 14, (Klein, et al., 2008). BCRs with increased affinity for the 
antigen will be preferentially selected by TH-cells and receive a survival signal from 
follicular dendritic cells (Heesters, et al., 2014). However, should the introduction of single 
nucleotide polymorphisms during SHM decrease the affinity of the BCR for the antigen, 
the centrocyte will undergo apoptosis. The high affinity centrocytes are then selected by 
TH-cells, while centrocytes that are not selected by T-cells undergo apoptosis (Heesters, et 
al., 2014). Approximately 90% of the selected centrocytes return to the dark zone of the 
germinal centre and continue SHM and the rest differentiate into memory B-cells or 
plasma cells, some of which undergo CSR (Klein, et al., 2008; Wang, et al., 2015b). 
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Figure 14: Somatic 
hypermutation and 
class-switch 
recombination in the 
germinal centre of 
lymph nodes 
Shown are the processes of 
SHM and CSR in mature 
activated B-cells occurring 
in the germinal centres of 
lymph nodes. Figure taken 
from (Heesters, et al., 2014). 
 
 
 
 CSR involves the different heavy chain constant region genes (µ, δ, γ, ε and α, 
which encode isotypes IgM, IgD, IgG, IgE and IgA, respectively) encoded on chromosome 
14. The different isotypes, with the exception of Cδ (encoding IgD), are separated by a 
switch (S) region, consisting of tandemly repetitive unit sequences that contain many 
palindromes, and a intronic promoter (I) region (Figure 15, (Kinoshita, et al., 2001)). 
Cytokines released from TH-cells determines the isotype the centrocyte should switch to by 
activating the intronic promoter 5' of the S region of the isotype of choice (Kinoshita, et 
al., 2001; King, 2009). IL-4 and IL-13 have been associated with class-switching to IgG4 
and IgE, IL-10 with IgG1 and IgG3 while IL-10 in combination with TNF-β is associated 
with IgA (Tangye, et al., 2002). 
 Once activated the same enzyme (AID) used in somatic hypermutation joins the 
two S regions between the current isotype and the isotype of choice and splices out the 
DNA in between the two regions (Figure 15, (Kinoshita, et al., 2001)). This splicing event 
brings the coding region of the new isotype closer to the VDJ exon of the heavy chain and 
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leaves everything downstream of the new isotype intact (Kinoshita, et al., 2001). 
Transcription and translation of the VDJ exon and the constant region results in the B-cell 
producing an antibody of a new isotype.  
 
 
Figure 15: Process of class-switch recombination  
Shown are steps involved in CSR that occur in the germinal centre of lymph nodes. Figure taken 
from (http://uthscsa.edu/micro-immunology/faculty/pclab/casalilab.asp). 
 
1.8.4. Antibody Constant Region Effector Functions 
IgM antibodies are the first to be produced and are often a marker of the acute immune 
response (Schroeder, et al., 2010). They are initially produced as a cell surface antibody 
but following antigen stimulation are secreted as pentameric molecules held together by a 
J-chain, which facilitates secretion in mucosal surfaces. IgM antibodies usually have low 
affinity, due to their lack of maturation, but high avidity due to their pentameric structure. 
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These antibodies are involved in opsonisation, in which they coat an antigen thereby 
facilitating ingestion by macrophages and complement.  
 IgD antibodies are generally co-expressed with IgM on the cell surface of antigen 
naive mature B-cells, however low levels of circulating IgD molecules have been found in 
human serum (Schroeder, et al., 2010). Their function in the immune response is largely 
unknown. Both IgM and IgD antibodies have a very short half-life, 5-8 days and 2.8 days, 
respectively (Vladutiu, 2000; Brekke, et al., 2003). 
 IgG antibodies are the most commonly expressed isotype in human serum, the only 
isotype that crosses the placenta and has the longest half-life (~20 days) (Brekke, et al., 
2003). This class of antibodies is further subdivided into four subclasses: IgG1, IgG2, 
IgG3 and IgG4 and ranked according to their serum levels where IgG1 is the most 
abundant and IgG4 the least (Schroeder, et al., 2010). All four subclasses, with the 
exception of IgG4, are able to activate complement. IgG1 and IgG3 generally bind protein 
antigens, while IgG2 and IgG4 tend to bind polysaccharide antigens. IgG antibodies are 
also involved in agglutination, antibody-dependent cellular-cytotoxicity (ADCC) and are 
able to neutralize toxins and viruses, where IgG3 has been shown to be particularly 
effective at neutralizing HIV (Schroeder, et al., 2010). 
 IgA antibodies are the most abundant in mucosal surfaces and secretions such as 
breast milk and saliva where it is expressed as a dimer (Woof, et al., 2005). They are 
involved in protection against toxins, bacteria and viruses in mucosal surfaces through 
direct neutralization or preventing binding to mucosal surfaces. IgA is generally not 
involved in activating complement but may be involved in ADCC. IgA is also found at low 
levels in the serum, usually as a monomer. There are two subclasses of IgA: IgA1 and 
IgA2, which differ at their hinge regions, where IgA1 is longer than IgA2 making it more 
sensitive to bacterial protease digestion (Woof, et al., 2005). Thus, IgA1 predominates in 
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the serum, while IgA2 predominates in mucosal surfaces, such as the genital tract where 
bacterial infections are more frequent.  
 IgE is the least abundant antibody in human sera and has the shortest half-life (~2 
days) (Stone, et al., 2010). It is involved in hypersensitivity, allergic reactions and 
response to parasitic worms. IgE antibodies are highly potent due to their high affinity for 
the FcεRI on mast cells, basophils, Langerhans and eosinophil cells. 
 
1.9. Antibody Repertoire Analysis and Next Generation Sequencing 
 In depth analysis of the antibody repertoire has been made possible with advances 
in next generation sequencing (NGS) technology such as Illumina MiSeq and HiSeq, 
Roche 454, Ion Torrent and PacBio. The depth of sequencing allowed by NGS enables one 
to sequence a greater representative of the ~1013 antibody repertoire, far greater than was 
previously achieved through Sanger sequencing. Additional advances in the sequencing 
chemistry have enabled greater read lengths covering more of the antibody sequence. One 
of the challenges of NGS, however, is correcting the errors created during sequencing as 
well as through PCR used to create the libraries that are being sequenced. Numerous 
bioinformatic tools have been developed, such as Sickle, BayesHammer and PANDAseq, 
specifically for Illumina MiSeq error correction (Schirmer, et al., 2015). Other 
experimental techniques such as cell or sample barcoding and digital drop PCR have been 
used for error correction through consensus sequencing and to ensure the amplification of 
single molecules (Robinson, 2014). Techniques such as single-cell sorting and linkage-
PCR have enabled the sequencing of paired heavy and light chain sequences from single 
B-cells (DeKosky, et al., 2013). Sequencing fully functional heavy and light chains from 
single B-cells opens up opportunities for identifying potent antibody responses to diseases 
or infections that could be useful in vaccine development. 
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 In HIV, antibody repertoire analysis has been used to identify antibodies against the 
virus as well as studying the evolution of antibodies during infection (Zhu, 2012; Liao, et 
al., 2013; Zhu, et al., 2013b; Zhu, et al., 2013a; Doria-Rose, et al., 2014; Wu, et al., 2015). 
Two studies used NGS to elucidate the co-evolutionary pathway of the virus and bNAbs 
targeting the CD4bs and the V1V2 region of gp120 (Liao, et al., 2013; Doria-Rose, et al., 
2014), discussed in more detail below. Other studies have used NGS to pair heavy and 
light chain sequences of antibodies that are clonally related to bNAbs 10E8, PGT135-137 
and PGT121 (Zhu, 2012; Zhu, et al., 2013b; He, et al., 2014), thereby enabling faster 
identification of potentially more potent and broad antibodies against HIV that may be 
useful in vaccine design. 
 
1.10. Current Status of Vaccine Development 
The development of an effective vaccine remains a high priority in the fight against the 
HIV pandemic. Traditionally vaccine design relies on the ability of the host during a 
natural infection to mount an immune response against the pathogen, clear the pathogen 
and protect the host from future infections through B-cell memory. The antigens that elicit 
the response are then mimicked in an immunogen designed to elicit the same natural host 
response. However, in HIV natural immune responses do not clear the virus nor do they 
protect against future infections, making vaccine design particularly complex.  
 Early HIV vaccine strategies focused on the traditional approach of initiating a 
humoral response (Wang, et al., 2015a). Although antibodies were induced they were not 
broadly neutralizing and failed to protect against HIV infection. Based on these failures the 
strategy of vaccine design changed from humoral to cellular responses, with some support 
given by non-human primate models in which T-cell responses were associated with 
prolonged survival and decreased viral set-point (Hirsch, et al., 1994; Shiver, et al., 2002). 
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The STEP trial (or HVTN 502 trial), focused on T-cell immunity, however, this vaccine 
failed to protect against HIV infection or decrease viral loads and was stopped prematurely 
due to an apparent increase in susceptibility to infection in the vaccinated arm compared to 
the placebo arm (Casimiro, et al., 2005).  
 The only human trial (RV144) that has shown some efficacy (~31.2%) was 
designed to elicit both T-cell and B-cell responses (Rerks-Ngarm, et al., 2009). This trial 
was conducted in Thailand with a prime-boost strategy using a vCP1521 canarypox vector 
and a AIDSVAX B/E gp120 subunit. The correlates of protection in this trial were 
antibodies against the V1V2 region of gp120, re-igniting the importance of the humoral 
response (Haynes, et al., 2012a). 
 A major HIV vaccine strategy is focused on the B-cell lineage immunogen design 
(Haynes, et al., 2012b). This strategy relies on the identification/isolation of antibodies 
with a high affinity and ability to neutralize numerous strains of the virus (Haynes, et al., 
2012b). Using the knowledge of the antibody heavy and light chains the co-evolution of 
the antibody lineage and virus during natural infection is studied through deep sequencing. 
The aim of this approach is to identify the unmutated common ancestor that was activated 
and gave rise to the antibody lineage as well as the viral strain that activated the lineage. 
Two longitudinal studies have observed the co-evolution of broadly neutralizing antibodies 
targeting the CD4bs and V1V2 regions of the HIV envelope (Liao, et al., 2013; Doria-
Rose, et al., 2014). The study involving CD4bs antibody CH103, revealed that modest 
levels of SHM (13-15%) accumulated over years of infection was required for broadly 
neutralizing activity and that it had an average CDRH3 length (Liao, et al., 2013). 
However, this lineage only achieved ~50% breadth. Often CD4bs bNAbs have high levels 
of SHM, such as VRC01 (30-34%) (Wu, et al., 2015). Conversely CAP256.VRC26, which 
targets the V1V2 region, required extremely long CDRH3 lengths (35aa) and had average 
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SHM (8-15%) (Doria-Rose, et al., 2014). The UCA antibody sequence from the CD4bs 
bNAb lineage was able to bind but not neutralize the transmitted founder virus of the 
respective donors, whereas the UCA of the CAP256.VRC26 lineage could both bind and 
neutralize the transmitted founder virus (Liao, et al., 2013; Doria-Rose, et al., 2014; Wu, et 
al., 2015). These studies have suggested that immunization with a similar set of viral 
envelopes that resulted in breadth could be a useful vaccine strategy. 
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2. STUDY OBJECTIVES 
Broadly neutralizing antibodies against HIV-1 are able to neutralize various strains of the 
virus and are likely to be a correlate of protection in an HIV vaccine. However, only ~20% 
of individuals infected with HIV-1 develop these types of antibodies and only after years 
of infection. The mechanisms by which these antibodies develop remain poorly 
understood. The aim of this project was to study host aspects associated with the 
development broadly neutralizing antibodies, specifically:  
 
To investigate the germline IGHV gene profiles in individuals who do and do not 
develop broadly neutralizing antibodies during HIV-1 infection 
The germline IGHV gene encodes the heavy chain variable region of rearranged 
antibodies, which is central to antigen binding. Studies on broadly neutralizing antibodies 
have shown biases in germline IGHV gene usage. Our hypothesis was that individuals who 
develop broadly neutralizing antibodies have distinct germline IGHV repertoires. Using 
Roche 454 and Illumina MiSeq next generation sequencing technologies, the germline 
IGHV repertoires of 28 South African women, including 13 who developed broadly 
neutralizing antibodies and 13 who did not despite chronic HIV infection were analysed. 
This project is described in Section B, Chapter 1.  
 
To assess strain-specific antibody evolution during HIV-1 infection 
Broadly neutralizing antibodies develop from strain-specific antibodies that arise within 
the first few months of infection and acquire neutralization breadth through somatic 
hypermutation. Our aim was to study the evolution of a strain-specific antibody (CAP88-
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CH06) lineage in a donor (CAP88) who failed to develop neutralization breadth to 
determine why some strain-specific antibodies do not become broad. Using Illumina 
MiSeq technology the heavy chain antibody repertoire of CAP88 was sequenced at seven 
time points (5, 8, 11, 15, 34, 38 and 121 weeks post-infection (w.p.i)) and used to trace the 
CAP88-CH06 lineage. We hypothesized that this lineage failed to become broadly 
neutralizing due to limited somatic hypermutation and evolution. This project is described 
in Section B, Chapter 2. 
 
To determine the glycan-binding profiles of HIV antibodies 
The envelope of HIV-1 is covered with glycans that protect vulnerable sites from the host 
antibody response. However, these glycans are often the target of broadly neutralizing 
antibodies. Our aim was to determine if increases in glycan-binding antibodies are a 
response to HIV infection or unique to individuals who develop broadly neutralizing 
antibodies. Glycan microarrays were used to determine the longitudinal glycan-binding 
profiles of serum IgG antibodies from 47 women, 27 of whom were HIV-positive and 20 
HIV-negative. The HIV-negative samples were used as controls to determine natural 
fluctuations in glycan-binding over-time. Of the 27 HIV-positive women, 12 developed 
bNAbs and 13 did not develop broadly neutralizing antibodies despite chronic HIV 
infection. We hypothesized that women with broadly neutralizing antibodies would have 
higher levels of glycan-binding antibodies than women who did not. This project is 
described in Section B, Chapter 3.  
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3. METHODS SUMMARY 
3.1. Samples 
Serum and peripheral blood mononuclear cells (PBMCs) were obtained from the Centre 
for the AIDS Programme of Research in South Africa (CAPRISA) 002 and 004 cohorts 
(Van Loggerenberg, et al., 2008; Abdool Karim, et al., 2010).  These cohorts included 
adult women (>18 years of age) of African ancestry with a high risk of HIV infection who 
have been followed throughout infection, and in some cases prior to infection, in urban and 
rural sites in KwaZulu-Natal, South Africa. All of the women used in this study were 
infected with HIV-1 subtype C.  
 We focused on women who developed bNAbs (referred to as BCN individuals) and 
a control group of women who do not (referred to as non-BCN individuals). A panel of 18 
viruses were used to test for neutralization breadth within these women. The panel 
consisted of 6 subtype A, 6 subtype B and 6 subtype C viruses. BCN individuals were 
defined as those whose serum was capable of neutralizing 30%-100% of the panel from 2 
years post-infection, while non-BCN individuals were only able to neutralized 0%-11%.  
Since high viral loads at 6 months post-infection have been associated with the 
development of neutralization breadth (Gray, et al., 2011b), BCN and non-BCN 
individuals were matched according to viral loads. Longitudinal serum samples from pre-
infection and yearly for three years from 47 CAPRISA women, involving 20 HIV-negative 
women and 27 HIV-positive women were used in Chapter 3 (Section B).  
 PBMCs were used to extract total nucleic acids (RNA and DNA) from 28 
CAPRISA participants used in Chapter 1 (Section B) and from CAP88 used in Chapter 2 
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(Section B). A single time point was used for each participant in Chapter 1 (Section B). 
While longitudinal PBMC samples were taken from 5, 8, 11, 17, 34, 38 and 121 weeks 
post-infection from CAP88, used in Chapter 2 (Section B).  
 Several monoclonal antibodies (mAbs) have been isolated from CAPRISA 
participants at the Centre for HIV and STI, HIV Virology Section at the National Institute 
of Communicable Diseases (NICD). Sequences from these mAbs as well as sequences 
from bNAbs, obtained from CATNAP (CATNAP, 2014), were used in Chapter 1 (Section 
B). The bNAbs used in Chapter 3 (Section B) were obtained through the AIDS Reagent 
Program (NIH AIDS Reagent, 2013) and IAVI's Neutralizing Antibody Center (IAVI, 
2013).  
 
3.2. Nucleic Acid extraction and cDNA Synthesis 
Genomic DNA was extracted from PBMCs in Chapter 1 (Section B) using a Promega 
Wizard Genomic purification kit, while total nucleic acids (RNA and DNA) were extracted 
from PBMCs using a Qiagen AllPrep DNA/RNA mini kit for Chapter 2 (Section B). The 
quality and quantity of the resulting RNA and DNA extractions were checked on a Nano 
spectrophotometer (Section B, Chapters 1 and 2). RNA was converted to cDNA using 
Random Hexamers, Invitrogen First Strand Buffer, DTT, RNAseOUT and Superscript III 
RT Enzyme (described in Section B, Chapter 2). 
 
3.3. Primer Design 
Novel primers were designed to amplify all seven germline IGHV subgroups in Chapter 1 
(Section B), based on the sequences of all known IMGT (IMGT, 2014) listed IGHV genes. 
In addition to the gene-specific sequence the primers were adapted for both 454 and MiSeq 
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sequencing. The 454 primers included forward and reverse adapters, tag sequences and 
four unique MID sequences as recommended by Roche for pooling four samples per run. 
The MiSeq primers included index binding tags and read sequences for paired-end reads, 
described in more detail in Section B, Chapter 1. 
 One IGHV4 forward primer and two reverse primers (IgG and IgA) were designed 
to amplify the CAP88-CH06 antibody lineage from CAP88. These primers were also 
adapted for MiSeq sequencing with the addition of index binding tags and read sequences 
for paired-end sequencing. This is described in more detail in Section B, Chapter 2. 
 
3.4. Library Construction for Next Generation Sequencing 
All 7 IGHV subgroups were PCR amplified 3x from gDNA for each of the 28 CAPRISA 
individuals used in Chapter 1 (Section B). All replicates from each subgroup were pooled 
to create a full germline IGHV repertoire per individual. For 454 sequencing, four 
individuals were pooled per sequencing run using MID tags encoded into the primer 
sequences to distinguish each individual from the sequencing data. For MiSeq sequencing 
13 individuals along with some replicates from the 454 sequencing were pooled and 
individuals distinguished using the Nextera indexing kit to add indexes to the PCR 
products prior to pooling and sequencing. This is described in more detail in Section B, 
Chapter 1. 
 The CAP88-CH06 antibody lineage was PCR amplified 10x from cDNA from each 
of the 7 time points (5, 8, 11, 17, 34, 38 and 121 w.p.i) from CAP88. Each replicate was 
pooled per time point and a Nextera indexing kit used to add indexes to the PCR products 
from each time point. All time points were pooled for sequencing on the Illumina MiSeq. 
This is described in more detail in Section B, Chapter 2. 
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3.5. Next Generation Sequencing 
Next generation sequencing (NGS) was used in Chapters 1 and 2 (Section B). In Chapter 1, 
both Roche 454 and Illumina MiSeq technologies were used to elucidate the germline 
IGHV repertoires in 28 South African women (described in more detail in Section B, 
Chapter 1). In Chapter 2, Illumina MiSeq was used to sequence the CAP88-CH06 antibody 
lineage during infection (described in more detail in Section B, Chapter 2). Both studies 
used a custom amplicon approach.  
 
3.6. Sequence Data Analysis 
Sequence data analysis in Chapter 1 (Section B) was done in collaboration with Dr Ram 
Shrestha, Imogen Wright and Professor Simon Travers from the South African National 
Bioinformatics Institute (SANBI) at the University of the Western Cape and Dr Katherine 
Jackson from Stanford University in California, USA. Sequences obtained from the Roche 
454 and Illumina MiSeq were separated based on the quality of the base calls and sequence 
length. High quality sequences were compared to a database of known germline IGHV 
alleles, obtained from the global Immunogenetics Database, IMGT (IMGT, 2014). 
Sequences were classified as IMGT alleles if they had perfect matches to IMGT listed 
germline IGHV alleles; non-IMGT alleles if they had mismatches to IMGT listed germline 
IGHV alleles (due to SNPs or indels) but matched non-IMGT immunogenetics databases 
or immunogenetics publications; and novel if they had no matches to either IMGT or non-
IMGT alleles and were observed in multiple individuals or across both 454 and MiSeq in 
one individual. The repertoires between BCN and non-BCN individuals were compared. 
The sequences from mAbs isolated in house and well characterised bNAbs, obtained from 
CATNAP (CATNAP, 2014) were used to identify germline gene usage in functional 
antibodies (described in more detail in Section B, Chapter 1). 
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 Sequence data analysis in Chapter 2 (Section B) was done in collaboration with Dr 
Zizhang Sheng, Dr Chaim Schramm and Professor Lawrence Shapiro at Columbia 
University in New York, USA. Sequences were separated according to the quality of the 
base calls and sequence length and adjusted for sequencing and PCR error. Using an 
antibodyomics pipeline, developed at Professor Shapiro's lab, high quality sequences were 
assigned V and J genes and compared to the sequence of the known strain-specific 
antibody (CAP88-CH06). Sequences with the same IGHV gene (IGHV4-39), IGHJ gene 
(IGHJ4) and ≥ 80% identity to the CDRH3 CAP88-CH06 were selected as clonally 
related. These clonally related sequences were then used to construct phylogenetic trees of 
the CAP88-CH06 lineage (described in more detail in Section B, Chapter 2). 
 
3.7. Glycan Microarrays 
Glycan microarrays were used in Chapter 3 (Section B). The printing and running of the 
glycan microarrays were done in collaboration with Sudipa Chowdhury, Shea Wright and 
Dr Jeff Gildersleeve at the National Cancer Institute (NCI) in Frederick, Maryland, USA. 
Microarrays containing 337 components were spotted in duplicate onto glass slides using a 
MicroGrid II array printer. Each glass slide contained 16 arrays to allow pooling of 
samples per slide. Each slide was incubated with serum and DyLightTM459 labelled anti-
human IgG and scanned on a Genepix microarray scanner (described in more detail in 
Section B, Chapter 3). 
 
3.8. Glycan Microarray Data Analysis 
Fluorescence intensities for each glycan array used in Chapter 3 (Section B) were 
calculated using the Genepix Pro 6.0 software. Average intensities were calculated for 
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duplicate spots and data was normalized to reference sera values. Fluorescence intensities 
were log transformed (log2) and used to determine the level of IgG binding for each glycan 
per sample. bNAbs were used to determine the array's ability to detect HIV-binding. 
Longitudinal HIV-negative sera were used as controls to determine natural levels in 
glycan-binding fluctuations over a three-year time frame. Longitudinal sera from HIV-
positive individuals (including pre-infection samples) were used to establish baseline 
values. Comparisons between HIV-positive individuals who develop neutralization breadth 
(BCN) and HIV-positive individuals who do not develop neutralization breadth (non-
BCN) despite equivalent antigenic load were used to determine if increases in glycan-
binding antibodies were a response to HIV infection or unique to BCN individuals. A 
gp120 competition assay, in which sera was incubated with gp120 or PBS prior to glycan 
array binding, was used to determine if glycan-binding detected on the arrays were HIV-
specific (described in more detail in Section B, Chapter 3). 
 
3.9. Statistical Analysis 
Two-tailed Fisher’s exact tests with 95% confidence intervals were used to test the 
difference in germline IGHV gene repertoires between the BCN and non-BCN sample 
groups (Section B, Chapter 1), compare the glycan-binding profiles of gp120 and PBS 
incubated sera and the glycan-binding profiles of BCN and non-BCN individuals (Section 
B Chapter 3). Fold-change differences were used to assess fluctuations in glycan-binding 
over time in the HIV-negative and positive sera (Section B, Chapter 3). Statistical analysis 
was not used in Chapter 2 (Section B).  
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1.1. ABSTRACT 
The human immunoglobulin repertoire is vast, producing billions of unique antibodies 
from a limited number of germline immunoglobulin genes. The immunoglobulin heavy 
chain variable region (IGHV) is central to antigen binding and is comprised of 48 
functional genes. Here we analysed whether HIV-1 infected individuals who develop 
broadly neutralizing antibodies show a distinctive germline IGHV profile. Using both 454 
and Illumina technologies we sequenced the IGHV repertoire of 28 HIV-infected South 
African women from the CAPRISA 002 and 004 cohorts, 13 of whom developed broadly 
neutralizing antibodies. Of the 259 IGHV alleles identified in this study, approximately 
half were not found in IMGT. This included 85 entirely novel alleles and 38 alleles that 
matched rearranged sequences in non-IMGT databases. Analysis of the rearranged VH 
genes of mAbs isolated from 7 of the CAPRISA women and previously isolated broadly 
neutralizing antibodies from other donors provided evidence that at least 8 novel or non-
IMGT alleles contributed to functional antibodies. Importantly, we found that despite a 
wide range in the number of IGHV alleles in each individual, including alleles used by 
known broadly neutralizing antibodies, there were no significant differences in germline 
IGHV repertoires between individuals who do and do not develop broadly neutralizing 
antibodies. This study reports novel IGHV repertoires and highlights the importance of a 
fully comprehensive immunoglobulin database for germline gene usage prediction. 
Furthermore, these data suggest a lack of genetic bias in broadly neutralizing antibody 
development in HIV-1 infection, with positive implications for HIV vaccine design.   
 51 
 
 
 
1.2. INTRODUCTION 
The induction of broadly neutralizing antibodies (bNAbs) is likely to be crucial for an 
efficacious HIV vaccine. While the majority of chronically HIV-infected individuals 
develop some level of cross-neutralizing activity (Hraber, et al., 2014), bNAbs are 
generally found in less than 20% of HIV-infected individuals (Stamatatos, et al., 2009). 
The mechanisms underlying bNAb emergence are largely unknown, but a better 
understanding of how these antibodies arise in natural infection would provide a blueprint 
for a vaccine designed to elicit them. Over the last few years a large number of potent and 
broad bNAbs have been isolated from selected HIV-infected donors. These bNAbs target 
conserved epitopes on the HIV envelope including the membrane proximal external region 
(MPER), V2 glycans, V3 glycans, CD4 binding site (CD4bs) and the gp120/gp41 interface 
(Kwong, et al., 2012; Scharf, et al., 2014). However, most bNAbs have unusual genetic 
features including high levels of somatic hypermutation (SHM), long CDRH3s (the 
complementarity determining region 3 on the heavy chain) (Breden, et al., 2011; Kwong, 
et al., 2012) and for some classes, biases in germline IGHV gene usage (Gorny, et al., 
2009; Breden, et al., 2011; Gorny, et al., 2011; Gorny, et al., 2012; Kwong, et al., 2012; 
Jardine, et al., 2013).  
 The VRC01 class of antibodies to the CD4bs (including NIH45-46, 12A12, 
3BNC117, VRC-PG04 and VRC-CH31 isolated from multiple donors) have been shown to 
preferentially use either IGHV1-2*02 or IGHV1-46*02 germline alleles (Scheid, et al., 
2011; Kwong, et al., 2012; West, et al., 2012). This preference is thought to be due to the 
electrostatic and hydrophobic contacts afforded by conserved residues in framework 1 
(FR1), CDRH2 and FR3 of this allele (some of these features are conserved in IGHV1-
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46*02 and IGHV1-3*01 which are also used by CD4bs antibodies) (Scheid, et al., 2011; 
Jardine, et al., 2013). Anti-HIV antibodies frequently use IGHV1 genes compared to 
healthy individuals (Gorny, et al., 2009; Breden, et al., 2011). In particular, IGHV1-69 is 
used by mAbs that target V2, the CD4 induced site (CD4i) and gp41 in HIV infection as 
well as other viral infections such as influenza (Corti, et al., 2010; Gorny, et al., 2012). 
The preference for this particular gene can be attributed to the interaction of hydrophobic 
residues in the CDRH2 with helical elements or hydrophobic β-sheets like those found on 
the hemagglutinin (HA) of influenza, and gp41 and gp120 of the HIV envelope (Gorny, et 
al., 2012; Lingwood, et al., 2012). The use of IGHV5-51*01 and IGHV5-51*03, which are 
underrepresented in mature antibodies, has also been reported to be favoured by anti-V3 
HIV antibodies (Gorny, et al., 2009; Gorny, et al., 2011).  
 The human germline IGHV repertoire consists of 7 IGHV subgroups, which are 
described in the International Immunogenetics Database (IMGT, 2014). These IGHV1-7 
subgroups include functional genes, open-reading frames (ORF) and pseudogenes with 
only functional genes being involved in antibody production. IGHV3 is the largest of the 
IGHV subgroups, with 21 functional genes, followed by IGHV1 and IGHV4 both with 10 
and IGHV2, IGHV5, IGHV6 and IGHV7 with three or less genes (Lefranc, 2001). Most of 
these genes have multiple alleles, including functional and non-functional alleles, which 
differ by either a single nucleotide polymorphism (SNP) or by multiple SNPs, which can 
be either synonymous or nonsynonymous, or frameshift mutations caused by indels that 
contribute diversity to the immunoglobulin gene repertoire. Furthermore, whole IGHV 
genes have been reported as duplicated or deleted from the germline repertoire of some 
individuals resulting in varied gene copy numbers (Watson, et al., 2012; Watson, et al., 
2013). IGHV genes make up the majority of the heavy chain variable region (VH) of 
mature antibodies and are central to antigen binding. Differences in germline IGHV 
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repertoires between different populations were recently highlighted in an extensive study 
of the human immunoglobulin gene locus (Watson, et al., 2013), where African 
individuals were found to be particularly diverse. 
 Given the propensity of some HIV mAbs to use restricted IGHV genes, we 
examined whether HIV-infected individuals who develop bNAbs have unique IGHV 
repertoires compared to individuals who do not, in order to determine whether the ability 
to develop these types of antibodies is genetically restricted.  
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1.3. METHODS AND MATERIALS 
1.3.1. Samples 
This study involved 28 adult (> 18 years) women of African ancestry (mostly Zulu 
speaking) with HIV-1 subtype C infection from the CAPRISA 002 (Van Loggerenberg, et 
al., 2008) and 004 cohorts (Abdool Karim, et al., 2010) who were being followed at urban 
and rural clinics in KwaZulu-Natal, South Africa. Of the 28 women, 13 developed bNAbs 
(referred to as BCN individuals) and 13 did not develop bNAbs (referred to as non-BCN 
individuals) despite chronic HIV infection and two were intermediate neutralizers 
(Appendix, Supplementary Table 1.1). BCN individuals were defined as those whose sera 
from 2 years post-infection were able to neutralize 33-94% (median 56%) of a panel of 18 
viruses, made up of 6 subtype A, 6 subtype B and 6 subtype C viruses of which 2 viruses 
were isolated from the women in the cohort. Non-BCN individuals neutralized 0-11% of 
the 18 viruses and had the same viral loads as the BCN individuals at 6 months post-
infection (to remove viral load biases associated with the development of bNAbs (Gray, et 
al., 2011b)). This study was given ethics clearance from the Human Research Ethics 
Committee for Medical Research in Johannesburg, South Africa (clearance number: 
M111104 for this study and M080470 for the CAPRISA parent study).  
 
1.3.2. DNA Extraction  
Genomic DNA was extracted from peripheral blood mononuclear cells (PBMCs) from 
each individual. Prior to extraction, PBMCs were thawed (at 37°C) and washed with 10ml 
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RPMI media with 10% FBS. Genomic DNA was extracted from the pellet from all 28 
individuals using a Promega Wizard Genomic purification kit. 
 
1.3.3. Primer Design and Amplicon Library Preparation 
Alignments were created for each IGHV subgroup using sequences obtained from 
ENSEMBL (ENSEMBL, 2013) and IMGT (IMGT, 2014). Forward primers (with the 
exception of IGHV1-F) were mapped to the intron in the leader sequence of each gene 
alignment. The reverse primers were mapped to the intron after the CDR3 region of each 
gene alignment. IGHV1, IGHV3 and IGHV4 primers were designed based on previously 
published primer sets (Wang, et al., 2011). New primers for IGHV2, IGHV5, IGHV6 and 
IGHV7 were designed based on related sequences for each subgroup. A total of eight 
primer sets were used to amplify all seven subgroups. The binding properties of the primer 
sets were determined using UCSC’s BLAT (BLAT, 2012) and NCBI’s BLAST (BLAST, 
2012). Additional next generation sequencing (NGS) specific sequences were added to the 
gene specific primers to allow sequencing of the Roche 454 and Illumina MiSeq. The 454 
primers included the 454-adapter sequence, key sequence and 10bp MID sequences (4 
unique sequences in total) (listed in Appendix, Supplementary Table 1.2). The Illumina 
MiSeq primers included a MiSeq index binding tag and the read 1 or read 2 tags (used for 
paired-end reads) (listed in Appendix, Supplementary Table 1.3). Nextera XT Indexing 
tags, which allow pooling of samples on the MiSeq, were added during library construction 
rather than included into the primer (further described in Section 1.3.4).  
 Each IGHV subgroup was amplified three times for each individual to ensure 
adequate coverage of the subgroup and minimise PCR bias. The PCR conditions for all 
eight amplicons and both 454 and Illumina primers were the same with the exception of 
the annealing temperatures: IGHV1, IGHV3a and IGHV5 at 56°C, IGHV2, IGHV6 and 
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IGHV7 at 59°C and IGHV3b and IGHV4 at 55°C. The PCR conditions were as follows: 
initial denaturation at 94°C for 3 minutes, 35 cycles of denaturation at 94°C for 15 
seconds, annealing for 45 seconds, extension for 1 minute at 72°C, final extension at 72°C 
for 8 minutes and held at 4°C. Each PCR contained 17.5µl dH2O, 2.5µl Roche FastStart 
HiFi 10x buffer with 18mM MgCl2, 0.5µl dNTP mix (10mM each), 1µl each primer 
(10uM), 0.25µl of Roche FastStart HiFi Enzyme (5U/µl) and 1µl of 10ng/µl DNA. The 
PCR amplicon lengths ranged from ~390-440bp. All replicates of the eight amplicons from 
each individual were pooled to create a full IGHV repertoire per individual. 
 
1.3.4. Next Generation Sequencing 
Fifteen individuals were sequenced on the Roche 454 GS Junior, with four individuals 
pooled per sequencing run. All clean-up procedures and sequencing on the Roche 454 GS 
Junior (Titanium) was done as per the manufacturers recommendations. 
 In order to confirm rare alleles that were only found in single individuals, eleven of 
the individuals sequenced on the GS Junior were re-sequenced on the Illumina MiSeq 
along with thirteen additional individuals. A custom amplicon sequencing approach was 
used for the Illumina MiSeq sequencing. Nextera XT Indexing tags were added to the 
pooled MiSeq amplicon libraries for each individual using 5µl of each Nextera XT index 
(two per sample), 1µl of cleaned PCR product (amplicon library prep), 0.5µl EpiCentre 
FailSafe enzyme, 25µl EpiCentre FailSafe PCR PreMix and 13.5µl dH2O. Thermocycler 
conditions: 72°C for 3 minutes, 95°C for 30 seconds, 12 cycles of 95°C for 10 seconds, 
55°C for 30 seconds and 72°C for 30 seconds followed by a final extension at 72°C for 5 
minutes. All products were checked on an Agilent bioanalyser and cleaned-up using 0.75x 
Ampure Beads, using the manufacturers protocol. Each sample was quantified on a Qubit 
and diluted to 8nM. A single 8nM pooled library was then created by pooling 4µl of each 
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diluted sample, 5µl of which was denatured using 5µl 0.2N NaOH, according to MiSeq 
protocol. A final concentration of 12pM denatured DNA library with 15% PhiX control 
was run onto the Illumina MiSeq, using the MiSeq reagent kit (version 2) with 2 x 250 
paired-end reads. 
 
1.3.5. Sequence Data Analysis 
Various bioinformatics languages were used to analyse the NGS data, including python, R 
and java as well as publically available bioinformatics tools. FASTQ files were extracted 
from the raw GS Junior output (.sff files) or automatically generated on the MiSeq. The 
resulting sequences were quality trimmed using QTrim (Shrestha, et al., 2014). Sequences 
with a minimum read length of 260bp and a mean quality score of 23 or higher (≥99% 
confidence) were considered high quality and used for downstream analyses. Paired-end 
MiSeq reads were merged using PEAR (Zhang, et al., 2014) after quality trimming. All 
identical sequences were collapsed to single unique reads. Unique reads compiled from 6 
or more identical sequences were used for further analysis while all unique reads compiled 
from less than 6 sequences were discarded from further analysis. The unique sequences 
were compared to a database of IGHV alleles downloaded from IMGT (IMGT, 2014) 
using a custom BLAST approach with match reward score of 2, mismatch penalty of 5, a 
gap penalty for insertions of 16 and a gap extension for deletions with a penalty of 4. All 
related sequences for each IGHV gene were aligned using RAMICS (Wright, et al., 2014).  
 Sequences with 100% matches to functional IMGT alleles were assigned as that 
particular IMGT allele. Sequences matching open reading frames or pseudogenes were 
removed from further analysis. Sequences with nonsynonymous and/or synonymous single 
nucleotide polymorphisms (SNPs), insertions or deletions compared to their top matched 
functional IMGT sequence were given the name of the top scoring IMGT match with the 
 58 
suffix “m” to denote a single mismatch (nonsynonymous and synonymous SNPs), e.g. 
IGHV1-2*5m and “mm” for multiple SNPs, insertions or deletions, e.g. IGHV1-2*5mm. 
Where more than one sequence with a single mismatch or multiple mismatches to the same 
top scoring IMGT functional sequence was observed, an additional numerical identifier 
was given to the name, for example: IGHV1-2*5m2 and IGHV1-2*5mm2. These 
sequences were compared to those listed in the Immunoglobulin Polymorphism Database 
(IgPdb, 2014), GenBank (GenBank, 2013), NCBI dbSNP (dbSNP, 2013) and NCBI’s 
IgBLAST (IgBLAST, 2014) and other published IGHV data (Boyd, et al., 2009; Jackson, 
et al., 2014; Parameswaran, et al., 2014; Wang, et al., 2014a; Wang, et al., 2014c). If 
100% matches were found in any of these databases or publications these sequences are 
described as non-IMGT alleles. If no match was found and sequences were observed in 
multiple individuals or in both sequencing platforms in a single individual, we report these 
as novel alleles. 
 Broadly neutralizing antibody (bNAb) sequences were obtained from CATNAP 
(CATNAP, 2014) or GenBank (GenBank, 2013). The germline IGHV gene usage for these 
bNAbs were also obtained from CATNAP (CATNAP, 2014) or the relevant bNAb 
isolation publication. The bNAb sequences were compared to our IGHV database, to see if 
any novel alleles might match these sequences better than their currently predicted 
germline IGHV gene usage. To do this we used blastn from BLAST 2.2.29+ with a match 
reward of 1, mismatch penalty of -1, gap deletions of 5, gap extension of 2, word size of 7 
and an E value threshold of 1e-10. Monoclonal antibodies (mAbs) have previously been 
isolated from 7 of the CAPRISA participants examined in this study using single-cell 
sorting and PCR amplification of the heavy and light chains (data unpublished). The 
majority of these mAbs were not HIV-specific. The sequences obtained from these mAbs 
were used to assign germline IGHV gene usage in each participant. 
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1.3.6. Statistical Analysis 
Two-tailed Fisher’s exact tests with 95% confidence intervals were used to test the 
difference in germline IGHV gene repertoires between the BCN and non-BCN sample 
groups.  
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1.4. RESULTS 
1.4.1. Comparison of NGS technologies 
The MiSeq gave 47x more data (7,093,765 quality reads vs. 150,542 quality reads on the 
454) in the 11 individuals sequenced on both technologies, even though some of the 
subgroups were not re-sequenced on the MiSeq. Based on the depth of coverage on the 
MiSeq we were able to pool more individuals per run (~3.5x as many, ~14 per MiSeq run 
compared to 4 on the 454). Approximately 70% (192/276) of the unique sequences 
amplified in this study were observed in both 454 and MiSeq. Of these 276 sequences, 16 
were excluded from further analysis as they were only observed in one individual on the 
454 only and not found in any other publications or databases. Based on the lower level of 
depth in the 454 data, the germline IGHV repertoires from the 4 individuals that were only 
sequenced on the 454 may be underrepresented (highlighted in Supplementary Table 1.1).  
 
1.4.2. Novel Germline IGHV Alleles in South African Women 
The germline IGHV gene repertoire of 28 HIV-infected women in the CAPRISA 002 and 
004 cohorts based in KwaZulu-Natal, South Africa were sequenced using both the 454 and 
Illumina NGS platforms. Sequences with perfect matches to IMGT (IMGT, 2014) listed 
alleles were given the IMGT allele name and are referred to as IMGT alleles. Sequences 
that did not match IMGT alleles due to synonymous or nonsynonymous mutations or 
indels but were matches to non-IMGT immunoglobulin gene databases (dbSNP, 2013; 
GenBank, 2013; IgBLAST, 2014; IgPdb, 2014) or immunoglobulin gene publications 
(Boyd, et al., 2009; Jackson, et al., 2014; Parameswaran, et al., 2014; Wang, et al., 2014a; 
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Wang, et al., 2014c) were referred to as non-IMGT alleles. Sequences with no matches to 
either IMGT or non-IMGT alleles and were observed in multiple individuals or across both 
technologies in one individual are hereafter referred to as novel alleles.  
 A total of 47 functional IGHV genes representing all seven subgroups were found 
in our cohort (Figure 1.1A). Only one published gene, IGHV3-NL1 first identified in 
Papua New Guinea (Wang, et al., 2011), was not detected. There was a wide range in the 
number of alleles associated with each gene with 20 alleles in the IGHV2-70 gene 
compared to only a single allele for the IGHV3-20 gene. Of the 259 alleles identified in 
this population, just over a half (~52%, n=136) had an exact match to those listed in 
IMGT, while ~15% (n=38) were non-IMGT alleles and ~33% (n=85) were novel alleles. 
Eighty-one of the 85 novel alleles (95%) were observed in more than one individual 
(Figure 1.1B). The 4 novel alleles observed in single individuals were confirmed with both 
454 and Illumina sequences. The most commonly observed novel alleles were IGHV6-
1*1m1 found in 25 individuals (~89%) and IGHV2-26*1m2 found in 20 individuals 
(~71%) both of which contained a single SNP compared to the known alleles. Overall, 
48% (n=60) of the novel and non-IMGT alleles identified in this study were found in at 
least 4 individuals indicating that many are fairly common. Furthermore this study 
significantly expanded the number of alleles for certain genes. For example, IGHV6-1, 
which previously only had 2 alleles reported in IMGT, was found to have 10 novel alleles 
and 1 non-IMGT allele (Figure 1.1). Similarly, IGHV2-26 was found to have 13 alleles 
(including 10 novel alleles and 2 non-IMGT) compared to 1 recorded in IMGT. Other 
significant expansions were in the IGHV1-69 and IGHV2-70 genes.  
 The majority (~97%, n=119) of novel and non-IMGT alleles had single or multiple 
SNPs (synonymous and nonsynonymous), with single nonsynonymous SNPs being the 
most common (Figure 1.2). One novel allele (IGHV2-26*1mm4, observed in 15 
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individuals) had 8 nonsynonymous SNPs (Figures. 1.1B and 1.2A). Four novel alleles had 
indels relative to their most closely matched IMGT allele and three of the four had 
additional SNPs. IGHV3-11*5mm, observed in two individuals, had a full codon insertion, 
while frameshifts as a result of single nucleotide deletions were found in IGHV4-59*8mm 
and IGHV4-61*2mm, each observed in two individuals, and IGHV6-1*1m8 that was 
found in six individuals (alignments of which can be seen in Appendix, Supplementary 
Figures 1.1-1.4). It is likely that the three alleles with the frameshift mutations are not 
functional but rather novel pseudogenes. 
 When the repertoires for each of the 28 individuals were analysed separately, it was 
apparent that there was a wide range in the number of alleles per individual (Figure 1.3). 
CAP295 had the largest number of alleles with 105 while CAP322 had the fewest at 23 
alleles. Each individual’s repertoire included IMGT, non-IMGT and novel alleles. There 
was variation in the number of alleles per IGHV family as some individuals lacked alleles 
for IGHV6 or IGHV7 while others had smaller numbers of IGHV2, IGHV4 or IGHV5 
alleles. This data suggests variations in copy number within this population with CAP295 
having duplicated genes and CAP322 having gene deletions, which would have to be 
confirmed through digital drop PCR. A phylogenetic tree of all 259 alleles, including 
IMGT, non-IMGT and novel alleles, sequenced in this study revealed separate clustering 
of each of the IGHV subgroups, with all of the novel and non-IMGT alleles clustering with 
their respective IMGT genes (Figure 1.4). 
 
1.4.3. Novel Germline IGHV Allele Usage in bNAbs 
In order to determine whether these novel and non-IMGT germline alleles are being used 
by the human immune system to generate functional antibodies, we analysed the germline 
gene usage of monoclonal antibodies (mAbs) isolated by single-cell PCR from seven 
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CAPRISA participants who were part of this study and 57 well known HIV-1 bNAbs. We 
identified 15 mAbs that made use of seven novel or non-IMGT alleles identified from 
NGS sequencing of the 28 individuals (Figure 1.5). Of these, two clonally related mAbs 
were HIV-1 specific (CAP255-37C and CAP255-18F). An example of one of the new non-
IMGT alleles used by two mAbs isolated from two different individuals (CAP177 and 
CAP248) is shown in Figure 1.5B. Based on the IGHV repertoires from CAP177 and 
CAP248 the germline IGHV gene predicted to be used by these two mAbs is IGHV2-
5*9m which has a Serine (S) at position 62 rather than a Glycine (G) present in the closest 
related IMGT allele IGHV2-5*09. All other SNPs found in these two mAbs, compared to 
the germline allele are likely the results of somatic hypermutation (SHM). Of the 
remaining seven novel and non-IMGT alleles used by these mAbs, 4 (57%) had a better 
match at the amino acid level and 3 (43%) at the nucleotide level compared to the closest 
matching IMGT allele (Figure 1.5A). Within the bNAbs we found 14 instances where the 
novel or non-IMGT alleles, identified in this study, provided the same or a better match 
than their currently predicted IMGT allele (Figure 1.5C). Two of the predicted alleles 
(IGHV4-39*7m2 and IGHV4-59*1m2) were also observed among the mAbs isolated from 
the CAPRISA participants. An example of alternate IGHV allele usage for the bNAbs is 
shown in Figure 1.5D, where PGT130 and PGT131 are more likely to be using IGHV4-
39*7m1 or IGHV4-39*7mm, which like the mAbs have a Valine (V) at the second amino 
acid, rather than a Leucine (L) as seen in IGHV4-39*07. Alignments of all other mAbs 
listed in figure 1.5A can be found in Appendix, Supplementary Figures 1.5-1.10. While 
alignments for all other bNAbs listed in Figure 1.5C can be found in Appendix, 
Supplementary Figures 1.11-1.15. 
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Figure 1.2: Number of single nucleotide changes (SNPs) in the novel and non-IMGT 
germline IGHV alleles 
A) Number of nonsynonymous SNPs observed in the novel and non-IMGT germline IGHV alleles. 
Shown are the number of novel (red) and non-IMGT (orange) alleles. B) Number of synonymous 
SNPs observed in the novel and non-IMGT germline IGHV alleles.  
 
 
Figure 1.3: Number of germline IGHV alleles for each individual 
A) Total number of novel, non-IMGT and IMGT alleles observed. Shown are the numbers of novel 
(red), non-IMGT (orange) and IMGT (blue) alleles. BCN individuals are highlighted in black and 
the non-BCN individuals in grey. B) Total number of alleles for each of the seven IGHV 
subgroups. Shown are the total numbers of alleles coloured according to IGHV subgroup. 
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Figure 1.4: Phylogenetic tree of all germline IGHV alleles observed in 28 South 
African individuals  
Shown are all IMGT, non-IMGT and novel alleles observed in this study. Alleles are coloured 
according to IGHV subgroup and the non-IMGT and novel alleles are highlighted in the grey 
boxes. 
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1.4.4. Comparison of Germline IGHV Repertoires in BCN and non-BCN Individuals  
Given that some HIV broadly neutralizing mAbs show biased heavy chain variable gene 
usage, we analysed the germline IGHV repertoires of BCN and non-BCN individuals to 
determine whether the ability to develop bNAbs was associated with a particular genotypic 
profile. Among the 28 CAPRISA women, 13 developed bNAbs in their plasma after 2-4 
years of HIV infection (referred to as BCN individuals), 13 women did not develop bNAbs 
(referred to as non-BCN individuals), despite matching viral loads, and two were 
intermediate neutralizers (Appendix, Supplementary Table 1.1, (Gray, et al., 2011b) and 
unpublished data). Comparison of the BCN and non-BCN individuals revealed that both 
groups had similar profiles of IGHV genes (Figure 1.6), approximately the same number of 
alleles for each of those genes (Figure 1.7) and the same number of potential alleles 
(Figure 1.3). The only gene with a difference between the two groups was IGHV3-30 (p-
value=0.035, although not significant following Bonferroni multiple testing correction); 
where non-BCN individuals had five more alleles (n=11) compared to the BCN individuals 
(n=6) (Figure 1.7). 
 We also compared the frequency of the specific germline IGHV alleles used by 
bNAbs between the non-BCN and BCN groups. Of the 57 monoclonal bNAbs targeting 
one of 4 different epitopes on the HIV envelope glycoprotein, most made use of IGHV1, 
IGHV3 and IGHV4 germline genes (Figure 1.8) and as reported above some may use 
novel/non-IMGT alleles (Figure 1.5C). Some alleles used by bNAbs were not observed in 
this study group. This included IGHV1-46*02, used by some CD4bs antibodies, however 
there were two other alleles for this gene, including IGHV1-46*01, that were found in all 
individuals. Similarly, IGHV3-15*05 (used by bNAb 10E8) and IGHV3-33*05 (used by 
bNAbs PG9 and PG16) were not observed in any of the individuals in this study, but other 
alleles were more commonly observed including some novel/non-IMGT alleles. The 
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IGHV1-2*02 allele which is also preferentially used by CD4bs antibodies (shown in blue 
in Figure 1.8) occurred at high frequencies in both the non-BCN and BCN groups. The 
most prevalent IGHV alleles in both groups were IGHV4-59*01 (used by the CD4bs 
bNAb CH103 and the V3/glycan bNAbs PGT121-123), IGHV1-2*02 (used by CD4bs 
mAbs), IGHV1-3*01 (used by the CD4bs bNAb IgG1b12) and IGHV2-5*01/05 (used by 
bNAb 2F5 that targets the MPER). Importantly, there was no difference in the frequency 
of any of these alleles between the 13 BCN and 13 non-BCN individuals. Thus, the 
inability of all HIV-infected individuals to develop bNAbs is not due to a paucity of the 
relevant alleles in their IGHV germline gene repertoires. 
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1.5. DISCUSSION 
We analysed the germline immunoglobulin heavy chain variable gene repertoire encoded 
in the genomic DNA of individuals from KwaZulu-Natal, South Africa and noted that 
~48% of the alleles seen in this population are not reported in IMGT. Some of these alleles 
(non-IMGT alleles) were described in published studies of re-arranged antibodies, 
although most alleles were novel and are described here for the first time to our 
knowledge. Further analysis of these IGHV repertoires revealed there to be no differences 
between those individuals who developed bNAbs to HIV compared to those who did not, 
despite equivalent antigenic load. Since the induction of these types of antibodies is 
considered essential for an effective HIV vaccine, these data suggest that the ability to 
develop bNAbs is not restricted by the IGHV repertoire in an individual. 
 Previous studies have reported differences in the frequencies of IGHV genes 
between different populations, with Africans showing particularly unique profiles (Watson, 
et al., 2013). The presence of IGHV3-64D, IGHV5-10-1 and IGHV7-4-1 has been 
reported to be lower in African (Luyha, Maasai and Yoruba) populations compared to 
Asian and European groups (Watson, et al., 2013). We found a similarly low frequency of 
IGHV3-64D (14%) in this Zulu-speaking South African population. However, IGHV5-10-
1 was observed at a higher prevalence (64%) compared to the studied African, Asian and 
European groups (0.03-16%, 20-21% and 34-48%, respectively) (Watson, et al., 2013), 
while IGHV7-4-1 frequencies were similar (75%) to those seen in Asian (~78%) and 
European (54-75%) groups (Watson, et al., 2013). IGHV1-69-2, IGHV3-43D and IGHV4-
38-2 genes have been reported to be common in African populations (Watson, et al., 2013) 
which we corroborated in our study for IGHV1-69-2 and IGHV4-38-2 (75% and 61%, 
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respectively). However, we observed IGHV3-43D*01 in only 29% (8/28) of individuals 
studied which is lower than the prevalence reported in other African groups (45-65%, 
(Watson, et al., 2013)). 
 We have shown that both novel and non-IMGT alleles are being used by mAbs 
isolated from individuals in this study as well as some well-characterised anti-HIV bNAbs. 
This included CH103 and 12 antibodies in the PGT121-137 series all of which were 
isolated from African donors (Simek, et al., 2009; Walker, et al., 2011; Liao, et al., 2013). 
Given that three of the novel and non-IMGT alleles (IGHV3-21*1m, IGHV4-39*1m2 and 
IGHV4-39*7m2) potentially being used by these bNAbs were fairly common in the South 
African individuals (39%, 36% and 21%, respectively), it is perhaps not surprising, that 
these have been found to contribute to functional antibodies in other African individuals. 
IGHV4-39*7m1 and IGHV4-39*7mm were less common in our study group, at 4% and 
11% respectively. The other novel and non-IMGT alleles used by mAbs isolated from the 
study participants were also fairly commonly observed ranging from 14-36%. Only two of 
the 15 mAbs isolated from the study participants were able to bind HIV, highlighting that 
the use of novel and non-IMGT alleles by functional antibodies is not HIV-specific and 
thus could play a role in immune responses to other diseases or infections. 
 Despite the wide range in the number of IGHV alleles present in each individual 
there were no differences in the overall germline IGHV repertoires between BCN and non-
BCN individuals. This extended to a sub-analysis of the genes and alleles used by known 
bNAbs whose frequency differed within the cohort but not between BCN and non-BCN 
groups. The only gene that showed a significant difference between the two groups was 
IGHV3-30, where non-BCN individuals had more alleles than BCN individuals. This gene 
is used by the CAP256-VRC26 family of broad and potent V1V2 antibodies, which were 
isolated from CAPRISA donor CAP256, a participant in this study (Doria-Rose, et al., 
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2014). We also noted that alleles IGHV1-46*02, IGHV3-15*05 and IGHV3-33*05 used 
by CD4bs, MPER and V2 glycan bNAbs, respectively, were not found in this South 
African cohort. Other alleles of these genes were however observed in this cohort, as well 
as allelic variants used by other bNAbs targeting the same epitopes. Thus, although the 
specific alleles used by these bNAbs were not present, it did not preclude these individuals 
from generating antibodies to these epitopes. In addition, CH103 and PGT121-123 which 
both use IGHV4-59*01 (or the non-IMGT allele IGHV4-59*1m2), target different 
epitopes, (CD4bs and V3 glycans, respectively), demonstrating that a single germline 
allele can be used by antibodies against numerous HIV Env targets. 
 The germline IGHV gene makes the greatest contribution to the unmutated 
common ancestor (UCA) antibody encoding the entire CDRH1, CDRH2 and FR1, FR2 
and FR3 regions. Elegant studies on the UCAs of the VRC01 class of antibodies, which 
use the VH1-2*02 allele, have shown how two glycans in the V5 region of the HIV 
envelope obstruct binding of the UCA (Jardine, et al., 2013; McGuire, et al., 2014). Such 
studies guide the design of suitable envelope immunogens able to trigger the VRC01-class 
of antibodies (Jardine, et al., 2013). However, other studies aimed at identifying UCA-
binding envelopes for PG9 and other bNAb lineages have been less successful, primarily 
because the UCA approximations used in such studies were predicted from highly mutated 
antibodies and using incomplete germline databases. The public availability of a 
comprehensive database of germline immunoglobulin genes, including data from this 
study, will significantly enhance the accuracy with which UCAs can be inferred. 
 By studying an under-represented population group in southern Africa, this 
investigation has greatly expanded the repertoire of germline IGHV genes. We further 
hypothesise that the IGHD and IGHJ germline genes, which make up the remainder of the 
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VH region of functional antibodies, are likely to be highly variable within this population 
as well, and thus warrant investigation.  
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1.6. CONCLUSIONS 
In this study we identified 85 novel germline IGHV alleles within the South African 
population that have not been previously described. We also identified 38 non-IMGT 
alleles, which have previously only been described in rearranged antibodies and not in the 
germline IGHV repertoire. The identification of non-IMGT alleles in the germline IGHV 
repertoire is an important discovery as it shows that the SNPs observed in these alleles 
compared to the IMGT alleles are already encoded in the genome rather than a 
consequence of somatic hypermutation. We have thus expanded the knowledge of the 
germline IGHV repertoire that is currently described in the global Immunogenetics 
database, IMGT. In addition we have shown that both novel and non-IMGT alleles are 
being used by mAbs isolated from study participants and possibly also by well described 
bNAbs. This knowledge will contribute to a better understanding of antibody response to 
HIV as well as other infections, immunizations and B cell pathologies. Importantly, we 
have also shown that the development of bNAbs against HIV is not restricted by the 
germline IGHV repertoire, which is significant for vaccine development, as it suggests that 
everyone has the potential to make antibodies capable of neutralizing all strains and 
subtypes of HIV. 
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2.1. ABSTRACT 
Strain-specific HIV-1 antibodies play an important role in shaping broadly neutralizing 
antibody responses during infection. We previously identified an HIV-1 subtype C infected 
individual (CAP88) with a potent strain-specific antibody response targeting the C3-V4 
region of gp120 that did not develop neutralization breadth. Plasma neutralization against 
the C3-V4 was first detected from 15 weeks post-infection, peaked at 26 weeks and then 
waned following viral escape. A strain-specific monoclonal antibody (CAP88-CH06) was 
isolated as an IgA1 isotype from donor CAP88 at 34 weeks post-infection. Here we studied 
the evolution of the CAP88-CH06 heavy chain by next generation sequencing from 5 
weeks through to 121 weeks of infection. IgA sequence transcripts that were identical 
matches to the mature CAP88-CH06 antibody, with 8.8% divergence, were detected at all 
7 time-points. This included the earliest time-point collected 10 weeks prior to the 
detection of plasma neutralizing activity and the latest time-point, collected long after the 
virus had escaped this response. The presumed unmutated common ancestor of this lineage 
was also detected at 5 weeks but disappeared after 11 weeks with very few intermediate 
sequences observed. We also identified clonally related IgG transcripts at 11 to 38 weeks 
but not at other time-points. This is the first study to examine the development of an early 
strain-specific HIV antibody lineage over years of infection. The limited evolution of the 
IgA isotype and the disappearance of the IgG isotype may have contributed to the inability 
of this lineage to develop neutralization breadth.   
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2.2. INTRODUCTION 
HIV-1 specific binding and neutralizing antibodies of varying breadth and potency 
targeting the envelope glycoprotein arise shortly after infection. Initial antibody responses 
can be detected as early as ~12 days post-infection that bind gp41 but are not neutralizing 
(Tomaras, et al., 2008). These responses are followed by strain-specific antibodies detected 
from 4-14 weeks after infection, typically gp120-directed and persisting throughout 
infection (Gray, et al., 2007; Euler, et al., 2012; West, et al., 2014). Strain-specific 
antibodies exert significant pressure on the virus forcing neutralization escape, often 
resulting in the development of other strain-specific antibodies targeting different regions 
(Moore, et al., 2009b; Wibmer, et al., 2013). In approximately 15-30% of HIV-1 infected 
individuals this co-evolution of virus and antibody leads to the development of broadly 
neutralizing antibodies (bNAbs) (Stamatatos, et al., 2009; West, et al., 2014; Moore, et al., 
2015). BNAbs are able to neutralize numerous strains of the virus but take approximately 
2-3 years post-infection to appear (Gray, et al., 2011b).  
 The targets of strain-specific neutralizing antibodies are usually localised to the 
variable regions of the viral envelope, allowing the virus to escape neutralization fairly 
easily (Moore, et al., 2009a). Most commonly this includes the V1V2 and C3-V4 regions 
of gp120, but V4 and V5 regions have also been implicated (Gray, et al., 2007; Moore, et 
al., 2008; Moore, et al., 2009b). In contrast the targets of bNAbs cluster within five more 
conserved regions of the HIV envelope; the V2 site, N332 supersite, CD4-binding site, 
gp120-gp41 interface and membrane external proximal region (MPER) (Wibmer, et al., 
2015). BNAbs tend to have unusual features such as long CDRH3 lengths and high levels 
of somatic hypermutation that are often required to neutralize at these sites. Thus, CD4bs 
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antibodies typified by the VRC01 bNAb lineage have levels of somatic hypermutation in 
excess of 30% (Wu, et al., 2015) while V1V2 bNAbs such as the CAP256-VRC26 lineage 
have extremely long CDRH3s (35 amino acids) with lower levels of SHM (8-15%) (Doria-
Rose, et al., 2014). In contrast, strain-specific antibodies tend to have average levels of 
somatic hypermutation (1-12%) and normal CDRH3 lengths (~16 amino acids) (West, et 
al., 2014; Zolla-Pazner, 2014). 
 The current paradigm in HIV vaccine development focuses on B-cell lineage 
immunogen design. This involves studying B-cell ontogeny through deep sequencing of 
highly affinity matured antibody heavy and light chains to identify the early B-cell 
unmutated common ancestor (UCA) that gave rise to the lineage (Haynes, et al., 2012b). 
To date two studies have analysed the evolution of bNAbs from acute through to chronic 
infection. While the UCA of the CH103 CD4bs lineage bound the early autologous virus, 
neutralization occurred only after a sufficient level of SHM had been achieved (Liao, et al., 
2013). In contrast the UCA of the CAP256.VRC26 V1V2 lineage both bound and 
neutralized the early autologous virus as a result of selection of a B-cell with a pre-existing 
long CDRH3 (Doria-Rose, et al., 2014). These data highlight the different pathways to 
acquire neutralizing activity although in both cases, SHM of the earlier strain-specific 
antibodies was required to achieve broad neutralization. 
 Strain-specific antibodies have also been shown to play an active role in shaping 
bNAb responses. In two subtype C infected individuals, neutralization escape from early 
strain-specific antibodies resulted in a shift of a glycan at position 334 to 332 in the C3 
region of gp120, which led to the development of bNAbs targeting the glycan at 332 
(Moore, et al., 2012). Similarly neutralization escape, through an Asparagine (N) to 
Aspartic Acid (D) change at position 167, driven by strain-specific antibodies targeting the 
V1V2 region of gp120 resulted in the development of bNAbs targeting the same region in 
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another donor (Wibmer, et al., 2013). In the CH103 lineage, breadth was achieved with the 
aid of a separate helper antibody lineage (CH235) that was initially strain-specific (Gao, et 
al., 2014).   
 We have previously described a strain-specific neutralizing antibody response in a 
CAPRISA 002 participant (CAP88), which was mapped to the C3-V4 region of gp120 
(Moore, et al., 2008; Moore, et al., 2009a). Plasma neutralization of the C3-V4 region was 
detected from 15 weeks post-infection, peaked at 26 weeks post-infection and then waned, 
concomitant with viral escape, but persisted throughout infection (Moore, et al., 2009a; 
Gray, et al., 2011a). The strain-specific monoclonal antibody (mAb) CAP88-CH06 was 
later isolated at 34 weeks post-infection (Gray, et al., 2011a). The heavy chain of this IgA1 
antibody was mapped to the germline IGHV4-39*01, D3-3*01 and J4*02 gene families 
with 8.8% SHM and a CDRH3 length of 18 aa. The light lambda chain was mapped to 
IGLV3-21*03 and IGLJ2*01 germline genes (Gray, et al., 2011a). Although potent strain-
specific responses developed in this participant, she did not develop breadth even after five 
years of infection. Here we report the evolution of the heavy chain of this CAP88-CH06 
lineage from 5-121 weeks post-infection in order to provide insight into why some strain-
specific antibodies do not develop neutralization breadth. 
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2.3. METHODS AND MATERIALS 
2.3.1. Samples 
Stored peripheral blood mononuclear cells (PBMCs) collected at seven time-points (5, 8, 
11, 17, 34, 38 and 121 weeks post-infection) from a participant (CAP88) in the Centre for 
the AIDS Programme of Research In South Africa (CAPRISA) 002 Acute Infection cohort 
were used for this study (Van Loggerenberg, et al., 2008). Ethics clearance was obtained 
from the Human Research Ethics Committee for Medical Research in Johannesburg, South 
Africa (clearance number: M111104 for this study and M080470 for the CAPRISA parent 
study). 
 
2.3.2. Total Nucleic Acid Extraction and cDNA Synthesis 
PBMCs were thawed at 37°C and decanted into a preheated 10ml RPMI buffer with 10% 
FBS. The samples were mixed by pipetting gently and centrifuged at 1200rpm for 10 
minutes. The supernatant was discarded and the cells re-suspended in 1ml RPMI buffer 
with 10% FBS and further centrifuged at 8000rpm for 3 minutes. The supernatant was 
once again removed leaving ~10-50µl with the pellet. A Qiagen AllPrep DNA/RNA mini 
kit was used to extract genomic DNA and total RNA from all seven samples as per the 
manufacturers specifications. Concentrations of the resulting nucleic acids were 
determined on a NanoDrop spectrophotometer. The RNA was converted to cDNA in two 
replicates as follows: 5µl Random Hexamers (150ng/µl) (obtained from Integrated DNA 
Technologies (IDT)) was added to 50µl total RNA, 5µl dNTPs (10mM each, Roche) and 
5µl dH2O which was heated to 65°C for 5 minutes and placed on ice for 1 minute. The 
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samples were centrifuged and the following added: 20µl 5x First strand buffer (Invitrogen, 
Life Technologies) 5µl 0.1M DTT (Invitrogen, Life Technologies), 5µl RNAseOUT 
(Invitrogen, Life Technologies) and 5µl Superscript III RT Enzyme (Invitrogen, Life 
Technologies) and placed in a thermocycler with the following conditions: 25°C for 5 
minutes, 50°C for 60 minutes, 70°C for 15 minutes and held indefinitely at 4°C. The two 
replicates of each sample were then pooled resulting in a final volume of 200µl cDNA. 
The gDNA extracted from these time points were stored for later use, while cDNA was 
used to sequence the CAP88-CH06 antibody lineage during infection. 
 
2.3.3. Primer Design 
An IGHV4 forward primer (CAGSTGCAGCTGCAGGAGTCGG) located at the 
beginning of framework 1 (FR1) and two reverse constant region primers matching IgA 
(CCAGCCCCAAGGTCTTCCCG) and IgG (GTCTTCCCCCTGGCRCCCTC) were used 
to amplify clonally related antibodies to CAP88-CH06 from seven time points. The 
forward primer was designed to amplify all IGHV4 genes including IGHV4-39 (the 
germline gene used by CAP88-CH06). The reverse IgA and IgG primers were taken from 
DeKoksy et al., (DeKosky, et al., 2013). MiSeq specific index binding site sequences 
(TCGTCGGCAGCGTC for forward and GTCTCGTGGGCTCGG for the reverse primers) 
and paired-end read sequences (AGATGTGTATAAGAGACAG) were incorporated into 
both the forward and reverse primers to allow sequencing on the Illumina MiSeq. 
	  
2.3.4. Library Construction and Illumina Sequencing 
Each sample was amplified ten times to ensure adequate coverage of the IGHV4 antibody 
repertoire and minimise PCR bias. A plasmid containing the CAP88-CH06 sequence was 
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also amplified, once using an IgA reverse primer and once using an IgG reverse primer. 
Both reactions used the IGHV4 forward primer and the same conditions as those used for 
the cDNA samples. The PCR conditions were as follows: initial denaturation at 95°C for 5 
minutes, 25 cycles of denaturation at 95°C for 30 seconds, annealing for 1 minute at 58°C, 
extension for 1 minute 30 seconds at 72°C, final extension at 72°C for 7 minutes and held 
at 4°C. Each PCR contained 29.2µl dH2O, 5µl Roche FastStart HiFi 10x buffer with 18mM 
MgCl2, 0.4µl dNTP mix (10mM each), 1µl each primer (10µM), 0.4µl of Roche FastStart 
HiFi Enzyme (5U/µl) and 2µl of 10ng/µl gDNA/cDNA. The PCR amplicon sizes were 
550-570bp. The amplicons were cleaned using 0.75x Ampure Beads as per the 
manufacturers recommendations. A limited cycle PCR was used to incorporate MiSeq 
Nextera XT indices into the amplicons, to allow pooling of multiple samples, using the 
Nextera XT indexing kit and the EpiCentre FailSafe PCR PreMix Selection Kit. The 
limited cycle PCR conditions were as follows: 5µl of each index (two per sample) was 
added to 1µl of DNA, 0.5µl FailSafe enzyme and 13.5µl dH2O, which was then placed into 
a thermocycler for 72°C for 3 minutes, 95°C for 30 seconds, 12 cycles of 95°C for 10 
seconds, 55°C for 30 seconds and 72°C for 30 seconds followed by a final extension at 
72°C for 5 minutes. All products were checked on an Agilent bioanalyser and cleaned-up 
using 0.75x Ampure Beads, using the manufacturers protocol. Each sample (including the 
two CAP88-CH06 plasmid control samples) was then quantified on a Qubit and diluted to 
8nM. A single 8nM pooled library was then created by pooling 4µl of each diluted sample, 
5µl of which was denatured using 5µl 0.2N NaOH, according to MiSeq protocol. A final 
concentration of 12pM denatured library with 15% PhiX control was run on the Illumina 
MiSeq using the reagent version 3 kit with 2 x 300bp paired-reads.  
 In order to confirm the presence of the mature CAP88-CH06 antibody in the 5 and 
8 weeks post-infection time points, cDNA from these original samples were re-amplified 
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and re-sequenced on the MiSeq at separate times, following the same protocol as 
described. A total of three MiSeq runs were used for this study, one including all seven 
time-points and two plasmid controls, the second using the 5 w.p.i sample only and the 
third using the 8 w.p.i sample only. 
 
2.3.5. Antibody Sequence Data Analysis and Antibodyomics Pipeline 
Paired-end FASTQ files for each time point were obtained from the MiSeq. An average of 
130 nucleotides were trimmed from the 3' ends of each reverse mate read to remove poor 
quality bases. The paired-end reads were merged into full-length reads for each time point 
using USEARCH (Edgar, 2010). The number of errors present in each read was estimated 
using USEARCH and all reads with an estimated value above 1 were removed (Edgar, 
2010). The merged FASTQ files were converted to FASTA files using fastq_to_fasta part 
of the FASTX tool kit (http://hannonlab.cshl.edu/fastx_toolkit/).  
 To measure the rate of sequencing error, we sequenced the CAP88-CH06 plasmid 
DNA with both IgA and IgG primers, as controls for the IgA and IgG sequences (see 
Section 2.4.1). For each control sample, the merged reads were aligned to CAP88-CH06 
using ClustalO (Sievers, et al., 2011) and the numbers of single nucleotide mismatch errors 
were counted for each read. This distribution was used to determine the threshold for a 
two-step clustering process for removing sequences potentially containing errors due to 
PCR or sequencing. In the first step all sequences in the dataset were clustered using 100% 
identity. All clusters containing only one read were defined as low coverage and likely 
contain sequencing errors and thus removed. The remaining non-redundant sequences were 
then clustered at 99% sequence identity with USEARCH (Edgar, 2010) and sequences 
represented by larger numbers of raw reads were given priority to be used as centroids for 
each cluster. The final coverage of a cluster was then calculated by summing the number of 
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raw reads of each member of a cluster, and clusters with coverage of less than 3 were 
removed. After the two steps of clustering, we successfully removed 99.9% of sequences 
containing sequencing errors in the control samples. The following parameters were used 
for the two-step clustering process: 1) usearch8.0.1517_i86osx32 -derep_fulllength 
input_file_name.fa -threads 24 -fastaout output_file_name.fa -sizeout -uc 
output_file_name.txt, 2) usearch8.0.1517_i86osx32-sortbysize input_file_name.fa -minsize 
2 -fastaout output_file_name.fa, 3) usearch8.0.1517_i86osx32-cluster_smallmem 
input_filename.fa -sortedby size -id 0.99 -sizein -sizeout -uc output_file_name.fa -
centroids output_file_name.txt, 4) usearch8.0.1517_i86osx32-sortbysize 
input_file_name.fa -minsize 3 -fastaout output_file_name.fa 
 An antibodyomics bioinformatics pipeline (in preparation for publication, Zhang et 
al.) was used to study the evolution of CAP88-CH06, by identifying lineage related 
antibodies from the MiSeq sequencing data of all time points. Briefly, merged reads with a 
read length less than 300 nucleotides or more than 600 nucleotides were removed and 
germline V and J genes were assigned to the remaining reads using NCBI Blast (Altschul, 
et al., 1997). Based on the boundaries of assigned V and J genes, the VDJ region was 
identified for each read and 5’ upstream and 3’ downstream sequences were removed. The 
3’ downstream sequence was further aligned to IgA and IgG constant regions separately 
using ClustalO (Sievers, et al., 2011) and assigned to either the IgA or IgG subtype based 
on sequence identity. The boundaries of CDRH3 were then identified using the conserved 
CXR motif at the 3’ end of V gene and WGXG motif in the J gene.  
 To find lineage related transcripts from each time point, all raw reads having the 
same germline V (IGHV4-39) and J (IGHJ4) gene assignment as CAP88-CH06 antibody 
were collected. The CDRH3 of each read was then aligned to that of CAP88-CH06 using 
ClustalO (Sievers, et al., 2011) and the sequence identity calculated. Sequences from the 
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raw read dataset with CDRH3 identity ≥ 80% to that of CAP88-CH06 were selected as 
lineage related raw reads. To remove reads containing PCR errors and/or sequencing 
errors, we performed the two steps of clustering as described previously. After the second 
step of clustering, a representative sequence was chosen (by USEARCH, (Edgar, 2010)) 
for each cluster and formed the unique sequence dataset. We further removed unique 
sequences containing errors manually and the curated sequences were used for downstream 
analyses.  
 To trace the developmental pathway of CAP88-CH06 antibody, a Maximum 
Likelihood phylogenetic tree was constructed with the lineage related unique reads from all 
time points using a GTR phylogenetic maximum likelihood model in seaview (Galtier, et 
al., 1996) and displayed in Dendroscope (Huson, et al., 2012).  
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2.4. RESULTS 
2.4.1. CAP88-CH06 Neutralization and Sequencing 
CAP88 is a subtype C infected participant from the CAPRISA 002 cohort who developed a 
potent autologous strain-specific HIV-1 antibody response (Van Loggerenberg, et al., 
2008; Gray, et al., 2011a). The antibody specificity was mapped to the C3-V4 region of the 
envelope and was first detected from 15 weeks post-infection (w.p.i) with a peak in 
neutralization at 26 w.p.i. This response was replaced by a second response targeting the 
V1V2 from 26 w.p.i., however, plasma neutralization against the C3-V4 region was still 
detectable even after 2 years post-infection (~106 w.p.i) (Figure 2.1, (Moore, et al., 
2009a)). Using gp120 containing the C3-V4 region of CAP88, seven antibodies were 
isolated from this participant at 34 w.p.i. by antigen-specific B-cell sorting (Gray, et al., 
2011a). One of these (CAP88-CH06) neutralized the transmitted/founder virus and acute 
infection viral clones isolated from CAP88 with an IC50 of 13ng/ml but failed to neutralize 
later clones containing escape mutations (Gray, et al., 2011a). CAP88-CH06 was isolated 
as an IgA1 strain-specific antibody with 8.8% divergence from the heavy chain germline 
IGHV4-39*01 gene.  
 In this study we examined the evolution of CAP88-CH06 heavy chain lineage 
throughout HIV-1 infection by next generation sequencing (NGS). Total nucleic acids 
were extracted from CAP88 peripheral blood mononuclear cells (PBMCs) taken at seven 
time points (5, 8, 11, 17, 34, 38 and 121 w.p.i). These time points were chosen to represent 
the various stages of evolution of this antibody response from first appearance in the 
plasma, peak breadth, and long after viral escape (Figure 2.1). The cDNA from each time 
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point was PCR amplified with an IGHV4 forward and two reverse primers for IgA and IgG 
and sequenced on the Illumina MiSeq. A plasmid sequence of CAP88-CH06 with a hybrid 
constant region derived from the original IgA antibody and the IgG1 vector was used as a 
control to determine PCR and sequencing error.  
 
Figure 2.1: Plasma neutralization of the 
C3-V4 region of CAP88 Env during 
HIV-1 infection 
Shown are the plasma neutralization titres 
against the C3-V4 region of CAP88 Env in 
grey and the seven time points (represented by 
the coloured bars) at which RNA was isolated 
to study the evolution of this antibody lineage.  
 
 A single MiSeq run was used to sequence all seven time points and the two IgA and 
IgG plasmid controls. Between 1.6 and 1.9 million raw reads were obtained from each time 
point with IgA and IgG sequences being equally distributed (Table 2.1). The most 
sequences were obtained at 5 weeks post-infection and the least at 17 weeks post-infection. 
The plasmid controls for IgA and IgG gave 109,556 and 168,527 paired reads, 
respectively. 
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Table 2.1: Number of reads obtained from the pooled MiSeq run containing all seven 
time points and plasmid controls 
Sample Number of raw reads 
Number of paired 
reads 
Number reads  
assigned to IgA 
Number reads  
assigned to IgG 
5 w.p.i 1,958,859 1,289,179 520,690 505,821 
8 w.p.i 1,765,059 1,191,063 521,546 427,381 
11 w.p.i 1,717,050 1,155,963 492,013 427,454 
17 w.p.i 1,660,629 1,114,587 466,903 422,808 
34 w.p.i 1,709,224 1,215,663 518,297 469,004 
38 w.p.i 1,684,162 1,105,684 472,869 401,787 
121 w.p.i 1,836,466 1,265,332 276,696 310,461 
IgA control 251,348 168,527 168,527 NA 
IgG control 193,182 109,556 NA 109,556 
Shown are the number of paired reads obtained from the first MiSeq run containing all time points 
and plasmid controls. The cDNA samples are coloured according to time point. 
 
2.4.2. CAP88-CH06 Plasmid Controls 
NGS is known for sequencing errors, which are often difficult to identify. We therefore 
used a CAP88-CH06 plasmid sequence with a hybrid IgA and IgG constant region as a 
control to identify the level of PCR and sequencing error. The plasmid was PCR amplified 
with the IgA and IgG reverse primers separately and sequenced under the same conditions 
as the seven cDNA samples taken from CAP88. Following sequencing, the reads were 
mapped back to the original plasmid sequence and identity-divergence plots used to show 
the percentage identity of the sequences to the CAP88-CH06 plasmid and the percentage 
of divergence or somatic hypermutation of the sequences from the germline gene (IGHV4-
39) used by CAP88-CH06 (Figure 2.2).  
 The majority of the sequences (~80%) were ≥99% identical to CAP88-CH06 with 
~8.8% somatic hypermutation. The remaining 20% of sequences had PCR or sequencing 
errors resulting in decreased identity to CAP88-CH06 (80-99%) and increased divergence 
from the germline (5-40%). Using a two-step clustering process, we removed 99.9% of the 
reads that contained sequencing errors (Figure 2.2). Some error containing reads remained 
in the IgG control even after the quality control (forming a "t" shape in Figure 2.2D). 
 95 
Figure 2.2: Identity-divergence 
plots for CAP88-CH06 IgA and 
IgG plasmid controls 
Shown are the percentage identity to 
CAP88-CH06 on the y-axis and the 
percentage divergence from the germline 
IGHV4-39 gene on the x-axis for each of 
the sequences obtained from the plasmid 
amplification using the IgA and IgG 
reverse primers before and after 
correcting for sequencing and PCR error. 
The log10 scale bar represents the number of sequences in the plot. 
 
2.4.3. CAP88-CH06 Clonally Related Antibodies 
An antibodyomics pipeline (described in Section 2.3.5) was used to assign V and J gene 
usage to the paired reads obtained from each of the seven time points, as well as the 
percentage identity to CAP88-CH06 and percentage divergence from IGHV4-39. Identity-
divergence plots were used to visualise the distribution of sequences obtained from each 
time point based on percentage identity to CAP88-CH06 and divergence from IGHV4-39. 
These sequences represent the raw data, which have not undergone the two-step clustering 
process (Figure 2.3A).  
 Within the IgA sequences, at 5 and 8 weeks post-infection we observed a small 
group of raw sequences with >90% identity to CAP88-CH06 with ~0% divergence from 
the germline. In addition we found a group of raw sequences that were 100% identical to 
CAP88-CH06 mAb with 8.8% divergence, each represented by a single unique sequence 
after QC (highlighted within the red block in Figure 2.3A). These two groups were also 
present in the IgA sequences at 11 weeks post-infection. By 17 weeks post-infection and 
throughout infection the germline-like group of sequences (~91% identity to CAP88-CH06 
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and ~0% divergence) disappeared and only the CAP88-CH06-like sequences (100% 
identity to CAP88-CH06 and 8.8% divergence) remained. At 34 weeks post-infection three 
distinct groups of sequences were observed; one which was CAP88-CH06 like, one with 
lower levels of divergence from the germline (6.7%) and one with increased levels of 
divergence from the germline (9.1%) compared to CAP88-CH06. 
 In order to confirm the presence of the fully matured CAP88-CH06 antibody at the 
early time-points, two additional MiSeq runs were performed. New PCR amplicons were 
amplified from the 5 and 8 week samples separately and sequenced on different MiSeq 
runs. Approximately 2.1 and 1.6 million reads were obtained from 5 and 8 weeks, 
respectively. Following the same two-step clustering process used in the first round of 
sequencing, we observed IgA transcripts that were identical to CAP88-CH06 in both time-
points confirming the presence of the mature antibody at 5 and 8 weeks of infection. 
 Within the IgG group we observed sequences with 90-92% identity to CAP88-
CH06 with less than 5% divergence from 11-17 weeks post-infection. At 34 weeks post-
infection very few sequences were observed with >90% identity to CAP88-CH06 and by 
38 weeks post-infection there were no sequences with >90% identity to CAP88-CH06.
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  In order to identify additional clonally related sequences to CAP88-CH06 a lower 
cut-off of ≥80% identity to the CAP88-CH06 CDRH3 was used as a filter. The number of 
unique clonally related sequences (obtained following the two-step clustering) for each 
time point are given in the top right corner of each plot and highlighted in pink in Figure 
2.3B. The coverage of the raw clonally related sequences for each time point are given in 
parenthesis. We observed clonally related sequences throughout infection within the IgA 
group, with 5, 8 and 11 weeks post-infection having 2 unique clonally related sequences, 
one of which represented the germline-like sequences (0.3% divergence and 91.9% 
identity to CAP88-CH06), and the other matching CAP88-CH06 (8.8% divergence and 
100% identity). At 17, 38 and 121 weeks post-infection only one unique sequence was 
observed, which was identical to CAP88-CH06. At 34 weeks post-infection 3 unique 
sequences were observed; one which was identical to CAP88-CH06, a second with 6.7% 
divergence and 97.9% identity and a third with 9.1% divergence and 96.1% identity (Table 
2.2). 
 Within the IgG group, clonally related sequences were only observed from 11 to 38 
weeks post-infection, all of which had ≤93% identity to CAP88-CH06. At 11 weeks post-
infection we observed 13 unique sequences with 1.7-2.8% divergence and 91.1-93.2% 
identity to CAP88-CH06. At 17 weeks post-infection only 4 unique sequences were 
observed with 2.8-4.1% divergence and 90.3-92.1% identity to CAP88-CH06. The number 
of clonally related sequences increased from 17-34 weeks post-infection. However the 
identities of these sequences to CAP88-CH06 were lower and they showed more 
divergence (84.6-90% and 5.8-11.7%, respectively) at 34 weeks post-infection compared 
to 17 weeks post-infection. At 38 weeks post-infection only one unique clonally related 
sequence was observed with 85% identity to CAP88-CH06 and 9.3% divergence.  
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Table 2.2: CAP88-CH06 clonally related IgA and IgG sequences  
Shown are the numbers of unique clonally related sequences for each time point for IgA and IgG 
isotypes. The numbers in parenthesis represent the total number of raw reads obtained for each 
unique sequence. Blocks highlighted in grey and text in bold represent the sequences that were 
identical to CAP88-CH06. 
 
  
Time -
Point 
IgA IgG 
Number of 
Unique 
Sequences 
% Identity 
to CAP88-
CH06 
% Divergence 
from IGHV4-39, 
(coverage) 
Number of 
Unique 
Sequences 
Identity to 
CAP88-
CH06 (%) 
% Divergence 
from IGHV4-39, 
(coverage) 
5 weeks 2 91.9 0.3 (86)  0     100 8.8 (13) 
8 weeks 2 91.9 0.3 (14)  0     100 8.8 (8)  
11 
weeks 2 
92.7 1.4 (192) 
13 
90.8 2.1 (260) 
91.1 2.4 (544) 
91.6 1.7 (31) 
91.6 2.8 (208) 
91.9 1.7 (138) 
91.9 2.1 (49) 
100 8.8 (39) 
91.9 2.1 (6) 
92.1 1.7 (4) 
92.1 2.4 (4) 
92.4 1.7 (20) 
92.4 2.8 (9) 
92.7 1.4 (8949) 
93.2 2.1 (624) 
17 
weeks 1 100 8.8 (5462) 4 
90.3 3.1 (620) 
90.6 2.8 (128) 
90.8 4.1 (685) 
92.1 2.8 (593) 
34 
weeks 3 
96.1 9.1 (51) 
11 
84.6 11.7 (4) 
85.3 10.0 (39) 
85.8 9.3 (69) 
97.9 6.7 (20) 
86.4 9.6 (7) 
86.6 8.6 (85) 
87.1 7.9 (27) 
87.4 7.2 (29) 
100 8.8 (19) 
87.9 7.9 (73) 
88.7 6.5 (3) 
89.2 5.8 (19) 
90.0 5.8 (27) 
38 
weeks 1 100 8.8 (1349) 1 85.0 9.3 (12) 
121 
weeks 1 100 8.8 (298)  0     
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2.4.4. CAP88-CH06 Phylogeny 
All unique clonally related sequences (listed in Table 2.2) obtained by selecting those 
using IGHV4-39 and IGHJ4, with ≥80% sequence identity to CAP88-CH06 CDRH3 and 
following the two-step clustering process, were used to create phylogenetic trees to study 
the evolution of this lineage. 
 The IgA clonally related sequences showed limited evolution with the mature 
antibody (CAP88-CH06) detected at 5 weeks of infection as a fully mature antibody with 
8.8% divergence that was maintained throughout infection (Figure 2.4). There was 
evidence of low divergence antibodies from 5-11 weeks post-infection (0.3-1.4% 
divergence) but no intermediate sequences (with divergence between 2-8.8%), with the 
exception of one sequence detected at 34 weeks post-infection. We were not able to 
distinguish between the two subtypes of IgA, namely IgA1 and IgA2 within these clonally 
related sequences, due to the primers used. It is however likely that these sequences are 
IgA1, since CAP88-CH06 was isolated as an IgA1 antibody. 
 Within the IgG sequences a greater level of evolution was observed (Figure 2.5). 
IgG is sub-divided into four subtypes (IgG1-4). Based on the primers used we determined 
that none of the IgG clonally related sequences were IgG4 but could be IgG1, IgG2 or 
IgG3 (we were not able to distinguish between these subtypes due to the primers used). 
CAP88-CH06 was included into this phylogenetic tree, even though the antibody was not 
observed as an IgG isoform, to give an indication of where the antibody would cluster. 
There appeared to be two distinct clusters of antibodies arising from the IgG group, the 
first (observed at the top of the phylogenetic tree) included two sequences from 11 weeks 
post-infection, three from 17 weeks post-infection and one each from 34 and 38 weeks 
post-infection. The second much larger cluster is composed mostly of 11 and 34 weeks 
post-infection samples and also contains the native CAP88-CH06 sequence. 
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Figure 2.4: Phylogenetic tree using clonally related IgA sequences 
Shown is a outgroup rooted (with IGHV4-39*01, top) phylogenetic tree of the 12 clonally related 
sequences to CAP88-CH06 (red square box). Sequences are coloured according to time point: 5 
w.p.i (red), 8 w.p.i (purple), 11 w.p.i (orange), 17 w.p.i (green), 34 w.p.i (light blue), 38 w.p.i (dark 
blue) and 121 w.p.i (pink). Sequences are labelled according to isotype, time point, percentage 
divergence and percentage identity to CAP88-CH06. The 1.4%-divergent sequence observed in 
both IgA and IgG transcripts is highlighted in grey. 
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Figure 2.5: Phylogenetic tree using clonally related IgG sequences 
Shown is a phylogenetic tree of the 29 clonally related sequences to CAP88-CH06 (red square 
box). Sequences are coloured according to time point: 11 w.p.i (orange), 17 w.p.i (green), 34 w.p.i 
(light blue) and 38 w.p.i (dark blue). Sequences are labelled according to isotype, time point, 
percentage divergence from IGHV4-39 and percentage identity to CAP88-CH06. The 1.4% 
divergent sequence that also found in IgA is highlighted in grey. 
 
 When joining isotypes to show the evolution of all clonally related sequences, we 
observed the lowest divergence (0.3-1.4%) sequences as an IgA isotype from 5 and 8 w.p.i 
(Figure 2.6). From 11 w.p.i the two isotypes form two distinct clusters. The first cluster 
includes the mature antibody (CAP88-CH06), which remained unchanged from 5 to 121 
w.p.i. The second cluster represents the IgG isoform, which appeared from 11 w.p.i with 
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1.4% divergence and evolved throughout infection up to 9.3% at 38 weeks post-infection 
after which it was no longer detectable. 
 
 
Figure 2.6: Phylogenetic tree of all clonally related sequences to CAP88-CH06 
Shown are each of the sequences (coloured according to time point: 5 w.p.i (red), 8 w.p.i (purple), 
11 w.p.i (orange), 17 w.p.i (green), 34 w.p.i (light blue), 38 w.p.i (dark blue) and 121 w.p.i (pink)) 
that are clonally related to CAP88-CH06. Sequences are labelled according to isotype, time point, 
percentage divergence from IGHV4-39 and percentage identity to CAP88-CH06. The 1.4%-
divergent sequence that was found in both IgA and IgG is highlighted in grey.  
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2.4.5. CAP88-CH06 Lineage Evolution 
All clonally related sequences were aligned according to the percentage divergence, with 
the less divergent sequences shown first and the SHM compared to the germline IGHV4-
39*01 and IGHJ4*02 genes (Figure 2.7). Two sequences were seen at multiple time-points 
and were thus only represented once with the time-points given in the sequence name and 
coloured accordingly. SHM was largely observed within the CDRH regions (highlighted in 
yellow) and FR3 with the majority occurring in the CDRH2 with all of the amino acids 
covering this region showing SHM. This was followed by CDRH1, CDRH3 and FR3 
having 92% (12/13), 61% (11/18) and 59% (22/38) of the amino acids in each region 
subject to SHM during evolution, respectively. We observed no SHM within the constant 
regions that were sequenced. 
 The majority of the somatic hypermutations observed within these sequences were 
single amino acid substitutions, however, some indels were observed. A three amino acid 
insertion (NSI at positions 30-32) in the CDRH1 was seen in one sequence obtained at 34 
weeks post-infection. A two amino acid insertion (RP, positions 61 and 62, highlighted in 
the dark yellow box in Figure 2.7) was observed within 3 IgA sequences, including the 
CAP88-CH06 antibody sequence. A deletion of a Serine (S) was observed at position 34 in 
one IgG sequence obtained from 38 weeks post-infection. The highest level of divergence 
seen within these sequences was 11.7%, seen at 34 w.p.i within the IgG transcripts.   
 The least mutated sequence was observed in the IgA transcripts obtained from 5 
and 8 weeks post-infection with 0.3% divergence. This sequence had a single amino acid 
change (valine, V) at position 2 with no other SHM compared to the germline gene. We 
also observed an identical sequence with low divergent sequence (1.4%) in both the IgA 
and IgG transcripts obtained at 11 w.p.i (highlighted in the red box in Figure 2.7). This 
transcript links the two isotypes in this lineage. 
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Figure 2.7: Alignment of CAP88-CH06 clonally related sequences 
Shown is an alignment of all IgA (bold) and IgG clonally related sequences compared to the 
germline IGHV4-39*01, IGHJ4*02, IgA and IgG primers used. The names of the sequences are 
coloured according to time point (5 w.p.i in light red, 8 w.p.i in purple, 11 w.p.i in orange, 17 w.p.i. 
in green, 34 w.p.i in light blue, 38 w.p.i in dark blue, 121 w.p.i in pink and CAP88-CH06 in dark 
red). Two sequences were seen in multiple time-points and are shown in multi-colours representing 
the different time-points. The CDRH regions are highlighted in yellow and the constant region 
highlighted in orange.  
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2.5. DISCUSSION 
We have tracked the evolution of a potent strain-specific anti-HIV antibody (CAP88-
CH06) during the course of infection. CAP88-CH06 is an IgA1 antibody with 8.8% 
divergence from the germline IGHV4-39 gene, targeting the C3-V4 region of gp120. Our 
sequencing data revealed IgA transcripts that were identical to CAP88-CH06 at all seven 
time-points (5, 8, 11, 17, 34, 38 and 121 weeks post-infection) examined. Very little 
evolution was observed within the IgA transcripts during infection. The putative UCA of 
the lineage was detected within the IgA transcripts at 5 and 8 weeks post-infection. At 11 
weeks post-infection an identical low divergent (1.4%) sequence was observed in both the 
IgA and IgG transcripts. The limited evolution of the IgA transcripts and the disappearance 
of the IgG transcripts during infection could be a reason why this particular lineage never 
became broadly neutralizing.  
 Previous studies from this participant showed plasma neutralization of the C3-V4 
region from 15 weeks post-infection, which peaked at 26 weeks post-infection and then 
waned but remained detectable throughout infection (last time point tested was 108 weeks 
post-infection, Figure 2.1) (Moore, et al., 2009a; Gray, et al., 2011a). Viral escape was 
detected by 26 weeks post-infection, as a result of a glycan introduced at position 339 and 
a Glutamic Acid (E) to Lysine (K) change at either position 343 or 350. Escape was 
followed by a second neutralization response targeting the V1V2 region (Moore, et al., 
2009a; Gray, et al., 2011a). The strain-specific antibody (CAP88-CH06) responsible for 
the C3-V4 neutralization was isolated at 34 weeks post-infection as an IgA1. The detection 
of the mature CAP88-CH06 antibody with 8.8% divergence in the IgA sequences from 17 
- 121 weeks post-infection in this study is consistent with the observation of plasma 
 107 
neutralization of the C3-V4 region despite viral escape (Moore, et al., 2009a; Gray, et al., 
2011a). However we detected transcripts identical to CAP88-CH06 at 5 and 8 weeks post-
infection even though the earliest plasma neutralization response was at 15 weeks post-
infection. We have previously noted inconsistent neutralization at 11 weeks (unpublished) 
suggesting that the TZM-bl neutralization assay used may not be sensitive enough to detect 
low levels of neutralization or that levels of antibody circulating at 5 and 8 weeks post-
infection were insufficient to cause neutralization of the virus.   
 The ability of an antibody to acquire 8.8% SHM within 5 weeks of HIV infection 
as we observed with CAP88-CH06 has been noted in other studies. Analysis of autologous 
responses against gp41 during acute HIV-1 infection showed SHM levels averaging 5% 
after 17 to 30 days post-infection, with some responses having as much as 15% SHM 
(Liao, et al., 2011). In non-human primate studies, antibodies with an average of 4-7% 
divergence were obtained from 6 weeks post SHIVAD8-infection, with one animal having 
an average of 13.2% SHM after 8 weeks post-infection (Francica, et al., 2015). Antibodies 
against influenza vaccination from newly recruited B-cells had on average 6.4% 
divergence after 7 days, with some antibodies having as high as 10% SHM (Wrammert, et 
al., 2008). Likewise antibodies elicited following the Pneumovax®23 had on average 6.6% 
SHM after 7 days (Smith, et al., 2013). We confirmed the presence of mature CAP88-
CH06 transcripts at both 5 and 8 weeks post-infection through the re-amplification of these 
time-points and re-sequencing with two separate MiSeq runs. These data suggest that upon 
HIV infection the CAP88-CH06 UCA acquired 8.8% SHM within 5 weeks and thereafter 
arrested its evolution. A study on early antibody responses to HIV infection has showed 
that many gp41-targetting antibodies were polyreactive and bound bacterial antigens (Liao, 
et al., 2011). This data suggested that these responses were a result of a memory response 
to non-HIV-1 antigens that was activated by HIV. Thus it is also a possibility that this 
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lineage may have been present prior to HIV infection and became activated upon infection. 
Pre-infection samples were not available from this participant to explore this possibility, 
however, polyreactivity of this lineage could be tested.  
 The sequence with very low divergence (0.3%) is likely to represent a close relative 
of the CAP88-CH06 UCA. The primers used to amplify these antibodies contained both a 
Valine (V) and Leucine (L) at position 2, thus the UCA is likely to have a Leucine at this 
position as is found in the germline IGHV4-39 sequence. The presence of this sequence at 
5 weeks could be due either to plasma cells and/or memory cells in response to early HIV 
infection (before 5 weeks post-infection). We were not able to distinguish between plasma 
and memory responses since total RNA was isolated from PBMCs.   
 The lack of intermediate IgA sequences between the putative UCA and mature 
antibody might suggest that the B-cell remained in the germinal centre acquiring mutations 
through SHM before leaving the lymph node expressing the high affinity B-cell receptor. 
Alternatively, intermediates could have been missed as a result of limited sequencing depth 
or due to our rigorous quality control criteria. One IgA sequence obtained at 34 weeks 
post-infection showed 9.1% divergence suggestive of some evidence of evolution of the 
IgA transcripts. However, since transcripts of the 8.8% CAP88-CH06 antibody were 
detected after this time-point (at 38 and 121 weeks), the 9.1%-divergent sequence could 
also be the result of sequencing or PCR error that was not corrected through the two-step 
clustering process or an off-track antibody that later disappeared. Additional investigations 
including expressing this more mutated antibody would help address this question.  
 Indels have been identified in a number of bNAbs (Wu, et al., 2010; Walker, et al., 
2011). A study examining indels in a large number of HIV antibodies showed that these 
were associated with chronic HIV infection and not restricted to bNAbs (Kepler, et al., 
2014). In this study we reveal that indels are also found in strain-specific lineages. 
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Furthermore neutralization of CAP88-CH06 was enhanced by the 2 amino acid insertion in 
the CDRH2 (data unpublished). Mutations in the framework regions have also been found 
to be important for neutralization (Klein, et al., 2013). Within the CAP88-CH06 lineage 
we observed many mutations within the third framework (FR3). However, the affects of 
these mutations on neutralization are yet to be established. 
 The presence of both IgA and IgG isotypes suggest a complex process of B-cell 
activation, maturation and class-switching within this lineage. During the process of class-
switch recombination some of the constant region genes are spliced out of the genome in 
an irreversible manner. The order of the constant region genes in the genome therefore 
determines whether certain class-switches can occur, enabling a switch forward but not 
backward. The order of the constant region genes are IgM/IgD, IgG3, IgG1, IgA1, IgG2, 
IgG4, IgE and IgA2 (Kinoshita, et al., 2001). The lack of clonally related IgG transcripts at 
5 and 8 weeks p.i. and the identification of an identical sequence at 11 weeks p.i. in both 
the IgA and IgG isotypes suggest that the IgG antibodies arose some time between 8 and 
11 weeks post-infection and that the IgA antibodies were present before the IgG. Since it 
would not be possible to class-switch from an IgA1 to an IgG1 or IgG3 it is likely that the 
IgG transcripts in this lineage are IgG2. Thus following activation (by the virus) between 
8-11 weeks, the B-cell moved to a germinal centre where it underwent affinity maturation 
and class-switched from an IgA1 to an IgG2 isotype. Teasing apart the class-switches and 
isotype specificity would require re-sequencing of the lineage using different IgA and IgG 
primers which would enable one to distinguish between the different IgA and IgG isotypes.  
 It is unclear why CAP88 never developed neutralization breadth ever after 5 years 
of infection. The CAP88-CH06 mAb isolated from this individual did not show high level 
of somatic hypermutation or long CDRH3 associated with bNAbs. This mAb also showed 
limited evolution and disappearance of the IgG isotype. Studies are ongoing to determine 
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the interplay between the virus and antibody in CAP88. Two previous longitudinal studies 
on individuals who develop bNAbs have shown that viral diversity preceded the 
emergence of breadth (Liao, et al., 2013; Doria-Rose, et al., 2014). More specifically 
mAbs from the CAP256-VRC26 lineage able to tolerate a diversity of immunotypes within 
the epitope show the greatest neutralization breadth (Bhiman, et al., 2015). Virological 
studies in CAP88 may shed light on why this antibody failed to develop breadth.  
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2.6. CONCLUSIONS 
We have studied the evolution of an IgA1 autologous strain-specific antibody (CAP88-
CH06) during HIV-1 infection. This antibody targets the C3-V4 region of gp120 and 
plasma neutralization was first detected at 15 w.p.i. The putative unmutated common 
ancestor of this lineage was observed at 5 and 8 w.p.i as an IgA isotype. Transcripts 
identical to CAP88-CH06 were observed within all seven time-points sequenced. The 
presence of CAP88-CH06 sequences well after viral escape (over 2 years post-infection) 
was consistent with plasma neutralization of this region within CAP88, from which this 
antibody was isolated. The IgA sequences showed very little evidence of evolution during 
infection. An identical sequence was observed as both an IgA and IgG isotype at 11 weeks 
post-infection and likely represents a BCR that was activated between 8-11 weeks, which 
gave rise to a transient clonally related clade of IgG antibodies. The IgG isotype could be 
targeting quasispecies circulating during infection, which disappears when the V1V2 
neutralization response is well established. The lack of continued evolution of the IgA 
isotype and the disappearance of the IgG isotype could be the reason why this autologous 
antibody lineage failed to produce breadth later in infection.   
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3.1. ABSTRACT 
The HIV-1 envelope is surrounded by glycans that are crucial for structural integrity as 
well as protecting conserved regions from host antibody responses. However, these 
glycans are also often the targets of broadly neutralizing antibodies that emerge in some 
HIV-infected individuals many years after infection. We studied the IgG anti-glycan 
antibody profiles of 20 HIV-negative and 27 HIV-positive women from the CAPRISA 002 
and 004 cohorts (this included 12 individuals who developed broadly neutralizing 
antibodies and 13 individuals who did not), with the aim of determining whether anti-
glycan antibodies are associated with HIV-1 infection or specific to individuals who 
develop broadly neutralizing antibodies. Amongst the HIV-negative individuals, IgG anti-
glycan antibodies fluctuated over a three year period but were nevertheless highly 
correlated within a single individual. In contrast, HIV-positive individuals had elevated 
levels of antibodies that bound high mannose N-linked glycans including Man8 that 
increased over time, peaking at three years of infection. Competition experiments using 
gp120 protein confirmed that at least a proportion of these mannose-specific antibodies 
were HIV-1 specific. In addition we observed high levels of IgG binding to Tn-peptides 
and glycolipids throughout HIV infection. However, the levels of these glycan-binding 
antibodies were not different between individuals who did and did not develop broadly 
neutralizing antibodies. This indicated that elevated levels of glycan-binding antibodies are 
a response to HIV-1 infection rather than specific to individuals who develop broadly 
neutralizing antibodies suggesting that the epitopes of broadly neutralizing antibodies are 
not uniquely immunogenic.  
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3.2. INTRODUCTION 
The HIV envelope is highly variable, complex and undergoes various conformational 
changes before and after attachment to the CD4 receptor on T-cells, the target cells during 
infection (Pancera, et al., 2014). The envelope is covered in viral spikes made up of 
trimeric gp120 and gp41 glycoproteins (Pancera, et al., 2014). gp120 binds the CD4 
receptor on the host's cell membrane enabling viral entry, while gp41 forms a link between 
gp120 and the viral membrane (Pancera, et al., 2014). Both gp120 and gp41 are heavily 
glycosylated with between 25-30 N-linked glycosylation sites that account for half of the 
molecular mass of the trimer, known as the glycan shield (Wang, 2013; Pancera, et al., 
2014). Although glycans are attached to the viral envelope through the host cell 
glycosylation pathways, they lack the typical processing methods seen in the host 
glycosylation pathways, resulting in inefficiently trimmed glycans (Bonomelli, et al., 
2011). The glycan shield on trimeric gp120 is mostly comprised of densely packed high 
mannose, particularly Manα1-2Man terminating glycans such as Man6-9GlcNAc2, and 
complex N-linked glycans although some O-linked glycans do occur (Zhu, et al., 2000; 
Doores, et al., 2010b; Go, et al., 2013). In addition to protecting immunogenic sites on the 
virus, these glycans are also essential for glycoprotein folding and are thus often conserved 
(Bonomelli, et al., 2011; Pancera, et al., 2014). 
 HIV-1 infection has been associated with a wide range of B-cell dysfunctions, 
including hypergammaglobulinemia (increased levels of circulating IgG), polyclonal 
activation, malignancies, exhaustion and an increase in subsets of B-cells not found in 
healthy individuals (Moir, et al., 2014). Many of the polyclonal B-cell responses are not 
HIV-specific, however, antibodies against HIV-1 do occur throughout infection (Morris, et 
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al., 1998; Tomaras, et al., 2008). The earliest antibody responses to HIV-1 can be detected 
from ~12 days post-infection and although they are able to bind gp41 on the HIV-1 viral 
spike they are not able to neutralize the virus (Tomaras, et al., 2008; Euler, et al., 2012). 
These responses are typically followed by non-neutralizing antibodies that bind monomeric 
gp120 approximately 2 weeks later (Euler, et al., 2012). The first neutralizing antibodies 
can be detected from approximately 3 months post-infection and are typically strain-
specific (only neutralize the infecting virus) and target variable regions on the viral 
envelope (Euler, et al., 2012; Moore, et al., 2015). The most relevant antibodies against 
HIV-1 in terms of vaccine development are broadly neutralizing antibodies (bNAbs), 
which are capable of neutralizing numerous strains of HIV-1 due to their affinity for 
conserved epitopes on the envelope (Moore, et al., 2015). These can be detected in natural 
HIV-1 infection from 2 years post-infection and only in approximately 15-30% of infected 
individuals (Euler, et al., 2012; Moore, et al., 2015). bNAbs typically target five sites on 
the viral spike which are the CD4 binding site on gp120, the membrane proximal external 
region (MPER) of gp41, the C-sheet of the V1V2 domain on gp120, V3/C3 site on gp120 
and the interface between gp120 and gp41 (Wibmer, et al., 2015).  
 Despite the glycan shield serving as a protective barrier against antibody responses, 
some bNAbs, such as 2G12, PG9, PG16, PGTs121-123, PGTs125-131, PGT135 and 
PGTs141-145 are able to neutralize various strains of HIV by binding glycans in the C-
sheet of V1V2 domain and the V3/C3 site on gp120 (Wang, 2013; Moore, et al., 2015). 
2G12 was the first identified bNAb capable of binding glycans and thus most widely 
studied (Trkola, et al., 1996). It however has fairly limited breadth and potency, while 
PG9, PG16 and the PGTs form some of the most broad and potent bNAbs, with PGT121-
123 and PGT125-128 being the most potent of the glycan-binding bNAbs (Walker, et al., 
2011; Wibmer, et al., 2015). 2G12, PGT121-123, PGT125-131 and PGT135 target the 
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N332 supersite on the V3 and V4 loop of gp120, with 2G12, PGT125-131 and PGT135 
binding high mannose N-linked glycans such as Man7-9 and PGT121-123 binding complex 
type glycans such as A2, N2 and NA2 (Mouquet, et al., 2012; Wang, 2013; Wibmer, et al., 
2015). PG9, PG16 and PGT141-145 target high mannose N-linked glycans at the N160 site 
of V2 region of gp120 with PG9 and PG16 having additional contacts with complex 
sialylated N-linked glycans at N156 or N173 (McLellan, et al., 2011; Walker, et al., 2011; 
Pancera, et al., 2013).  
 Over the years glycan arrays have been developed to study the glycan-binding 
properties of serum antibodies (Von Gunten, et al., 2009; CFG, 2014). These have proven 
to be particularly useful in determining the types of glycan structures that are bound by 
HIV-1 bNAbs (Walker, et al., 2011; Mouquet, et al., 2012; Shivatare, et al., 2013). In 
addition anti-glycan antibody responses in sera of non-human primates after Ad5hr-SIV 
vaccination and SIV infection (Campbell, et al., 2013) and potential HIV vaccine 
responses in rabbits have been assayed on arrays (Luallen, et al., 2008; Astronomo, et al., 
2010; Dunlop, et al., 2010). Longitudinal human sera studies on glycan arrays are usually 
limited to 1-3 months and since bNAbs take years to develop during infection it is 
important to understand anti-glycan antibody profiles in humans over greater time frames.  
 Here we study serum anti-glycan antibody profiles of HIV-positive individuals 
(including 12 individuals who make broadly neutralizing antibodies during infection and 
13 individuals who do not) before and after infection for three years. We have previously 
mapped the plasma antibody responses in 8 of the 12 individuals who make broadly 
neutralizing antibodies, of which 6 target glycans at the V3, V2 or MPER. Our aim was to 
determine whether elevated levels of anti-glycan antibodies are a response to HIV infection 
or are unique to individuals who make bNAbs. This information might guide the design of 
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an immunogen needed for an effective HIV vaccine that stimulates glycan reactive 
antibodies. 
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3.3. METHODS AND MATERIALS 
3.3.1. Serum Samples 
 Serum samples used in this study were obtained from the Centre for the AIDS 
Programme of Research in South Africa (CAPRISA) CAP002 Acute Infection Study (Van 
Loggerenberg, et al., 2008) and the CAP004 Tenofovir Gel Trial (Abdool Karim, et al., 
2010) cohorts. These studies involved adult (> 18 years) women of African ancestry, with 
a high risk of HIV infection that were being followed in urban and rural clinics in 
KwaZulu-Natal, South Africa. Sera from 47 women (27 HIV-positive and 20 HIV-
negative) were obtained from four time points (pre-infection and yearly for 3 years).  
 The HIV-positive individuals (infected with HIV-1 subtype C) were classified 
according to their plasma neutralization breadth at 2-3 years post infection. Those with 
broadly cross-neutralizing activity were capable of neutralizing 33-94% (median 53%) of a 
panel of 18 viruses (referred to as BCN individuals) and those with no broadly cross-
neutralizing activity, neutralized 0-11% of the viruses (referred to as non-BCN 
individuals). Those who neutralized 11-30% were termed intermediate neutralizers. The 18 
viruses used in the panel were made-up of six subtype A, six subtype B and six subtype C 
viruses, of which two subtype C viruses were isolated from the women in this cohort. Of 
the 27 HIV-positive individuals used in this study, 12 were BCN, 13 were non-BCN and 
two were intermediate neutralizers. The neutralization assays were done routinely in the 
HIV virology laboratory at the National Institute for Communicable Diseases (NICD) and 
data provided for this study. Since high viral loads at 6 months post-infection are 
associated with the development of bNAbs (Gray, et al., 2011b) all BCN and non-BCN 
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individuals were matched based on their viral load. Information regarding breadth, 
duration of infection and viral loads for these individuals can be found in Appendix, 
Supplementary Table 3.1. Samples from 20 HIV-negative individuals were used as a 
control to assess normal fluctuations in glycan-binding over a three-year period. All human 
serum samples were heat-inactivated, for 30 minutes in a 56°C water bath, prior to binding 
on the glycan arrays, as is standard procedure when working with serum or plasma and 
shown not to affect antibody function (Montefiori, 2009).  
 Both the parent study involving the CAPRISA cohorts and this particular study 
were granted ethics clearance under the following certificate numbers: M080470 for the 
parent study and M111104 for this study. 
 
3.3.2. Array Fabrication and Binding 
Glycan array fabrication and binding assays were done in the Chemical Biology 
Laboratory at the National Cancer Institute in Frederick, MD, USA as part of a Fogarty 
traineeship with Dr Jeff Gildersleeve. Sudipa Chowdhury and Shea Wright performed 
repeat assays and additional experiments under the supervision of Dr Jeff Gildersleeve, Dr 
Christopher Campbell and Dr Saddam Muthana.  
 These glycan arrays were previously used to assess anti-glycan antibody responses 
in non-human primates after SIV vaccination and infection (Campbell, et al., 2013). In this 
study arrays were fabricated as described (Campbell, et al., 2010) with  the exception of 
the addition of a washable fluorescent dye, DyLight™649 (0.7 µg/mL, ThermoScientific), 
to the print buffer as an indicator of successful liquid deposition and spot morphology and 
Triton X-100 concentration was 0.0001% instead of 0.006%. The array format and binding 
assay was analysed for reproducibility and validated with numerous antibodies and lectins 
 122 
as previously described (Manimala, et al., 2005; Manimala, et al., 2006; Manimala, et al., 
2007; Oyelaran, et al., 2009; Campbell, et al., 2010; Wang, et al., 2014b).  
 The arrays were composed of 337 components (of which 245 were unique), 
including N-linked carbohydrates, glycolipids, and glycopeptides (for a full list of array 
components, see Appendix, Supplementary Table 3.2). Of the 337 array components, ten 
were controls (BSA, HSA, linkers used to attach the glycans to the glass slides and the 
fluorochromes used to detect antibody binding) that were used to assess the technical 
reproducibility of the arrays and were excluded from downstream analysis. Prior to each 
experiment, slides were pre-scanned on a Genepix 4000A microarray scanner (Molecular 
Devices Corporation) and analysed with Genepix Pro 6.0 for technical faults. If the arrays 
were found to be of good quality a 16-well module (Grace Bio-Lab) was affixed to the 
slide to create 16 independent array wells allowing 16 samples to be tested per array.  
 The slides were blocked overnight at 4°C with 3% BSA (w/v) in PBS and washed 6 
times with PBST. Samples were diluted in PBST buffer containing 3% bovine serum 
albumin (BSA, Sigma) and 1% human serum albumin (HSA, Sigma). 50 µL of each 
sample was run in duplicate on two different wells on different slides. All samples were 
then incubated at 37°C with gentle agitation (100 RPM) for 4 h. After washing 3 times 
with PBST, bound antibodies were detected by incubating with DyLight™549-conjugated 
goat anti-human IgG (Jackson ImmunoResearch Laboratories, Inc.) diluted 1:500 in PBS 
containing 3% HSA and 1% BSA for 2 h at 37 °C with gentle agitation. After washing 7 
times with PBST, slides were removed from modules, immersed in wash buffer for 5 min, 
and centrifuged at 1000 rpm for 5 min. 
 Seven well-characterised bNAbs were used to assess the ability of the glycan arrays 
to detect HIV-specific glycan-binding. PG16 and 2G12 were obtained from the NIH AIDS 
Reagent Program (NIH AIDS Reagent, 2013). PGT121, PGT125, PGT126, PGT128 and 
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PGT130 were provided by the IAVI's Neutralizing Antibody Center (Scripps Research 
Institute, La Jolla, CA (IAVI, 2013)). 
 Reference serum, consisting of pooled human sera, used as controls to assess 
reproducibility of the arrays, was purchased from Valley Biomedical Products and Services 
(Winchester, VA).  
 
3.3.3. Image Analysis and Data Processing  
Slides were scanned at 10µm resolution with a Genepix 4000A microarray scanner 
(Molecular Devices Corporation) and analysed with Genepix Pro 6.0 software as 
previously reported (Campbell, et al., 2010). Spots were defined as circular features with a 
diameter of 90µm. The background-corrected median was used for data analysis, and 
technical faults (e.g. missing spots) were flagged and excluded from further analysis. To 
minimize the impact of noise in our comparisons, spots with intensities lower than 150 
were considered too low to be measured accurately and were set to 150.  
 For human serum sample data, duplicate spot averages were calculated and 
normalized to the reference samples. Log-transformation (base 2) was applied for each 
slide, and the final data value was obtained from the normalized average of data from both 
slides. For HIV-1 bNAbs, the average of duplicate spots was calculated. 
 
3.3.4. gp120 Competition Assay  
To determine if glycan-binding profiles were HIV-specific, sera with high Man8 binding 
levels were incubated with purified monomeric ConC gp120 (100 µg/mL) or PBS alone at 
room temperature for 15 minutes. Monomeric ConC gp120 was expressed as described in 
Gray et al., (Gray, et al., 2011a) and purified using a Galanthus Nivalis lectin (Stratagene). 
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Sera incubated with or without gp120 were run on the same glycan array slide to minimize 
variability. A total of three wells (six replicate spots) were analysed. 
 Since samples incubated with or without gp120 could be compared directly to each 
other, a well-to-well signal comparison was performed during data analysis to account for 
batch-to-batch and slide-to-slide variability. After flagging and excluding data with 
technical faults (e.g. missing spots) from analysis, the average relative fluorescence unit 
(RFUs) for each individual well was calculated using the two duplicate spot signals. To 
adjust for printing defects, the maximum and minimum averaged values were determined. 
If the values for a particular array component differed by more than 20-fold, all data from 
that array component were removed from further analysis. From the remaining data, the 
median signal was calculated, adjusted for PMT (photomultiplier tube) voltage, and signals 
below threshold were set to 150 as described above. 
 
3.3.5. Statistical and Data Analysis 
Fold change differences between any two time points, calculated by subtracting one time 
point (e.g. 1 year) from another (e.g. year 0) and unlogging the data (2(logged value)), were 
used to assess the differences in glycan-binding over time for the HIV-negative samples. 
Two different techniques were created to assess the glycan-binding profiles during HIV 
infection: 1) comparing the levels of glycan-binding in the HIV-positive samples to HIV-
negative samples and 2) comparing the levels of glycan-binding during HIV infection to 
matched pre-infection samples.  
 In Method 1, an HIV-negative range of IgG glycan-binding was determined for 
each glycan from all pre-infection and HIV-negative samples. Glycans with binding levels 
≥2-fold than the top-binding observed in the HIV-negative range in two or more HIV-
infected individuals were taken as significant. This method involved all time points from 
 125 
the 20 HIV-negative individuals, 12 pre-infection samples and all post-infection samples 
from 27 HIV-positive individuals.  
 Method 2 focused on 11 HIV-positive individuals that had a pre-infection sample 
and two consecutive HIV-positive time points. All glycans that showed ≥2-fold increases 
in glycan-binding over time compared to pre-infection in at least two individuals were 
considered significant.  
 A Student's paired t-test was used to compare the binding profiles of three-year 
post-infection sera from eight individuals incubated with PBS or gp120 and fold-change 
differences were calculated between groups. Glycans with p-value ≤ 0.05 were considered 
significant. A Student's two-sampled unpaired t-test was used to calculate the differences 
between the BCN and non-BCN groups yearly post-infection. Bonferroni correction for 
multiple testing was applied to comparisons between BCN and non-BCN individuals. 
Glycans with p-values ≤ 0.05 were considered significant.   
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3.4. RESULTS 
3.4.1. Detection of bNAb Binding on Glycan Arrays 
Glycan arrays consisting of 337 (of which 245 are unique) array components spotted onto a 
glass slide were used to study longitudinal serum anti-glycan IgG binding profiles from 
HIV-negative and HIV-positive individuals. The components on the array included N-
linked glycans, Tn-peptides, glycans derived from glycolipids and glycoproteins. Ten 
controls (including BSA, HSA, the linkers used to attach the glycans to the glass slides and 
the fluorochromes (Cy3 and Cy5) used to detect binding) were removed from downstream 
analysis. These arrays were designed to capture predominant glycan antibodies and have 
previously been used to assess the anti-glycan antibody responses to SIV-vaccination and 
SIV-infection in non-human primates (Campbell, et al., 2013). Prior to the analysis of 
serum anti-glycan IgG profiles we assessed binding of HIV-specific anti-glycan antibodies 
using well-characterised bNAbs. In order to compare the glycan-binding for these bNAbs 
to other glycan array studies only glycan hits with relative fluorescence values (RFU) ≥ 
3000 (log211) were considered, since this was the cut-off used in the previous studies.  
 The seven bNAbs used were 2G12, PG16, PGT121, PGT125, PGT126, PGT128 
and PGT130. The majority of these bNAbs (2G12, PGT125, PGT126, PGT128 and 
PGT130) target high mannose N-linked glycans on the V3 loop of gp120. PGT121 targets 
complex glycans on the V3 loop of gp120 and PG16 targets both complex and high 
mannose N-linked glycans on the V2 loop of gp120. Six of the seven bNAbs showed 
binding above log211 for least two glycans (Figures 3.1A and C). The hits observed for 
these bNAbs were similar to what has been reported in other glycan array experiments 
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(Walker, et al., 2011; Mouquet, et al., 2012; Shivatare, et al., 2013;  CFG, 2014), shown in 
Figure 3.1B. The only bNAb with no binding above 3000 (log211) was PG16, which is 
known to bind a complex trimer specific epitope. A previous study also showed no binding 
on an array due to the complexity of the epitope (Shivatare, et al., 2013). We detected 
PGT121 binding to NA2 (A2, A2F and N2 previously associated with PGT121 were not 
on this array (Walker, et al., 2011; Mouquet, et al., 2012; CFG, 2014)). The majority (5/7) 
of the bNAbs bound high mannose N-linked glycans Man8 and Man9. In addition to the 
glycans previously described we found binding to (Tg (Thyroglobulin), FABP (fatty acid 
binding protein), ManT (branched Man3 glycan) and Gal-α (galactose-α). Binding to Tg 
was observed for 3/7 bNAbs (PGT125, PGT128 and PGT130), whereas the remaining 
three were recognised by single bNAbs (Figure 3.1).  
 
3.4.2. Natural Fluctuations in Anti-Glycan IgG Antibodies in HIV-Negative  
 Individuals 
Prior to the identification of HIV-specific glycan-binding responses, we aimed to 
understand natural serum IgG anti-glycan antibody variation over a three-year time frame. 
Previous studies have shown that fluctuations over 1-3 months in healthy individuals are 
small, and that changes greater than 2.6-fold occur infrequently (Oyelaran, et al., 2009). 
However, variations in anti-glycan antibody levels over 1-3 year time frames have not been 
studied. Therefore, we profiled serum samples from 20 HIV-negative individuals (from the 
CAPRISA 002 and 004 cohorts) followed yearly for 3 years (time points 0, 1, 2, and 3 
years). 
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 Overall, IgG antibody profiles from the same individual at different time points 
were highly correlated, with Pearson correlation coefficients typically ≥0.9. An example of 
such is shown in Figure 3.2 where the glycan-binding profiles of CAP39 during year 0 and 
year 1 have an r2 value of 0.90. Although profiles for the same patient at different time 
points were highly correlated we observed fluctuations across all time points at levels 
greater than those seen over 1- 3 months. For example, across all HIV-negative individuals 
and all time points, 2.6-fold changes were observed for about 10% of the glycans, 4-fold 
changes were observed for about 3% of the glycans and 10-fold changes were observed for 
less than 0.5% of the glycans. 
 
Figure 3.2: IgG antibody profiles within 
individuals 
Shown are the log2 binding values (representing the 
RFU values) for CAP39 at year 0 (x-axis) and year 1 
(y-axis).  
 
 
 
 
 
 
 
 
 Fluctuations were not consistent across individuals with some (CAP1 for example) 
having few glycan changes between time points and others (CAP39 and CAP54) having 
drastic changes in glycan-binding between time points (Figure 3.3). In addition some 
individuals (CAP11 and CAP17) had fewer than 10% of the glycans increasing or 
decreasing ≥2.6-fold, while others (CAP15 and CAP39 for example) had over 25% of the 
glycans either increasing or decreasing ≥2.6-fold between time points.  
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 While substantial changes could be observed in certain individuals at certain time 
points, anti-glycan antibody signals oscillated throughout the three years, rather than 
continually increasing or decreasing. The results suggest a fluctuation about a steady state 
level for essentially all the antibody populations that we were measuring in the HIV-
negative individuals. Thus we concluded that comparing a single time point between HIV-
infected and pre-infection samples could give rise to a high proportion of false positives or 
perceived HIV-responses, especially if small numbers of HIV-infected individuals were 
tested. 
 
3.4.3. Induction of IgG Anti-Glycan Antibodies During HIV infection 
Based on the level of fluctuations observed within the HIV-negative samples over time we 
used two methods to identify responses to HIV-1 infection in the longitudinal HIV-positive 
samples. In the first method, an HIV-negative binding range was defined for each of the 
glycans on the array based on the levels of binding to these glycans for each of the HIV-
negative samples. Glycans that were ≥2-fold higher in ≥ two individuals in the HIV-
positive time points compared to the HIV-negative binding range were selected as having a 
potential HIV-response. The second method focused on 11 individuals with pre-infection 
and two or more consecutive post-infection time points. Glycans were selected if they were 
increased ≥2-fold in two consecutive HIV positive time points in ≥2 people compared to 
their matched pre-infection sample.  
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Method 1: Glycans with Elevated Levels of Binding in HIV-Positive Compared to HIV-
Negative Samples  
All time points from the 27 HIV-positive individuals were compared to the level of 
binding in the HIV-negative samples (20 HIV-negative individuals over three years and 12 
pre-infection samples). Fifteen glycans out of 327 (4.6%) were ≥2-fold higher in ≥ two 
HIV-positive individuals at any time point compared to the HIV-negative range. These 15 
glycans included four N-linked glycans, two glycolipids, six Tn-peptides, one Lewis 
antigen, one glycoprotein and one non-human glycan, listed in Table 3.1. Of the four N-
linked glycans three are high mannose glycans (Man5, Man8 and Man9), all of which have 
been associated with bNAbs (Figure 3.1). Interestingly, the average fold-change for the N-
linked mannose glycans increased with duration of infection, up to 14.9-fold at three years 
for Man5, as well as in the number of individuals with elevated binding during infection. 
Three glycans (GT3-Sp - 03, Ac-A-Tn(Thr)-S-G - 05 and Ac-S-Tn(Thr)-G-G - 03) had ≥2-
fold increases throughout infection. The majority of these changes were seen in one or two 
individuals at one and three years post-infection.  
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Table 3.1: Glycans with increased binding in HIV-positive compared to HIV-negative 
samples  
Glycan Type Glycan Name CAPRISA ID 
One Year 
Post-Infection 
Two Years 
Post-Infection 
Three Years 
Post-Infection 
n 
Fold 
above 
HIV-
negatives 
n 
Fold 
above 
HIV-
negatives 
n 
Fold 
above 
HIV-
negatives 
N-linked 
Man5 
221, 295, 
312   1 3.8 2 14.9 
Man8 
65, 137, 
200, 206, 
221, 244 
  3 2.5 4 6 
Man9 8, 200, 221   1 3.3 3 5.1 
NA3 221, 310 1 2.3   1 4 
Tn-peptides 
Ac-A-Tn(Thr)-
S-G - 05 
206, 256, 
332 1 2.8 1 2 2 2.2 
Ac-A-Tn(Thr)-
S-G - 08 206, 256 1 3   1 2 
Ac-S-Tn(Thr)-
Tn(Thr)-G - 05 8, 256 1 3   1 2.9 
Ac-S-Tn(Thr)-
Tn(Thr)-G - 09 8, 283 1 2.3   1 2.3 
Ac-S-Tn(Thr)-
G-G - 03 
206, 256, 
312, 332 1 2.1 2 2.2 2 2.4 
Ac-P-Tn(Thr)-
T-G - 08 248, 256 2 2.1     
Glycolipids 
GT2-Sp - 08 314, 322 1 2.8   1 2.1 
GT3-Sp - 03 88, 225, 314, 322 2 3 2 3.2 2 3.4 
Glycoprotein Hsp90 (heat shock protein) 8, 256 1 3.4   1 3.6 
Lewis 
Antigen 
LeX 
(monomeric) 229, 312 2 2.5     
Non-human Fuc-b - 04 248, 314 2 2.6   1 2.2 
Highlighted in blue are the glycans that were also bound by bNAbs on the array. "n" represents the 
number of individuals with elevated glycan-binding levels. Fold values represent the average fold 
above the HIV-negative samples for all individuals with ≥2-fold binding for each glycan. 
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Method 2: Glycans Elevated in HIV infection Compared to Matched Pre-Infection Samples 
Eleven individuals (out of 27) had pre-infection samples and two consecutive post-
infection time points and were used for this method. Based on these 11 individuals, 39 
glycans appeared to increase with HIV-1 infection, and are listed in Table 3.2.  
 N-linked glycans account for 23% (9/39) of the selected glycans followed by Tn-
peptides (21%, 8/39) and glycolipids and glycoproteins both accounting for 13% (5/39). 
Ten of the 39 glycans (26%), including Man8, were also selected in Method 1 and/or bound 
by some of the bNAbs tested (Figure 3.1, highlighted in Table 3.2). Although many of 
these glycans were not selected in Method 1 they are related to those previously selected. 
For example, GT3-Sp - 07 has the glycan as GT3-Sp - 03 with a larger number of copies 
per molecule of BSA spotted onto the array (for higher density), and LacNac-Man5 is 
related to Man5. The r2 values for each of these glycans ranged from 0.03 to 0.47, with 
NGA5B (N-linked glycan) having the lowest and Hep-5000 (Heparin polysaccharide) 
having the highest.  
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Table 3.2: List of glycans with elevated levels during HIV-1 infection compared to 
matched pre-infection samples 
Type of Glycan Number of Glycans Name of Glycan 
N-linked 9 Man1 - 04, Man1 - 12, GlcNAc-Man3, Man3, LacNAc-Man5, Man8, NA4, NGA2B, NGA5B 
Tn-peptides 8 
Ac-A-Tn(Thr)-S-G - 05, Ac-P-Tn(Thr)-T-G - 05,  
Ac-S-Tn(Thr)-A-G - 04, Ac-S-Tn(Thr)-G-G - 03,  
Ac-S-Tn(Thr)-S-G - 24, Ac-S-Tn(Thr)-Tn(Thr)-G - 05,  
Ac-S-Tn(Thr)-Tn(Thr)-G - 09,  
Ac-Tn(Ser)Tn(Ser)Tn(Ser)-G - 03 
glycolipids 5 GD1b, GQ2-Sp - 03, GT2-Sp - 08, GT3-Sp - 03,  GT3-Sp - 07 
glycoproteins 5 Alpha-1-acid glycoprotein, Fetuin (asialo),  OSM (asialo), hsp90, Tg 
TF-peptides 3 
DTVPLPTAHGTSASSTG, 
DTVPLP-TF(Thr)-AHGTSASSTG, 
DTVPLPTAHGT-TF(Ser)-ASSTG 
GAG (heparin) 2 Hep-5000 (Heparin),  Hep-N-acetylated (Heparin-N-acetylated) 
Lewis 2 6'-sulpho-LeA, Sialyl LeA 
non-human 1 Fuc-b - 04 
Sialylated 
carbohydrate 1 DSLNT 
Type  2 
carbohydrate 1 LNnH-11 
GlcNAcb 
carbohydrate 1 Ac-S-Ser(GlcNAcB)-S-G-7 
Glc 
carbohydrate 1 Maltopentaose 
Shown in red are the glycans that were also selected using Method 1 (Table 3.1), in blue are the 
glycans that were also bound by bNAbs (Figure 3.1) and in pink if selected in Method 1 and bound 
by bNAbs. 
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Anti-Glycan Antibodies Capable of Binding gp120  
Since some of the glycans that were elevated in Methods 1 and 2 might be unrelated to 
HIV-1, we used a gp120 competition assay to determine if antibodies that bound these 
glycans were HIV-1 specific. Sera from eight HIV-positive individuals (listed in 
Appendix, Supplementary Table 3.3), with high levels to Man8, were incubated with the 
HIV glycoprotein gp120 prior to glycan array binding. PBS was used as a control and 
differences between PBS and gp120 incubated sera with p-values ≤0.05 were considered 
significant. Any reduction in glycan-binding after gp120 incubation was identified as HIV-
specific.   
 We observed 48 glycans that showed a reduction in glycan-binding and three that 
had an increase in glycan-binding in the gp120-incubated sample compared to the PBS-
incubated sample (listed in Table 3.3). Of the 48 glycans that had a reduction in glycan-
binding following gp120 incubation, 16 (33%) were shown to be elevated in the HIV-
positive individuals compared to the HIV-negative and/or during HIV infection compared 
to pre-infection (highlighted in red in Table 3.3). The majority of these were N-linked high 
mannose glycans and Tn-peptides (12/15, 80%). The p-values and fold-change differences 
observed for all 51 glycans (including gp120 as a control) can be found in Appendix, 
Supplementary Table 3.4.  
 gp120, used as a control on the array, showed a 21.4-fold reduction in median 
binding in the gp120 incubated sera compared to the PBS-incubated sera (Figure 3.4). Of 
the 51 glycans affected by the gp120 assay, 11 (22%) had a ≥2-fold difference between the 
PBS and gp120-incubated samples (Figure 3.4). These eleven glycans are made up of N-
linked high mannose glycans (Man7-9), Tn-peptides, a glycolipid, heparin, blood group 
antigens, a GlcNAc carbohydrate and a carcinoembryonic antigen (CEA). All glycans, 
except CEA, showed a reduction in binding in the gp120-incubated sample compared to 
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the PBS-incubated sample. The highest reduction in glycan-binding was seen in Man8 
(10.9-fold, p-value = 0.007).  
 
Table 3.3: List of glycans significantly affected by the gp120 competition assay 
Type Number of Glycans Name 
N-linked 5 GlcNAc-Man3, LacNAc-Man5,  Man7, Man8, Man9 
Mannose  
5 Man-a - 20, Mana1-6Man-a - 15,  
ManT, G2M4 - 07,  
Galb1-6Man-a - 13 
Tn-peptide 
15 Ac-A-Tn(Thr)-S-G - 05 & 08,  Ac-P-Tn(Thr)-T-G - 05,   
Ac-S-Tn(Ser)-S-G - 04 & 22,  Ac-S-Tn(Thr)-A-G - 04,   
Ac-S-Tn(Thr)-G-G - 03 & 07,  Ac-S-Tn(Thr)-S-G - 04,   
Ac-Tn(Ser)Tn(Ser)Tn(Ser)-G - 03,  Ac-Tn(Thr)-Tn(Thr)-Tn(Thr)-G - 08,   
Ac-T-Tn(Thr)-P-G - 04 & 08,  Ac-V-Tn(Thr)-S-G - 04 & 08 
Glycolipid 3 GM2-Sp - 14, Gb4 - 09 & tetra 
Glycoprotein 3 CEA, fetuin (asialo), hsp90 
Heparin 1 Hep-5000 
Blood Group 4 BG-A1, BG-H1, BG-H2, Globo H 
Lewis Antigen 1 Sialyl LeX 
Fucosylated 2 Fuc-a, Fuc-b 
GalNAc 
carbohydrate 
7 GalNAc-a - 04 & 22, GalNAca1-6Galb - 04, GlcNAca1-4Galb - 03 & 20, 
GalNAc-b - 21, GlcNAc-b - 21 
Glc carbohydrate 1 Glc-b - 23 
GlcNAc 
carbohydrate 
1 3'GN-Di-LacNAc-Sp - 06 
Type 2 
carbohydrate 
3 LacNAc - 22 & trimeric, LNnT - 04 
Highlighted in red are the glycans that were selected in either Method 1, Method 2 and/or bound by 
bNAbs. Highlighted in green are the glycan with elevated binding after gp120 incubation, all other 
glycans showed a reduction in the gp120-incubated samples. 
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 Overall we identified several glycans that were increased in HIV-positive 
individuals compared to HIV-negative individuals and matched pre-infection samples, 
some of which were HIV specific (decreased when incubated with gp120 prior to glycan 
array binding) (listed in Table 3.4). Of these glycans N-linked mannose glycans and 
Heparin (Hep-5000) showed increased levels binding and number of individuals with the 
duration of infection (Figure 3.5). In contrast the Tn-peptides, glycolipids and fucosyl-b 
were elevated throughout HIV-1 infection (Figure 3.6).  
 
Table 3.4: List of glycans that were elevated during HIV infection 
Glycan Type Glycan Name bNAbs Method 1 
Method 
2 
gp120 
assay 
N-linked 
GlcNac-Man3   ✔ ✔ 
LacNac-Man5   ✔ ✔ 
Man7 ✔   ✔ 
Man8 ✔ ✔ ✔ ✔ 
Man9 ✔ ✔  ✔ 
ManT ✔   ✔ 
Tn-peptide 
Ac-A-Tn(Thr)-S-G  ✔ ✔ ✔ 
Ac-P-Tn(Thr)-T-G   ✔ ✔ 
Ac-S-Tn(Thr)-A-G   ✔ ✔ 
Ac-S-Tn(Thr)-G-G  ✔ ✔ ✔ 
Ac-S-Tn(Thr)-S-G   ✔ ✔ 
Ac-Tn(Ser)-Tn(Ser)-Tn(Ser)-G   ✔ ✔ 
Ac-S-Tn(Thr)-Tn(Thr)-G  ✔ ✔  
Glycolipids GT2 
 ✔ ✔  
GT3  ✔ ✔  
Glycoprotein hsp90 (heat shock protein) 
 ✔ ✔ ✔ 
Tg (thyroglobulin) ✔  ✔  
Heparin 
(GAG) Hep-5000 (Heparin) 
  ✔ ✔ 
Non-human Fuc-b-04  ✔ ✔ ✔ 
 
 HIV-specificity was confirmed by a reduction in binding following gp120-
incubation. Although ManT also showed reduced glycan-binding following gp120-
incubation, the levels in the HIV-positive samples were not significantly elevated 
compared to the pre-infection samples (Appendix, Supplementary Figure 3.1A). We 
observed high levels of binding to some of the Tn-peptides in HIV-negative individuals 
(Appendix, Supplementary Figure 3.1 B-E). Likewise, one HIV-negative individual 
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(CAP39 at one year post-infection) also had elevated binding levels to Thyroglobulin (Tg), 
bound by some bNAbs (PGT125, PGT128 and PGT130, shown in Figure 3.1 and 
Appendix, Supplementary Figure 3.1G). Heat shock protein (hsp90) was higher in some 
HIV-positive samples at one year and three years but not at 2 years post-infection 
compared to the HIV-negative and pre-infection samples (Appendix, Supplementary 
Figure 3.1F).  
 
3.4.4. BCN vs. non-BCN Glycan-Binding Profiles 
Since the HIV envelope is covered with glycans and many well characterized bNAbs bind 
these glycans we aimed to determine if elevated levels of anti-glycan antibodies are a 
response to HIV-1 or unique to individuals who develop broadly neutralizing antibodies. 
Thus we compared the log2 binding values for each of the glycans on this array between 
the BCN and non-BCN individuals, across all time points (pre-infection, one, two and 
three years post-infection). Differences with p-values ≤0.05 after Bonferroni correction 
were considered significant.  
 We observed 17/327 glycans (5%) that were significantly lower in the BCN group 
compared to the non-BCN group for all time points (pre-infection and yearly for three 
years post-infection), (Table 3.5 and Figure 3.7). However, when comparing each time 
point separately there were no differences between the two groups. The majority of these 
glycans were sialylated carbohydrates and Lewis antigens. We observed no differences 
between the BCN and non-BCN individuals for the glycans that were elevated during HIV-
1 infection (listed in Table 3.4). 
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Table 3.5: List of glycans significantly lower in BCN vs. non-BCN individuals 
Glycan Type Glycan Glycan Number in Figure 3.7 
Sialylated 
carbohydrates 
3'S(Gc)LeC−Sp − 05 & - 12 1 & 2 
3'SLeC−Sp − 05 & - 12 3 & 4 
9OAc3'SLeC−Sp − 05 & - 12 5 & 6 
3'−KDNLeC−Sp − 04 & - 12 7 & 8 
Lewis antigens Di−LeC−Sp − 06 & 16 9 & 10 LeC−Sp − 06 & - 07 & - 15 11, 12 & 13 
GlcNAc 
carbohydrate 3'GN type1−Sp − 04 & - 16 14 &15 
Non-Human Ara5 16 Galb1−4Gal 17 
Glycans shown are those that were lower in the BCN group compared to the non-BCN group with 
p-values (after Bonferroni correction) ≤0.05.  
 
In summary elevated levels of glycan-binding antibodies were observed within HIV-
infected individuals. These glycans were mostly N-linked high mannose glycans and Tn-
peptides. Some glycans showed increased binding with the duration of infection, while 
others showed elevated levels of binding throughout infection. These elevated levels of 
glycan-binding were observed in both BCN and non-BCN individuals. However, BCN 
individuals showed lower levels of glycan-binding to some sialylated carbohydrates and 
Lewis antigens. 
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3.5. DISCUSSION 
Using a glycan array we have identified glycan-binding antibodies that were elevated 
during HIV infection. These glycans were mostly N-linked mannose glycans, Tn-peptides 
and glycolipids. In particular we observed elevated levels of N-linked high mannose 
binding (Man7-9) with the duration of infection with Man8 having an average of 6-fold 
increases at 3 years post-infection. Tn-peptides and glycolipids were constantly elevated 
throughout infection compared to HIV-negative samples. We also observed lower levels of 
sialylated glycans and Lewis antigens in the BCN group compared to the non-BCN group, 
but no differences between the groups for the glycans that were elevated during HIV-1 
infection. This suggests that elevated levels of glycan-binding antibodies were common in 
HIV-1 infection rather than specific to individuals who make broadly neutralizing 
antibodies. 
 We first used well-characterized bNAbs (2G12, PG16, PGT121, PGT125, PGT126, 
PGT128 and PGT130) to validate the array's ability to detect HIV-related anti-glycan 
responses. We observed the same glycan-binding profiles of these bNAbs on this array as 
those previously described (Scanlan, et al., 2002; Walker, et al., 2011; Mouquet, et al., 
2012; Amin, et al., 2013; Shivatare, et al., 2013; CFG, 2014). In addition we found high 
levels of binding to Tg by PGTs125, 128 and 130 and FABP by PGT126 that have not 
been previously described. We also found high levels of binding to a branched Man3 
(ManT) glycan, which is a fragment of many high mannose glycans. 
 This array has been used previously to assess glycan-binding antibodies following 
SIV-vaccination and SIV-infection, showing human and macaque anti-glycan antibody 
profiles to be similar (Campbell, et al., 2013). In addition they observed few IgM and IgG 
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responses to mannose glycans (Manα1-6Manα and Man6) but significantly elevated levels 
of IgM and IgG binding to Tn-peptides in the sera of macaques following vaccination and 
infection (Campbell, et al., 2013). The lack of elevated binding to the high mannose N-
linked glycans were likely the result of animals being followed for an insufficient length of 
time (just over a year) as high mannose responses in our study were typically seen later in 
infection with the greatest differences observed at 3 years post-infection. Tn-peptides are 
precursors of O-linked glycans and in normal mammalian cells the Tn-portion of the O-
linked glycans are masked during the glycosylation pathway. However, in HIV infection 
the normal glycosylation pathways are altered revealing the Tn-portion of these O-linked 
glycans on the glycan shield (Campbell, et al., 2013). In addition anti-Tn-peptide 
antibodies have been associated with the neutralization of HIV-1 by preventing fusion of 
the virus into infected cells (Hansen, et al., 1991; Hansen, et al., 1992). Other studies using 
these arrays have ruled out competition by lectins such as MBL (mannose binding lectin). 
All array experiments are done using 1:50 diluted sera and the concentration of MBL in the 
sera would be insufficient to bind the glycans on the array (unpublished data). In addition 
the binding of the lectins to the glycans on the array requires calcium and the assay is 
conducted in the absence of calcium (unpublished data). Thus it is unlikely that MBL 
would non-specifically interfere with this assay.  
 Many studies on glycan arrays using human sera have been limited to 1-3 months 
and since bNAbs against HIV-1 typically arise from 2 years post-infection it was important 
to understand natural fluctuations in glycan-binding over a similar time frame. By studying 
the levels of anti-glycan antibodies in HIV-negative individuals yearly for three years we 
observed fluctuations of IgG anti-glycan antibodies throughout the three years, at levels 
that were greater than those observed within 1-3 months (Oyelaran, et al., 2009; Zhang, et 
al., 2010). We also noted that the differences in glycan-binding tended to oscillate over 
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time, rather than a steady increase or decrease and differences were greater in some 
individuals. We note, however, that the HIV-negative individuals studied here are at a high 
risk of contracting infections (Van Loggerenberg, et al., 2008; Abdool Karim, et al., 2010) 
and thus may have higher levels of glycan-binding antibodies. Based on these findings we 
concluded that comparing a single post-infection time point to pre-infection might result in 
false positive associations or perceived HIV-responses and thus we developed two 
methods of identifying anti-glycan antibody responses to HIV.   
 In the first method we compared the level of glycan-binding in the HIV-negative 
and HIV-positive samples and observed 15 glycans that were ≥2-fold elevated in ≥2 
individuals. These 15 glycans included Man5, Man8, Man9, Tn-peptides and two 
glycolipids.  Man5, Man8, Man9 are found on the HIV envelope and have been associated 
with the epitopes of bNAbs against HIV (Scanlan, et al., 2002; Walker, et al., 2011; 
Mouquet, et al., 2012; Amin, et al., 2013; Shivatare, et al., 2013; CFG, 2014). Tn-peptides, 
as previously mentioned, were also elevated in macaque sera following SIV-vaccination 
and infection and are able to prevent fusion of the virus into infected cells (Hansen, et al., 
1991; Hansen, et al., 1992; Campbell, et al., 2013). The glycolipids that were elevated in 
our study are ganglioside glycosphingolipids, which are found on the HIV-1 envelope and 
have been associated with the uptake of HIV-1 into mature dendritic cells (Hatch, et al., 
2009; Izquierdo-Useros, et al., 2012; Puryear, et al., 2012; Izquierdo-Useros, et al., 2014). 
Ganglioside glycosphingolipids on the envelope of HIV-1 attach to the cellular receptor 
Siglec-1 found on mature dendritic cells enabling the incorporation of HIV-1 into the 
dendritic cell and the subsequent transfer to CD4+ T-cells (Izquierdo-Useros, et al., 2014). 
 Our second method compared the anti-glycan-binding levels of 11 individuals 
before and after HIV-1 infection. We found 39 glycans (compared to 15 glycans in the first 
method) that were elevated ≥2-fold in two consecutive HIV-infected samples and in ≥2 
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individuals. These 39 glycans included additional N-linked glycans, Tn-peptides and 
glycolipids as those seen in the first method. We also found elevated binding to 
Thyroglobulin that was also bound by bNAbs on the array. Thyroglobulin is a glycoprotein 
produced by the thyroid gland as part of thyroid hormone production (Hoffmann, et al., 
2007). Thyroid dysfunction has been widely associated with HIV-1 infection as well as 
elevated levels of anti-thyroglobulin autoantibodies in both infected children and adults as 
a result of the thyroid dysfunction (Fundarò, et al., 1998; Hoffmann, et al., 2007; 
Noureldeen, et al., 2012; Ownby, 2012; De Carvalho, et al., 2013).  
 Although eight glycans (18%, 8/45) were identified in both methods, we observed 
more anti-glycan responses in the second method compared to the first. Many of the 
elevated levels of anti-glycan antibodies observed in the second method are likely a 
consequence of HIV infection rather than antibodies binding HIV or may be unrelated to 
HIV since many of the glycans that were elevated in this method were seen at levels 
similar to the HIV-negative individuals. In addition, this method was limited to 11 
individuals with pre-infection samples and likely missed some HIV-responses due to 
reduced sample size.  
 A gp120 competition assay was used confirm HIV-specific anti-glycan antibody 
responses. We observed decreases in binding following gp120-incubation compared to the 
PBS-incubated control sample for N-linked glycans (including Man8), Tn-peptides and 
glycolipids. The greatest difference in binding between the PBS and gp120-incubated 
samples was observed for Man8 with the gp120-incubated sample being 10.9-fold lower 
than the PBS-incubated sample. In addition we observed a 3.1-fold decrease in heparin 
following gp120 incubation. Heparin was also elevated in the HIV-positive samples 
compared to pre-infection and has been observed to inhibit viral infectivity including HIV-
1 (Baba, et al., 1988; Nagumo, et al., 1988; Howell, et al., 1996; Harrop, et al., 1998). 
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Since monomeric gp120 was used for this assay we acknowledge that this would not detect 
antibodies that bind to epitopes in gp41 or those requiring the trimeric structure such as 
MPER, V1V2 and gp120-gp41 interface. A similar assay would need to be conducted 
using trimeric proteins.  
 Comparisons of anti-glycan antibody profiles between BCN and non-BCN 
individuals, highlighted 17 glycans that were lower in the BCN individuals compared to 
non-BCN individuals when all time points (including pre-infection) were grouped. These 
glycans were mostly sialylated carbohydrates and Lewis antigens. There were no 
differences between the groups when comparing each time point separately; suggesting 
that decrease in binding to these glycans was not a consequence of infection. There were 
no differences between the BCN and non-BCN groups for the glycans that were elevated 
during HIV-1 infection, suggesting that elevated levels of glycan-binding antibodies are a 
response to HIV-1 infection rather than specific to individuals who make broadly 
neutralizing antibodies.  
  The antibody specificities of eight BCN individuals in this study have previously 
been mapped to various parts of the HIV envelope glycoprotein (Moore, et al., 2011; 
Moore, et al., 2012; Moore, et al., 2013; Wibmer, et al., 2013). The plasma from six of 
these individuals bind glycans at either N332 on the V3 loop, N160 on the V2 loop or 
N276 on the CD4 binding site. Since antibody responses to the HIV envelope involve five 
different targets (CD4 binding site, MPER, C sheet of V1/V2, V3/C3 and the gp120/gp41 
interface (Moore, et al., 2015)), some of which do not involve glycans, it is likely that 
some of the BCN and non-BCN individuals used in this study target regions on the 
envelope that are not glycan related, and thus differences between the two groups would 
not be observed on the glycan array. In addition we used total serum IgG on the arrays, 
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thus binding and strain-specific antibody responses in these individuals might have diluted 
out the effect of the broadly neutralizing antibody responses. 
 Since some bNAbs target glycans on the glycan shield of gp120 and an effective 
HIV vaccine is likely to require bNAbs, many studies have focused on glycans as potential 
immunogens for vaccine design (reviewed in: Horiya, et al., 2014). Most of these studies 
have focused on Man9 binding of 2G12. Synthetic oligomannose constructs of Man9 have 
been used to assess their affinity to 2G12 and whether they elicit an immunologic response 
as a potential immunogen for vaccine design (Wang, 2013; Horiya, et al., 2014). These 
constructs include divalent cyclic peptides with Man9, tetravalent Man9 clusters, 
heteromultivalent clustering of high mannose glycans clustered with galactopyranoside 
scaffolds, cyclic peptide scaffolds, cholic acid scaffolds, PAMAM dendrons or 
bacteriophage Qβ scaffold (Wang, 2013; Horiya, et al., 2014). Many of these constructs 
have shown affinity for 2G12 but mostly at levels lower than 2G12's affinity for gp120 
(Wang, 2013; Horiya, et al., 2014). Immunogenicity studies of these constructs have 
yielded anti-mannose antibodies but show either low or no cross reactivity with gp120 
(Wang, 2013; Horiya, et al., 2014). Other studies involving Candida albicans have been 
more successful at yielding high mannose binding antibodies (Doores, et al., 2010a). Part 
of the failure of these synthetic glycans to elicit an appropriate cross-reactive response can 
be attributed to the scaffolds used, which affect the folding and orientation of the glycans 
and may impact antigenicity and immunogenicity (Wang, 2013; Horiya, et al., 2014). 
Another explanation might be because high mannose N-linked glycan responses take 
longer to appear as seen in this study. Since responses to Tn-peptides and glycolipids were 
seen throughout infection, and these glycans are found on the HIV-1 envelope and are 
involved in the viral host cells entry (Hansen, et al., 1991; Hansen, et al., 1992; Izquierdo-
Useros, et al., 2014) they warrant further investigation.   
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3.6. CONCLUSIONS 
We have identified an increase in IgG anti-glycan antibodies against high mannose N-
linked glycans, Tn-peptides and glycolipids during HIV-1 infection. We noted that 
responses to high mannose N-linked glycans tend to occur during chronic infection with 
the highest levels of binding seen at 3 years post-infection, while elevated levels of binding 
to Tn-peptides and glycolipids occur constantly throughout HIV-1 infection. We found no 
differences in binding levels to these glycans between BCN and non-BCN individuals, 
suggesting that elevated levels of N-linked high mannose, Tn-peptides and glycolipids 
binding antibodies are a response to HIV-1 infection rather than specific to individuals 
who develop broadly neutralizing antibodies. N-linked high mannose glycans have been 
widely studied in HIV-vaccine immunogen design since they are bound by many bNAbs, 
but have showed little efficacy thus far. Tn-peptides and glycolipids, however, are also 
found on the HIV-1 envelope and although involved in HIV-infectivity they have not been 
studied in terms of immunogen design. Since responses to N-linked high mannose glycans 
are seen later in infection while responses to Tn-peptides and glycolipids were seen 
constantly throughout infection, further investigation into the role of these glycans during 
infection might be warranted.   
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GENERAL CONCLUSIONS 
The best means of preventing new HIV-1 infections would be through a vaccine. Broadly 
neutralizing antibodies (bNAbs) have been a central focus in vaccine design because of 
their ability to neutralize numerous strains of HIV-1 and non-human primate studies using 
bNAbs have shown them to be protective (Sanders, et al., 2002; Moldt, et al., 2012; 
Barouch, et al., 2013; Ko, et al., 2014). Eliciting bNAbs by vaccination, however, has 
failed thus far. Studies have shown that approximately 15-30% of HIV-1 infected 
individuals develop bNAbs but after years of infection and that approximately 50% of 
HIV-infected individuals are capable of neutralizing ~50% of viruses (Stamatatos, et al., 
2009; Hraber, et al., 2014). These antibodies tend to have unusual features such as high 
levels of somatic hypermutation probably accounting for the length of time required for 
them to develop (West, et al., 2014) and/or long CDRH3s lengths present in rare 
populations of naive B cells (Briney, et al., 2012; Doria-Rose, et al., 2014). Understanding 
of the mechanisms by which bNAbs develop, however, remain limited, although we do 
know that in this particular cohort high viral loads and decreased CD4 T-cell counts 
contributed toward the development of bNAbs (Gray, et al., 2011b). In addition the 
selection of B-cells following somatic hypermutation and class-switch recombination is 
mediated by T Follicular Helper (TFH) cells (Heesters, et al., 2014). The aim of this study 
was to understand host factors associated with broadly neutralizing antibodies against 
HIV-1 subtype C. It focused on three main aspects: 1) genetic variation in the heavy chain 
variable region genes (IGHV) responsible for encoding the majority of the antigen binding 
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part of antibodies, 2) evolution of a potent autologous anti-HIV IgA antibody during 
infection and 3) serum glycan-binding IgG antibodies during infection.  
 Previous studies have shown that CD4-binding site antibodies frequently use 
restricted germline IGHV genes such as IGHV1-2*02 and IGHV1-46*02 (Scheid, et al., 
2011; Kwong, et al., 2012; West, et al., 2012). This led to our hypothesis that individuals 
who develop bNAbs may have unique germline IGHV repertoires. However, after 
sequencing all seven IGHV subgroups, containing 48 functional IGHV genes and over 130 
alleles, we observed no differences in the IGHV repertoire between individuals in the 
CAPRISA cohort who did and did not develop bNAbs during infection (Scheepers, et al., 
2015). This finding has positive implications for vaccine design, as it suggests that the 
development of bNAbs is not limited by the germline IGHV repertoire. In addition this 
study greatly expanded the number of germline IGHV sequences through the identification 
of 85 novel alleles and 38 alleles that have previously only been observed in rearranged 
antibody sequences. The germline IGHV gene repertoire is used as a basis from which 
germline gene usage is predicted from functional antibodies. These predictions are crucial 
when inferring intermediate sequences and the unmutated common ancestor (UCA) of 
antibody lineages. The inferred intermediates and UCA of lineages suggest a pathway of 
antibody evolution against a particular infection and is a current paradigm in HIV vaccine 
design. The deposition of sequences from this study into public databases (IgPdb, IMGT 
and CATNAP) will assist with more reliable germline assignments of isolated mAbs and 
better UCA predictions. Based on these data it is highly likely that other germline 
immunoglobulin genes including the heavy chain diversity (IGHD), heavy chain joining 
(IGHJ) and heavy chain constant region (Fc) genes will show a similar level of diversity. 
In addition immunoglobulin genes that make up the light chains, are also likely to contain 
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genetic variants that are not represented in the current germline immunoglobulin gene 
repertoire database (IMGT).  
 Since we revealed that the development of bNAbs is not reliant on germline IGHV 
repertoires, we next chose to investigate the evolutionary pathway of a potent strain-
specific HIV-1 antibody in the hope of gaining insights into why some antibodies become 
broad and others not. Studies have shown that some bNAbs require long CDRH3 lengths 
and others high levels of somatic hypermutation (Liao, et al., 2013; Doria-Rose, et al., 
2014). Longitudinal studies have shown that strain-specific antibodies have the ability to 
develop breadth if the right viral epitopes are exposed through viral escape or they are able 
to drive the development of another broadly neutralizing antibody lineage (Moore, et al., 
2012; Wibmer, et al., 2013; Gao, et al., 2014). In this study we tracked the evolution of a 
strain-specific antibody (CAP88-CH06) that did not develop breadth despite persisting for 
years after viral escape. An IgA clade of this lineage with identical sequences to CAP88-
CH06 was observed during early infection (5 weeks) and long after viral escape (2 years) 
and had very little evolution during infection. A transient clonally related IgG clade that 
developed after the IgA antibodies was also observed. We hypothesise that this antibody 
lineage was not able to develop breadth due to the limited evolution of the IgA antibodies 
and the disappearance of the IgG antibodies. Studies aimed at examining viral evolution in 
this donor (CAP88) over the same time period are underway. In particular we plan to 
determine if the lack of antibody evolution within the IgA clade of antibodies is due to 
limited evolution within the C3-V4 region (the target epitope of this mAb) and whether the 
disappearance of the IgG clade of antibodies was a result of complete viral escape. This is 
based on previous studies showing an accumulation of mutations occurring in the bNAb 
epitopes within the viral populations isolated from the respective donors prior to the 
development of the bNAbs (Liao, et al., 2013; Doria-Rose, et al., 2014). Understanding the 
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dynamics between the viral and antibody evolution in this donor may give greater insight 
as to why she did not develop neutralization breadth despite chronic infection.  
 Glycans on the HIV envelope are often targets of bNAbs, thus we aimed to 
understand the glycan-binding profile of serum IgG antibodies during HIV infection and 
whether glycan-binding was specific to individuals who develop bNAbs or just a 
consequence of infection. We found elevated levels of glycan-binding during HIV 
infection in individuals who did and did not develop broadly neutralizing antibodies. This 
data suggested that glycan-binding is a consequence of HIV-1 infection and that everyone 
is capable of making antibodies against glycans present on the HIV envelope. It is 
important to note that in this study total serum IgG rather than HIV-1 specific antibodies 
were used. Thus the abundant levels of binding antibodies in the serum could have 
overwhelmed the ability to identify bNAbs, many of which also target conformational 
epitopes that would not be detected on the arrays. In addition to detecting antibodies to 
high mannose N-linked glycans, which are known to be targets of bNAbs, we observed 
elevated levels of binding to Tn-peptides and glycolipids not previously associated with 
bNAbs. Isolating monoclonal antibodies against these glycans might provide insights into 
their role in HIV infection. 
 Overall this study has shown that bNAbs are not limited by individual germline 
IGHV repertoires, that strain-specific antibodies may require continued evolution to 
develop breadth and that glycan-binding antibodies are a consequence of HIV infection 
rather than specific to individuals who develop bNAbs. Such information contributes to a 
better understanding of how bNAbs develop which is hoped will help in the design of an 
HIV vaccine capable of inducing them.  
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Supplementary Table 1.2: Germline IGHV primers for 454 sequencing 
Four different MID (MID1-4) sequences were used to allow pooling of four samples per run. Two 
reverse primers (3a and 3b) were used for IGHV3 to ensure all IGHV3 genes would be amplified. 
 
Primer ID Adapter, Tag and MID sequence IGHV sequence 
MID1-VH1-F CGTATCGCCTCCCTCGCGCCATCAGACGAGTGCGT CAGCTKGTRCARTCTGGRSCTG 
MID1-VH1-R CTATGCGCCTTGCCAGCCCGCTCAGACGAGTGCGT AGGATGTGGKTTYTCACACTGTG 
MID1-VH2-F CGTATCGCCTCCCTCGCGCCATCAGACGAGTGCGT TTCTCCACAGGGGTCTTRTC 
MID1-VH2-R CTATGCGCCTTGCCAGCCCGCTCAGACGAGTGCGT CCTGGGCTGTGTCTYTGTGGT 
MID1-VH3-F CGTATCGCCTCCCTCGCGCCATCAGACGAGTGCGT TGTTTGCAGRTGTCCARTGT 
MID1-VH3a-R CTATGCGCCTTGCCAGCCCGCTCAGACGAGTGCGT TRRCYTCYCCTCRCTGTG 
MID1-VH3b-R CTATGCGCCTTGCCAGCCCGCTCAGACGAGTGCGT GTGTYTCTMRYACAGTAATACA 
MID1-VH4-F CGTATCGCCTCCCTCGCGCCATCAGACGAGTGCGT GGCTCACTGTGKGTYTYTCTGTT 
MID1-VH4-R CTATGCGCCTTGCCAGCCCGCTCAGACGAGTGCGT CTCACACTCACCTCCCCTCA 
MID1-VH5-F CGTATCGCCTCCCTCGCGCCATCAGACGAGTGCGT CCMYACAGGAGTCTGTKCCG 
MID1-VH5-R CTATGCGCCTTGCCAGCCCGCTCAGACGAGTGCGT GGTTTCTCTCACTGTGTGTCT 
MID1-VH6-F CGTATCGCCTCCCTCGCGCCATCAGACGAGTGCGT TTTTGTCTCCAGGTGTCCT 
MID1-VH6-R CTATGCGCCTTGCCAGCCCGCTCAGACGAGTGCGT GACTTCCCCTCACTGTGTCT 
MID1-VH7-F CGTATCGCCTCCCTCGCGCCATCAGACGAGTGCGT CTCTCCACAGGTRCCYACTCC 
MID1-VH7-R CTATGCGCCTTGCCAGCCCGCTCAGACGAGTGCGT TCAGGATGTGGGTTTCCACA 
MID2-VH1-F CGTATCGCCTCCCTCGCGCCATCAGACGCTCGACA CAGCTKGTRCARTCTGGRSCTG 
MID2-VH1-R CTATGCGCCTTGCCAGCCCGCTCAGACGCTCGACA AGGATGTGGKTTYTCACACTGTG 
MID2-VH2-F CGTATCGCCTCCCTCGCGCCATCAGACGCTCGACA TTCTCCACAGGGGTCTTRTC 
MID2-VH2-R CTATGCGCCTTGCCAGCCCGCTCAGACGCTCGACA CCTGGGCTGTGTCTYTGTGGT 
MID2-VH3-F CGTATCGCCTCCCTCGCGCCATCAGACGCTCGACA TGTTTGCAGRTGTCCARTGT 
MID2-VH3a-R CTATGCGCCTTGCCAGCCCGCTCAGACGCTCGACA TRRCYTCYCCTCRCTGTG 
MID2-VH3b-R CTATGCGCCTTGCCAGCCCGCTCAGACGCTCGACA GTGTYTCTMRYACAGTAATACA 
MID2-VH4-F CGTATCGCCTCCCTCGCGCCATCAGACGCTCGACA GGCTCACTGTGKGTYTYTCTGTT 
MID2-VH4-R CTATGCGCCTTGCCAGCCCGCTCAGACGCTCGACA CTCACACTCACCTCCCCTCA 
MID2-VH5-F CGTATCGCCTCCCTCGCGCCATCAGACGCTCGACA CCMYACAGGAGTCTGTKCCG 
MID2-VH5-R CTATGCGCCTTGCCAGCCCGCTCAGACGCTCGACA GGTTTCTCTCACTGTGTGTCT 
MID2-VH6-F CGTATCGCCTCCCTCGCGCCATCAGACGCTCGACA TTTTGTCTCCAGGTGTCCT 
MID2-VH6-R CTATGCGCCTTGCCAGCCCGCTCAGACGCTCGACA GACTTCCCCTCACTGTGTCT 
MID2-VH7-F CGTATCGCCTCCCTCGCGCCATCAGACGCTCGACA CTCTCCACAGGTRCCYACTCC 
MID2-VH7-R CTATGCGCCTTGCCAGCCCGCTCAGACGCTCGACA TCAGGATGTGGGTTTCCACA 
MID3-VH1-F CGTATCGCCTCCCTCGCGCCATCAGAGACGCACTC CAGCTKGTRCARTCTGGRSCTG 
MID3-VH1-R CTATGCGCCTTGCCAGCCCGCTCAGAGACGCACTC AGGATGTGGKTTYTCACACTGTG 
MID3-VH2-F CGTATCGCCTCCCTCGCGCCATCAGAGACGCACTC TTCTCCACAGGGGTCTTRTC 
MID3-VH2-R CTATGCGCCTTGCCAGCCCGCTCAGAGACGCACTC CCTGGGCTGTGTCTYTGTGGT 
MID3-VH3-F CGTATCGCCTCCCTCGCGCCATCAGAGACGCACTC TGTTTGCAGRTGTCCARTGT 
MID3-VH3a-R CTATGCGCCTTGCCAGCCCGCTCAGAGACGCACTC TRRCYTCYCCTCRCTGTG 
MID3-VH3b-R CTATGCGCCTTGCCAGCCCGCTCAGAGACGCACTC GTGTYTCTMRYACAGTAATACA 
MID3-VH4-F CGTATCGCCTCCCTCGCGCCATCAGAGACGCACTC GGCTCACTGTGKGTYTYTCTGTT 
MID3-VH4-R CTATGCGCCTTGCCAGCCCGCTCAGAGACGCACTC CTCACACTCACCTCCCCTCA 
MID3-VH5-F CGTATCGCCTCCCTCGCGCCATCAGAGACGCACTC CCMYACAGGAGTCTGTKCCG 
MID3-VH5-R CTATGCGCCTTGCCAGCCCGCTCAGAGACGCACTC GGTTTCTCTCACTGTGTGTCT 
MID3-VH6-F CGTATCGCCTCCCTCGCGCCATCAGAGACGCACTC TTTTGTCTCCAGGTGTCCT 
MID3-VH6-R CTATGCGCCTTGCCAGCCCGCTCAGAGACGCACTC GACTTCCCCTCACTGTGTCT 
MID3-VH7-F CGTATCGCCTCCCTCGCGCCATCAGAGACGCACTC CTCTCCACAGGTRCCYACTCC 
MID3-VH7-R CTATGCGCCTTGCCAGCCCGCTCAGAGACGCACTC TCAGGATGTGGGTTTCCACA 
MID4-VH1-F CGTATCGCCTCCCTCGCGCCATCAGAGCACTGTAG CAGCTKGTRCARTCTGGRSCTG 
MID4-VH1-R CTATGCGCCTTGCCAGCCCGCTCAGAGCACTGTAG AGGATGTGGKTTYTCACACTGTG 
MID4-VH2-F CGTATCGCCTCCCTCGCGCCATCAGAGCACTGTAG TTCTCCACAGGGGTCTTRTC 
MID4-VH2-R CTATGCGCCTTGCCAGCCCGCTCAGAGCACTGTAG CCTGGGCTGTGTCTYTGTGGT 
MID4-VH3-F CGTATCGCCTCCCTCGCGCCATCAGAGCACTGTAG TGTTTGCAGRTGTCCARTGT 
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MID4-VH3a-R CTATGCGCCTTGCCAGCCCGCTCAGAGCACTGTAG TRRCYTCYCCTCRCTGTG 
MID4-VH3b-R CTATGCGCCTTGCCAGCCCGCTCAGAGCACTGTAG GTGTYTCTMRYACAGTAATACA 
MID4-VH4-F CGTATCGCCTCCCTCGCGCCATCAGAGCACTGTAG GGCTCACTGTGKGTYTYTCTGTT 
MID4-VH4-R CTATGCGCCTTGCCAGCCCGCTCAGAGCACTGTAG CTCACACTCACCTCCCCTCA 
MID4-VH5-F CGTATCGCCTCCCTCGCGCCATCAGAGCACTGTAG CCMYACAGGAGTCTGTKCCG 
MID4-VH5-R CTATGCGCCTTGCCAGCCCGCTCAGAGCACTGTAG GGTTTCTCTCACTGTGTGTCT 
MID4-VH6-F CGTATCGCCTCCCTCGCGCCATCAGAGCACTGTAG TTTTGTCTCCAGGTGTCCT 
MID4-VH6-R CTATGCGCCTTGCCAGCCCGCTCAGAGCACTGTAG GACTTCCCCTCACTGTGTCT 
MID4-VH7-F CGTATCGCCTCCCTCGCGCCATCAGAGCACTGTAG CTCTCCACAGGTRCCYACTCC 
MID4-VH7-R CTATGCGCCTTGCCAGCCCGCTCAGAGCACTGTAG TCAGGATGTGGGTTTCCACA 
 
Supplementary Table 1.3: Germline IGHV primers for Illumina sequencing  
Read 1 and Read 2 sequences were used for MiSeq 2x250bp paired-end sequencing. As with the 
454 sequencing two IGHV3 reverse primers (IGHV3a and 3b) were used to ensure full coverage of 
the IGHV3 subgroup. 
 
Name Index Binding Site Read 1/Read2 Gene Specific Primer 
IGHV1 -Forward TCGTCGGCAGCGTC AGATGTGTATAAGAGACAG CAGCTKGTRCARTCTGGRSCTG 
IGHV-Reverse GTCTCGTGGGCTCGG AGATGTGTATAAGAGACAG AGGATGTGGKTTYTCACACTGTG 
IGHV2-Forward TCGTCGGCAGCGTC AGATGTGTATAAGAGACAG TTCTCCACAGGGGTCTTRTC 
IGHV2-Reverse GTCTCGTGGGCTCGG AGATGTGTATAAGAGACAG CCTGGGCTGTGTCTYTGTGGT 
IGHV3-Forward TCGTCGGCAGCGTC AGATGTGTATAAGAGACAG TGTTTGCAGRTGTCCARTGT 
IGHV3a-Reverse GTCTCGTGGGCTCGG AGATGTGTATAAGAGACAG TRRCYTCYCCTCRCTGTG 
IGHV3b-Reverse GTCTCGTGGGCTCGG AGATGTGTATAAGAGACAG GTGTYTCTMRYACAGTAATACA 
IGHV4-Forward TCGTCGGCAGCGTC AGATGTGTATAAGAGACAG GGCTCACTGTGKGTYTYTCTGTT 
IGHV4-Reverse GTCTCGTGGGCTCGG AGATGTGTATAAGAGACAG CTCACACTCACCTCCCCTCA 
IGHV5-Forward TCGTCGGCAGCGTC AGATGTGTATAAGAGACAG CCMYACAGGAGTCTGTKCCG 
IGHV5-Reverse GTCTCGTGGGCTCGG AGATGTGTATAAGAGACAG GGTTTCTCTCACTGTGTGTCT 
IGHV6-Forward TCGTCGGCAGCGTC AGATGTGTATAAGAGACAG TTTTGTCTCCAGGTGTCCT 
IGHV6-Reverse GTCTCGTGGGCTCGG AGATGTGTATAAGAGACAG GACTTCCCCTCACTGTGTCT 
IGHV7-Forward TCGTCGGCAGCGTC AGATGTGTATAAGAGACAG CTCTCCACAGGTRCCYACTCC 
IGHV7-Reverse GTCTCGTGGGCTCGG AGATGTGTATAAGAGACAG TCAGGATGTGGGTTTCCACA 
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Supplementary Figure 1.1: Nucleotide sequence alignment for IGHV3-11*5mm 
Shown is an alignment of IGHV3-11*5mm and IGHV3-11*05 sequences with a 3 nucleotide 
insertion (highlighted in orange) in the complementarity determining region 2 (CDR2) and 2 SNPs 
(highlighted in yellow) within framework 3 (FR3). Missing data in the sequence is represented by 
"-". 
 
 
Supplementary Figure 1.2: Nucleotide sequence alignment for IGHV4-59*8mm1 
Shown is an alignment of IGHV4-59*8mm1 (likely to be a pseudogene) and IGHV4-59*08 
sequences with a single nucleotide deletion (highlighted in orange) in the complementarity 
determining region 2 (CDR2) and a SNP (highlighted in yellow) in the framework 2 region (FR2). 
Missing data in the sequence is represented by "-". 
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Supplementary Figure 1.3: Nucleotide sequence alignment for IGHV4-61*2mm 
Shown is an alignment of IGHV4-61*2mm (likely to be a pseudogene) and IGHV4-61*02 with 
two single nucleotide deletions (highlighted in orange) in the framework 2 region (FR2) and 
complementarity determining region 2 (CDR2) and two SNPs (highlighted in yellow) in framework 
1 (FR1) and framework 2 (FR2) regions. Missing data in the sequence is represented by "-". 
 
 
Supplementary Figure 1.4: Nucleotide sequence alignment for IGHV6-1*1m8 
Shown is an alignment for IGHV6-1*1m8 (likely to be a pseudogene) and IGHV6-1*01 with a 
single nucleotide deletion (highlighted in orange) in the framework 3 (FR3) region. Missing data in 
the sequence is represented by "-". 
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Supplementary Figure 1.5: Germline IGHV gene usage for CAP255-75D 
CAP255-75D is predicted to use IGHV1-18*1m. The closest matching IMGT allele is IGHV1-
18*01. Both CAP255-75D and IGHV1-18*1m have an Aspartic Acid (D) at position 66, in the 
complementarity determining region 2 (CDR2), compared to Asparagine (N), highlighted in 
yellow, as seen in IGHV1-18*01 at the same position. All other changes in the antibody sequence 
are likely due to somatic hypermutation. Missing data in the sequence is represented by "-". 
 
 
Supplementary Figure 1.6: Germline IGHV gene usage for CAP255-37C and 
CAP255-18F 
CAP255-37C and CAP255-18F are predicted to use IGHV1-69*6m. The closest matching IMGT 
allele is IGHV1-69*06. CAP255-37C, CAP255-18F and IGHV1-69*6m have an Arginine (R) at 
position 59, in framework 2 (FR2) compared to Glycine (G), highlighted in yellow, as seen in 
IGHV1-69*06 at the same position. All other changes in the antibody sequence are likely due to 
somatic hypermutation. Missing data in the sequence is represented by "-". 
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Supplementary Figure 1.7: Germline IGHV gene usage for CAP255-53E 
CAP255-53E is predicted to use IGHV3-15*1m. The closest matching IMGT allele is IGHV3-
15*01. Both CAP255-53E and IGHV3-15*1m have an Adenine (A) at position 165, in the 
framework 2 (FR2), compared to Guanine (G), highlighted in yellow, as seen in IGHV3-15*01 at 
the same position. This change is synonymous and therefore doesn’t change the amino acid 
sequence. All other changes in the antibody sequence are likely due to somatic hypermutation. 
Missing data in the sequence is represented by "-". 
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Supplementary Figure 1.8: Germline IGHV gene usage for CAP177-2D, 13F, 60B, 6C 
and 13G 
Five mAbs (2D, 13F, 60B, 6C and 13G) isolated from CAP177 were predicted to use IGHV3-
30*2m. The closest matching IMGT allele is IGHV3-30*02. All five mAbs and IGHV3-30*2m 
have a Cytosine (C) at position 192 in the framework 1 (FR1), compared to Thymine (T), 
highlighted in yellow, as seen in IGHV3-30*02 at the same position. This change is synonymous 
and therefore doesn’t change the amino acid sequence. All other changes in the antibody sequence 
are likely due to somatic hypermutation. Missing data in the sequence is represented by "-". 
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Supplementary Figure 1.9: Germline IGHV gene usage for CAP177-23-3G, 1C and 
5G 
CAP177-23-3G was predicted to use IGHV4-39*7mm, which has a Guanine (G) at position 4 
(which causes a Leucine (L) to Valine (V) amino acid change at position 2) within framework 1 
(FR1), and Cytosine (C) at position 298 (no amino acid change) in the complementarity 
determining region 3 (CDR3), highlighted in yellow, compared to a Cytosine (C) and Guanine (G) 
at the same positions, respectively. The other two mAbs (CAP177-1C and CAP177-5G) were 
predicted to use either IGHV4-39*7mm or IGHV4-39*7m1. The difference between IGHV4-
39*7mm and IGHV4-39*7m1 is the G298C which is present on IGHV4-39*7mm but absent on 
IGHV4-39*7m1. All other changes in the antibody sequence are likely due to somatic 
hypermutation. Missing data in the sequence is represented by "-". 
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Supplementary Figure 1.10: Germline IGHV gene usage for CAP255-91B and 71E  
CAP255-91B and CAP255-71E were predicted to use IGHV4-59*1m2, all of which have a 
Histidine (H) at position 32, within the complementarity determining region 1 (CDR1), compared 
to the closest matching IGHV4-59*01 which has a Tyrosine (Y) at the same position (highlighted 
in yellow). All other changes are likely due somatic hypermutation. Missing data in the sequence is 
represented by "-". 
 
 
Supplementary Figure 1.11: Germline IGHV gene usage for 2G12 
2G12 has been reported to use IGHV3-21*01 (Xiao, et al., 2009). However, when compared to our 
database of IMGT, novel and non-IMGT alleles, 2G12 is just as likely to be using IGHV3-21*1m. 
The difference between IGHV3-21*01 and IGHV3-21*1m is highlighted in yellow, where IGHV3-
21*01 has a Guanine (G) at position 291, in the complementarity determining region 3 (CDR3), 
IGHV3-21*1m has an Adenine (A) and 2G12 has a Cytosine (C) at the same position. The 
difference between IGHV3-21*01 and IGHV3-21*1m doesn’t change the amino acid sequence. All 
other changes are likely due somatic hypermutation. Missing data in the sequence is represented by 
"-". 
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Supplementary Figure 1.12: Germline IGHV gene usage for CH103  
CH103 has been reported to use IGHV4-59*01 (Liao, et al., 2013). However, when compared to 
our database of IMGT, novel and non-IMGT alleles, CH103 is just as likely to be using IGHV4-
59*1m2. The difference between IGHV4-59*01 and IGHV4-59*1m2 is highlighted in yellow, 
where IGHV4-59*01 has a Tyrosine (Y) at position 32, in the complementarity determining region 
1 (CDRH1), IGHV4-59*1m2 has a Histidine (H) and CH103 has a Threonine (T) at the same 
position. All other changes are likely due somatic hypermutation. Missing data in the sequence is 
represented by "-". 
 
 
Supplementary Figure 1.13: Germline IGHV gene usage for PGTs121-123  
PGTS121-123 have been reported to use IGHV4-59*01 (Walker, et al., 2011). However, when 
compared to our database of IMGT, novel and non-IMGT alleles, PGT121-123 are just as likely to 
be using IGHV4-59*1m2. The difference between IGHV4-59*01 and IGHV4-59*1m2 is 
highlighted in yellow, where IGHV4-59*01 has a Tyrosine (Y) at position 32, in the 
complementarity determining region 1 (CDR1), IGHV4-59*1m2 has a Histidine (H) and the PGTs 
have a Serine (S), Asparagine (N) or Alanine (A) at the same position. All other changes are likely 
due somatic hypermutation. Missing data in the sequence is represented by "-". 
 
 182 
 
Supplementary Figure 1.14: Germline IGHV gene usage for PGTs125-128 
PGTS125-128 have been reported to use IGHV4-39*07 (Walker, et al., 2011). However, when 
compared to our database of IMGT, novel and non-IMGT alleles, PGT125-128 are just as likely to 
be using IGHV4-39*7m2. The difference between IGHV4-59*07 and IGHV4-39*7m2 is 
highlighted in yellow, where IGHV4-39*07 has a Guanine (G) at position 316, within the 
complementarity determining region 3 (CDR3) IGHV4-39*7m2 has a Cytosine (C) and the PGTs 
have a Thymine (T) at the same position. All other changes are likely due somatic hypermutation. 
Missing data in the sequence is represented by "-". 
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Supplementary Figure 1.15: Germline IGHV gene usage for PGTs135-137  
PGTS135-137 have been reported to use IGHV4-39*07 (Walker, et al., 2011). However, when 
compared to our database of IMGT, novel and non-IMGT alleles, PGT125-128 are just as likely to 
be using IGHV4-39*7m1/7m2/7mm. The differences between IGHV4-59*07 and IGHV4-
39*7m1/7m2/7mm are highlighted in yellow, where IGHV4-39*07 has a Cytosine (C) at position 4 
in framework 1 (FR1) and Guanine (G) at position 316 in the complementarity determining region 
3 (CDR3). IGHV4-39*7m1 and IGHV4-39*7mm have a Guanine, while IGHV4-39*7m2 has a 
Cytosine (C) at position 4 and the PGTs have a either a Guanine (G), Thymine (T) or Cytosine at 
the same position. At position 316 IGHV4-39*7m2 and IGHV4-39*7mm have a Cytosine as do all 
three PGTs. All other changes are likely due somatic hypermutation. Missing data in the sequence 
is represented by "-". 
 	  
  
 184 
 
The Journal of Immunology
Ability To Develop Broadly Neutralizing HIV-1 Antibodies Is
Not Restricted by the Germline Ig Gene Repertoire
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The human Ig repertoire is vast, producing billions of unique Abs from a limited number of germline Ig genes. The IgH V region
(IGHV) is central to Ag binding and consists of 48 functional genes. In this study, we analyzed whether HIV-1–infected individuals
who develop broadly neutralizing Abs show a distinctive germline IGHV profile. Using both 454 and Illumina technologies, we
sequenced the IGHV repertoire of 28 HIV-infected South African women from the Centre for the AIDS Programme of Research
in South Africa (CAPRISA) 002 and 004 cohorts, 13 of whom developed broadly neutralizing Abs. Of the 259 IGHV alleles
identified in this study, approximately half were not found in the International Immunogenetics Database (IMGT). This included
85 entirely novel alleles and 38 alleles that matched rearranged sequences in non-IMGT databases. Analysis of the rearranged H
chain V region genes of mAbs isolated from seven of these women, as well as previously isolated broadly neutralizing Abs from
other donors, provided evidence that at least eight novel or non-IMGT alleles contributed to functional Abs. Importantly, we
found that, despite a wide range in the number of IGHV alleles in each individual, including alleles used by known broadly
neutralizing Abs, there were no significant differences in germline IGHV repertoires between individuals who do and do not
develop broadly neutralizing Abs. This study reports novel IGHV repertoires and highlights the importance of a fully compre-
hensive Ig database for germline gene usage prediction. Furthermore, these data suggest a lack of genetic bias in broadly
neutralizing Ab development in HIV-1 infection, with positive implications for HIV vaccine design. The Journal of Immunology,
2015, 194: 4371–4378.
T he induction of broadly neutralizing Abs (bNAbs) is likelyto be crucial for an efficacious HIV vaccine. Although themajority of chronically HIV-infected individuals develop
some level of cross-neutralizing activity (1), bNAbs are generally
found in ,20% of HIV-infected individuals (2). The mechanisms
underlying bNAb emergence are largely unknown, but a better
understanding of how these Abs arise in natural infection would
provide a blueprint for a vaccine designed to elicit them. Over the
last few years a large number of potent and broad bNAbs have
been isolated from selected HIV-infected donors. These bNAbs
target conserved epitopes on the HIV envelope, including the
membrane proximal external region (MPER), V2 glycans, V3
glycans, CD4 binding site (CD4bs), and the gp120/gp41 interface
(3, 4). However, most bNAbs have unusual genetic features, in-
cluding high levels of somatic hypermutation (SHM), long CDRH3s
(the complementary determining region 3 on the H chain) (3, 5),
and, for some classes, biases in germline IgH V region (IGHV) gene
usage (3, 5–9).
The VRC01 class of Abs to the CD4bs (including NIH45-46,
12A12, 3BNC117, VRC-PG04, and VRC-CH31 isolated from
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multiple donors) was shown to preferentially use either IGHV1-2*02
or IGHV1-46*02 germline alleles (3, 10, 11). This preference is
thought to be due to the electrostatic and hydrophobic contacts
afforded by conserved residues in framework (FR)1, CDRH2, and
FR3 of this allele (some of these features are conserved in IGHV1-
46*02 and IGHV1-3*01, which are also used by CD4bs Abs) (9,
10). Anti-HIV Abs frequently use IGHV1 genes compared with
non-HIVAbs (5, 6). In particular, IGHV1-69 is used by mAbs that
target V2, the CD4 induced site, and gp41 in HIV infection, as
well as other viral infections, such as influenza (8, 12). The
preference for this particular gene can be attributed to the interac-
tion of hydrophobic residues in the CDRH2 with helical elements
or hydrophobic b-sheets like those found on the hemagglutinin of
influenza and gp41 and gp120 of the HIV envelope (8, 13). The
use of IGHV5-51*01 and IGHV5-51*03, which are underrepre-
sented in mature Abs, also was reported to be favored by anti-V3
HIV Abs (6, 7).
The human germline IGHV repertoire consists of seven IGHV
subgroups, which are described in the International Immunoge-
netics Database (IMGT; www.imgt.org). These IGHV1–7 subgroups
include functional genes, open-reading frames, and pseudogenes
with only functional genes being involved in Ab production (14).
IGHV3 is the largest of the IGHV subgroups, with 21 functional
genes, followed by IGHV1 and IGHV4 (both with 10 functional
genes), and IGHV2, IGHV5, IGHV6, and IGHV7 (with three or
fewer genes) (14). Most of these genes have multiple alleles, in-
cluding functional and nonfunctional alleles that differ by either
a single nucleotide polymorphism (SNP) or by multiple SNPs,
which can be either synonymous or nonsynonymous, or frameshift
mutations caused by indels that contribute diversity to the Ig gene
repertoire. Furthermore, whole IGHV genes were reported to have
been duplicated or deleted from the germline repertoire of some
individuals, resulting in varied gene copy numbers (15, 16). IGHV
genes make up the majority of the H chain V region (VH) of
mature Abs and are central to Ag binding. Differences in germline
IGHV repertoires between different populations were highlighted
recently in an extensive study of the human Ig gene locus (16), in
which African individuals were found to be particularly diverse.
Given the propensity of some HIV mAbs to use restricted IGHV
genes, we examined whether HIV-infected individuals who develop
bNAbs have unique IGHV repertoires compared with individuals
who do not, to determine whether the ability to develop these types
of Abs is genetically restricted.
Materials and Methods
Samples and ethics statement
This study involved 28 adult (.18 y) women of African ancestry (mostly
Zulu speaking) with HIV-1 subtype C infection from the Centre for the
AIDS Programme of Research in South Africa (CAPRISA) 002 (17) and
004 (18) cohorts who were being followed at urban and rural clinics in
KwaZulu-Natal, South Africa. Of the 28 women, 13 developed broadly
neutralizing anti-HIV Abs, 13 did not develop broadly neutralizing Abs
despite chronic HIV infection, and 2 were intermediate neutralizers
(Supplemental Table I). Throughout this article, “BCN” is used to refer to
the HIV-infected women who develop broadly neutralizing Abs, and “non-
BCN” refers to women who did not develop broadly neutralizing Abs.
BCN individuals were defined as those whose sera from 2 y postinfection
were able to neutralize 33–94% (median 56%) of a panel of 18 viruses,
made up of 6 subtype A, 6 subtype B, and 6 subtype C viruses, of which 2
viruses were isolated from the women in the cohort. Non-BCN individuals
neutralized 0–11% of the 18 viruses and had the same viral loads as the
BCN individuals at 6 mo postinfection [to remove viral load biases asso-
ciated with the development of bNAbs (19)].
This study was given ethics clearance from the Human Research Ethics
Committee for Medical Research in Johannesburg, South Africa (clearance
number M111104 for this particular study and M080470 for the CAPRISA
parent study).
DNA extraction
Genomic DNA was extracted from PBMCs from each individual. Prior to
extraction, PBMCs were thawed (at 37˚C) and washed with 10 ml RPMI
1640 with 10% FBS. Genomic DNAwas extracted from the pellet from all
28 individuals using a Promega Wizard Genomic purification kit.
Primer design and amplicon library construction
Alignments were created for each IGHV subgroup using sequences ob-
tained from ENSEMBL (http://www.ensembl.org/index.html) and IMGT
(http://www.imgt.org/). Forward primers (with the exception of IGHV1-F)
were mapped to the intron in leader sequence. The reverse primers were
mapped to the intron after the CDR3 region. IGHV1, IGHV3, and IGHV4
primers were designed based on previously published primer sets (20).
New primers for IGHV2, IGHV5, IGHV6, and IGHV7 were designed
based on related sequences for each subgroup. A total of eight primer sets
was designed to amplify all seven subgroups. The binding properties of the
primer sets were determined using University of California Santa Cruz’s
BLAT database (https://genome.ucsc.edu/cgi-bin/hgBlat?command=start)
and the National Center for Biotechnology Information (NCBI)’s basic
local alignment search tool (BLAST). Additional next-generation se-
quencing (NGS)-specific sequences were added to the gene-specific pri-
mers to allow sequencing of the Roche 454 and Illumina MiSeq. The 454
primers included the 454 adapter sequence, key sequence, and 10-bp MID
sequences (four unique sequences in total; primers are listed in Supplemental
Table II). The Illumina MiSeq primers included a MiSeq index-binding tag
and the read 1 or read 2 tags (used for paired-end reads; primers are listed
in Supplemental Table III). Nextera XT Indexing tags, which allow pooling
of samples on the MiSeq, were added during library construction rather
than included into the primer.
Each IGHV subgroup was amplified three times for each individual to
ensure adequate coverage of the subgroup andminimize PCR bias. The PCR
conditions for all eight amplicons and both 454 and Illumina primers were
the same, with the exception of the annealing temperatures: 56˚C for
IGHV1, IGHV3a, and IGHV5; 59˚C for IGHV2, IGHV6, and IGHV7; and
55˚C for IGHV3b and IGHV4. The PCR conditions were as follows: initial
denaturation at 94˚C for 3 min, 35 cycles of denaturation at 94˚C for 15 s,
annealing for 45 s, extension for 1 min at 72˚C, final extension at 72˚C for
8 min, and held at 4˚C. Each PCR contained 17.5 ml dH2O, 2.5 ml Roche
FastStart High Fidelity 103 buffer with 18 mM MgCl2, 0.5 ml deoxyri-
bonucleotide triphosphates mix (10 mM each), 1 ml each primer (10 mM),
0.25 ml Roche FastStart High Fidelity Enzyme (5 U/ml), and 1 ml 10 ng/ml
DNA. The PCR amplicon lengths ranged from ∼390 to 440 bp. All rep-
licates of the eight amplicons from each individual were pooled to create
a full IGHV repertoire for each individual.
Next-generation sequencing
Fifteen individuals were sequenced on the Roche 454 GS Junior, with four
individuals pooled per sequencing run. All clean-up procedures and se-
quencing on the Roche 454 GS Junior (Titanium) was done as per the
manufacturer’s recommendations.
To confirm rare alleles that were only found in single individuals, 11 of
the individuals sequenced on the GS Junior were resequenced on the
Illumina MiSeq along with 13 additional individuals. A custom amplicon-
sequencing approach was used for the MiSeq sequencing. Nextera XT
Indexing tags were added to the pooled MiSeq amplicon libraries for each
individual using 5 ml each Nextera XT index (two per sample), 1 ml
cleaned PCR product (amplicon library prep), 0.5 ml Epicentre FailSafe
enzyme, 25 ml Epicentre FailSafe PCR PreMix, and 13.5 ml dH2O.
Thermocycler conditions were 72˚C for 3 min, 95˚C for 30 s, 12 cycles of
95˚C for 10 s, 55˚C for 30 s, and 72˚C for 30 s, followed by a final ex-
tension at 72˚C for 5 min. All products were checked on an Agilent
Bioanalyzer and cleaned up using 0.753 AMPure Beads, according to the
manufacturer’s protocol. Each sample was quantified on a Qubit and di-
luted to 8 nM. A single 8-nM pooled library was created by pooling 4 ml
each diluted sample, 5 ml of which was denatured using 5 ml 0.2 N NaOH,
according to the MiSeq protocol. A final concentration of 12 pM denatured
DNA library with 15% PhiX control was run onto the Illumina MiSeq,
using the MiSeq reagent kit (version 2) with 2 3 250 paired-end reads.
Sequence data analysis
FASTQ files were extracted from the raw GS Junior output (.sff files) or
automatically generated on the MiSeq. The resulting sequences were quality
trimmed using QTrim (21). Sequences with a minimum read length of 260 bp
and a mean quality score $ 23 ($ 99% confidence) were considered high
quality and used for downstream analyses. Paired-end MiSeq reads were
merged using PEAR (22), after quality trimming. All identical sequences
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were collapsed to single unique reads. Unique reads compiled from six or
more identical sequences were used for further analysis, whereas all unique
reads compiled from less than six sequences were discarded from further
analysis. The unique sequences were compared with a database of IGHV
alleles downloaded from IMGT using a custom BLAST approach with
a match reward score of 2, a mismatch penalty of 5, a gap penalty for
insertions of 16, and a gap extension for deletions with a penalty of 4. All
related sequences for each IGHV gene were aligned using RAMICS (23).
Sequences with 100%matches to functional IMGTalleles were assigned
as that particular IMGT allele. Sequences matching open-reading frames
or pseudogenes were removed from further analysis. Sequences with non-
synonymous and/or synonymous SNPs, insertions, or deletions compared with
their top matched functional IMGT sequence were given the name of the top-
scoring IMGT match with the suffix “m” to denote a single mismatch
(nonsynonymous and synonymous SNPs) (e.g., IGHV1-2*5m) and “mm” for
multiple SNPs, insertions, or deletions (e.g., IGHV1-2*5mm). If more than
one sequence with a single mismatch or multiple mismatches to the same top-
scoring IMGT functional sequence was observed, an additional numerical
identifier was given to the name (e.g., IGHV1-2*5m2 and IGHV1-2*5mm2).
These sequences were compared with those listed in the Ig Polymorphism
Database, GenBank, NCBI’s dbSNP, NCBI’s IgBLAST, and other published
IGHV data (24–28). If 100% matches were found in any of these databases or
publications, these sequences are described as non-IMGT alleles. If no match
was found, and sequences were observed in multiple individuals or in both
sequencing platforms in a single individual, we report these as novel alleles.
bNAb sequences were obtained from the HIV Sequence Database -
CATNAP (http://www.hiv.lanl.gov/components/sequence/HIV/neutralization/
main.comp) or GenBank. The germline IGHV gene usage for these se-
quences also was obtained from CATNAP or the relevant publication. The
bNAb sequences were compared with our IMGT, non-IMGT, and novel
allele sequences, using blastn from BLAST 2.2.29+ with a match reward
of 1, a mismatch penalty of 21, gap deletions of 5, a gap extension of 2,
a word size of 7, and an E value threshold of 1e210. mAbs were isolated
previously from seven of the CAPRISA participants examined in this study
using single-cell sorting and PCR amplification of the H and L chains
(N. Mkhize, E. Gray, and L. Morris, unpublished observations). The majority
of these mAbs were not HIV specific. The sequences obtained from these
mAbs were used to assign germline IGHV gene usage in each participant.
Statistical analysis
The two-tailed Fishers exact test with 95% confidence intervals was used to
assess the difference in germline gene repertoires between the BCN and
non-BCN sample groups.
Results
Novel germline IGHV alleles in South African women
The germline IGHV gene repertoire of 28 HIV-infected women in
the CAPRISA 002 and 004 cohorts, based in KwaZulu-Natal, South
Africa, were sequenced using both the 454 and Illumina NGS
platforms. Sequences with perfect matches to alleles listed in
IMGT (29) were given the IMGTallele name and are referred to as
FIGURE 1. Novel germline IGHValleles in 28 South African individuals. (A) Number of alleles observed for each IGHV gene. Shown are the numbers
of novel (red), non-IMGT (orange), and IMGT (blue) alleles. (B) Prevalence of novel and non-IMGT germline IGHV alleles. (C) Number of non-
synonymous changes in each allele compared with top-matched IMGT allele. (D) Number of synonymous changes in each allele compared with top-
matched IMGT allele. (E) Total number of IMGT, novel, and non-IMGT germline IGHV alleles. BCN individuals are highlighted in black, and non-BCN
individuals are highlighted in gray. (F) Total number of germline alleles from each IGHV subgroup. Shown are the total numbers of alleles colored
according to IGHV subgroup.
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IMGT alleles. Sequences that did not match IMGT alleles as
a result of synonymous or nonsynonymous mutations or indels,
but were matches to non-IMGT Ig gene databases (30–33) or Ig
gene publications (24–28), were given the published name and are
referred to as non-IMGT alleles. Sequences with no matches to
either IMGT or non-IMGT alleles and were observed in multiple
individuals or across both technologies in one individual are re-
ferred to as “novel” alleles.
A total of 47 functional IGHV genes representing all seven
subgroups was found in our cohort (Fig. 1A). Only one published
gene, IGHV3-NL1, first identified in Papua New Guinea (20), was
not detected. There was a wide range in the number of alleles
associated with each gene, with 20 alleles in the IGHV2-70 gene
compared with only a single allele for the IGHV3-20 gene. Of the
259 alleles identified in this population, just over half (∼52%, n =
136) had an exact match to those listed in IMGT, whereas ∼15%
(n = 38) were non-IMGT alleles, and ∼33% (n = 85) were novel
alleles. Eighty-one of the eighty-five novel alleles (95%) were
observed in more than one individual (Fig. 1B). The four novel
alleles observed in single individuals were confirmed with both
454 and Illumina sequences. The most commonly observed novel
alleles were IGHV6-1*1m1 found in 25 individuals (∼89%) and
IGHV2-26*1m2 found in 20 individuals (∼71%), both of which
contained a single SNP compared with the known alleles. Overall,
48% (n = 60) of the novel and non-IMGT alleles identified in this
study were found in at least four individuals, indicating that many
are fairly common. Furthermore, this study significantly expanded
the number of alleles for certain genes. For example, IGHV6-1,
which only had 2 alleles reported in IMGT was found to have 10
novel alleles and 1 non-IMGT allele (Fig. 1A, 1B). Similarly,
IGHV2-26 was found to have 13 alleles (including 10 novel
alleles and 2 non-IMGT alleles) compared with 1 recorded in
IMGT. Other significant expansions were in the IGHV1-69 and
IGHV2-70 genes.
The majority (∼97%, n = 119) of novel and non-IMGT alleles
had single or multiple SNPs (synonymous and nonsynonymous),
FIGURE 2. Phylogenetic tree of all germline IGHValleles observed in 28 South African individuals. Shown are all IMGT, non-IMGT, and novel alleles
observed in this study. Alleles are colored according to IGHV subgroup, and the non-IMGT and novel alleles are highlighted in the gray boxes.
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with single nonsynonymous SNPs being the most common
(Fig. 1C, 1D). One novel allele (IGHV2-26*1mm4, observed in 15
individuals) had eight nonsynonymous SNPs (Fig. 1B, 1C). Four
novel alleles had indels relative to their most closely matched
IMGT allele, and three of the four had additional SNPs. IGHV3-
11*5mm, observed in two individuals, had a full codon insertion,
whereas frameshifts as a result of single nucleotide deletions were
found in IGHV4-59*8mm and IGHV4-61*2mm, each observed in
two individuals, and IGHV6-1*1m8, which was found in six
individuals. It is likely that these three alleles with the frameshift
mutations are not functional, but rather are novel pseudogenes.
When the repertoires for each of the 28 individuals were ana-
lyzed separately, it was apparent that there was a wide range in the
number of alleles/individual (Fig. 1E, 1F). CAP295 had the largest
number of alleles (n 5 105), whereas CAP322 had the fewest
(n5 23). Each individual’s repertoire included IMGT, non-IMGT,
and novel alleles. There was variation in the number of alleles/
IGHV family, because some individuals lacked alleles for IGHV6
or IGHV7, whereas others had smaller numbers of IGHV2,
IGHV4, or IGHV5 alleles. A phylogenetic tree of all 259 alleles,
including IMGT, non-IMGT, and novel alleles, sequenced in this
study revealed separate clustering of each of the IGHV subgroups,
with all of the novel and non-IMGT alleles clustering with their
respective IMGT genes (Fig. 2).
Novel germline IGHV allele usage in bNAbs
To determine whether these novel and non-IMGT germline alleles
are being used by the human immune system to generate functional
Abs, we analyzed the germline gene usage of mAbs isolated from
seven of the CAPRISA participants in this study. We found 15
mAbs that made use of seven novel or non-IMGT alleles identified
from NGS of the 28 individuals (Fig. 3A). Of these, two clonally
related mAbs were HIV-1 specific (CAP255-37C and CAP255-
18F). An example of one of the non-IMGT alleles used by two
mAbs isolated from two individuals (CAP177 and CAP248) is
shown in Fig. 3B. Based on the IGHV repertoires from CAP177
and CAP248, the germline IGHV gene predicted to be used by
these two mAbs is IGHV2-5*9m, which has a serine (S) at po-
sition 62 rather than a glycine (G) present in the closest related
IMGT allele IGHV2-5*09. Compared with the germline allele, all
other SNPs found in these two mAbs are likely the results of
SHM. Of the remaining seven novel and non-IMGT alleles used
by these mAbs, four (57%) had a better match at the amino acid
level and three (43%) had a better match at the nucleotide level
compared with the closest matching IMGT allele (Fig. 3A). We
also analyzed the IGHV gene usage of 57 well-known HIV-1
bNAbs and found 14 instances in which the novel or non-IMGT
alleles, identified in this study, provided the same or a better match
than did their currently predicted IMGT allele (Fig. 3C). Two of
the predicted alleles (IGHV4-39*7m2 and IGHV4-59*1m2) also
were observed among the mAbs isolated from the CAPRISA
participants. An example of alternate IGHV allele usage for the
bNAbs is shown in Fig. 3D: PGT130 and PGT131 are more likely
to be using IGHV4-39*7m1 or IGHV4-39*7mm, which like the
mAbs have a valine (V) at the second amino acid, rather than
a leucine (L), as seen in IGHV4-39*07.
Comparison of germline IGHV repertoires in BCN and
non-BCN individuals
Given that some HIV broadly neutralizing mAbs show biased
variable H chain gene usage, we analyzed the germline IGHV
repertoires of BCN and non-BCN individuals to determine whether
the ability to develop bNAbs was associated with a particular
genotypic profile. Among the 28 CAPRISAwomen, 13 developed
bNAbs in their plasma after 2–4 y of HIV infection; 13 women did
not develop bNAbs, despite matching viral loads; and 2 were in-
termediate neutralizers [Supplemental Table I (19) and N. Mkhize,
E. Gray, and L. Morris, unpublished observations]. Comparison of
the BCN and non-BCN individuals revealed that they had similar
profiles of IGHV genes (Fig. 4A), approximately the same number
of alleles for each of those genes (Fig. 4B), and the same number
of potential alleles (Fig. 1E, 1F). The only gene that showed
FIGURE 3. Novel IGHValleles used by isolated mAbs and some bNAbs. (A) Germline IGHVallele usage for isolated mAbs from study participants. The
germline IGHV alleles used, as well as their corresponding IMGT allele, nucleotide, and amino acid substitutions between the two alleles, are shown. (B)
Alignment of germline IGHV allele usage for isolated mAbs from two study participants. Highlighted in yellow are the differences in amino acids at
position 62: G (glycine) and S (serine). Amino acid changes not highlighted in the figure are likely a result of SHM during Ab maturation. (C) Germline
IGHV allele usage for selected bNAbs. The published IMGT predicted allele and alternate allele(s) predicted from IGHV alleles in 28 South African
individuals are shown. (D) Alignment of predicted germline IGHV allele usage for PGT130 and PGT131. Highlighted in yellow are the differences at the
second amino acid: V (valine) and L (leucine). Amino acid changes not highlighted in the figure are likely a result of SHM during Ab maturation.
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statistical significance between the two groups was IGHV3-30
(p = 0.035, although significance was lost following Bonferroni
multiple testing correction); non-BCN individuals had five more
alleles (n = 11) compared with BCN individuals (n = 6) (Fig. 4B).
We also compared the frequency of the specific germline IGHV
alleles used by broadly neutralizing mAbs between the non-BCN
and BCN groups. Of the 57 monoclonal bNAbs targeting one of
four different epitopes on the HIV envelope glycoprotein, most
made use of IGHV1, IGHV3, and IGHV4 germline genes (Fig. 4C),
and, as reported above, some may use novel/non-IMGT alleles
(Fig. 3C). This included IGHV1-46*02, used by some CD4bs
Abs; however, there were two other alleles for this gene, including
IGHV1-46*01, which were found in all individuals. Similarly,
IGHV3-15*05 (used by bNAb 10E8) and IGHV3-33*05 (used by
bNAbs PG9 and PG16) were not observed in any of the individ-
uals in this study, but other alleles were more commonly observed,
FIGURE 4. Comparison of germline IGHV repertoires between BCN and non-BCN individuals. (A) Number of BCN and non-BCN individuals
with each of the functional IGHV genes in their IGHV repertoire. (B) Number of alleles observed for each of the functional IGHV genes in BCN
and non-BCN individuals. (C) Number of BCN and non-BCN individuals with the same IGHV alleles in their repertoire as those used by
monoclonal bNAbs.
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including some novel/non-IMGT alleles. The IGHV1-2*02 allele,
which is also used preferentially by CD4bs Abs (shown in blue
in Fig. 4C), occurred at high frequency in both the non-BCN and
BCN groups. The most prevalent IGHV alleles in both groups
were IGHV4-59*01 (used by the CD4bs bNAb CH103 and the
V3/glycan bNAbs PGT121–123), IGHV1-2*02 (used by CD4bs
mAbs), IGHV1-3*01 (used by the CD4bs bNAb IgG1b12), and
IGHV2-5*01/05 (used by bNAb 2F5 that targets the MPER).
Importantly, there was no difference in the frequency of any of
these alleles between the 13 BCN and 13 non-BCN individuals.
Thus, the inability of all HIV-infected individuals to develop
bNAbs is not due to a paucity of the relevant alleles in their IGHV
germline gene repertoires.
Discussion
We analyzed the germline IgH variable gene repertoire encoded in
the genomic DNA of individuals from KwaZulu-Natal, South
Africa, and noted that ∼48% of the alleles seen in this population
are not reported in IMGT. Some of these alleles (non-IMGT
alleles) were described in published studies of rearranged Abs,
although most alleles were novel and are described in this article
for the first time, to our knowledge. Further analysis of these
IGHV repertoires revealed there to be no differences between
individuals who developed bNAbs to HIV and those who did not,
despite equivalent antigenic load. Because the induction of these
types of Abs is considered essential for an effective HIV vaccine,
these data suggest that the ability to develop bNAbs is not re-
stricted by the IGHV repertoire.
Previous studies reported differences in the frequencies of IGHV
genes between different populations, with Africans showing par-
ticularly unique profiles (16). The presence of IGHV3-64D,
IGHV5-10-1, and IGHV7-4-1 was reported to be lower in Afri-
can (Luyha, Maasai, and Yoruba) populations compared with
Asian and European groups (16). We found a similarly low fre-
quency of IGHV3-64D (14%) in this Zulu-speaking South African
population. However, IGHV5-10-1 was observed at a higher prev-
alence (64%) compared with the studied African, Asian, and
European groups (0.03–16, 20–21, and 34–48%, respectively) (16),
whereas IGHV7-4-1 frequencies were similar (75%) to those seen
in Asian (∼78%) and European (54–75%) groups (16). IGHV1-69-2,
IGHV3-43D, and IGHV4-38-2 genes were reported to be common
in African populations (16), which we corroborated in our study for
IGHV1-69-2 and IGHV4-38-2 (75 and 61%, respectively). However,
we observed IGHV3-43D*01 in only 29% (8/28) of individuals
studied, which is lower than the prevalence reported in other African
groups (45–65%) (16).
We showed that both novel and non-IMGTalleles are being used
by mAbs isolated from individuals in this study, as well as some
well-characterized anti-HIV bNAbs. This included CH103 and 12
Abs in the PGT121-137 series, all of which were isolated from
African donors (34–36). Given that three of the novel and non-
IMGT alleles (IGHV3-21*1m, IGHV4-39*1m2, and IGHV4-
39*7m2) potentially being used by these bNAbs were fairly
common in the South African individuals (39, 36 and 21%, re-
spectively), it is perhaps not surprising that these were found to
contribute to functional Abs in other African individuals. IGHV4-
39*7m1 and IGHV4-39*7mm were less common in our study
group (4 and 11%, respectively). The other novel and non-IMGT
alleles used by mAbs isolated from the study participants also
were fairly commonly observed, ranging from 14 to 36%. Only 2
of the 15 mAbs isolated from the study participants were able to
bind HIV, highlighting that the use of novel and non-IMGT alleles
by functional Abs is not HIV specific and, thus, could play a role
in immune responses to other diseases or infections.
Despite the wide range in the number of IGHValleles present in
each individual, there were no differences in the overall germline
IGHV repertoires between BCN and non-BCN individuals. This
extended to a subanalysis of the genes and alleles used by known
broadly neutralizing mAbs whose frequency differed within the
cohort but not between BCN and non-BCN groups. The only gene
that showed a difference between the two groups was IGHV3-30:
non-BCN individuals had more alleles than did BCN individuals.
IGHV3-30 is used by the CAP256-VRC26 family of broad and
potent V1V2 Abs, which were isolated from CAPRISA donor
CAP256, a participant in this study (37). We also noted that al-
leles IGHV1-46*02, IGHV3-15*05, and IGHV3-33*05, used by
CD4bs, MPER, and V2 glycan bNAbs, respectively, were not
found in this South African cohort. However, other alleles of these
genes were observed in this cohort, as well as allelic variants used
by other bNAbs targeting the same epitopes. Thus, although the
specific alleles used by these bNAbs were not present, it did not
preclude these individuals from generating Abs to these epitopes.
In addition, CH103 and PGT121-123, which both use IGHV4-
59*01 (or the non-IMGT allele IGHV4-59*1m2), target different
epitopes (CD4bs and V3 glycans, respectively), demonstrating
that a single germline allele can be used by Abs against numerous
HIV envelope targets.
The germline IGHV gene makes the greatest contribution to
the unmutated common ancestor (UCA) Ab encoding the entire
CDRH1, CDRH2, FR1, FR2, and FR3 regions. Elegant studies on
the UCAs of the VRC01 class of Abs, which use the VH1-2*02
allele, showed how two glycans in the V5 region of the HIV en-
velope obstruct binding of the UCA (9, 38). Such studies guide the
design of suitable envelope immunogens able to trigger the
VRC01 class of Abs (9). However, other studies aimed at iden-
tifying UCA-binding envelopes for PG9 and other bNAb lineages
were less successful, primarily because the UCA approximations
used in such studies were predicted from highly mutated Abs and
using incomplete germline databases. The public availability of
a comprehensive database of germline Ig genes, including data
from this study (available from the authors), will significantly
enhance the accuracy with which UCAs can be inferred.
By studying an underrepresented population group in southern
Africa, this investigation has greatly expanded the repertoire of
germline IGHV genes. We further hypothesize that the IGHD and
IGHJ germline genes, which make up the remainder of the VH
region of functional Abs, are also likely to be highly variable
within this population and, thus, warrant investigation. Further-
more, we showed that some of these novel and non-IMGT alleles
are functionally active in both HIVand non-HIVAbs. This knowledge
will contribute to a better understanding of the Ab response to HIV,
as well as other infections, immunizations, and B cell pathologies.
Importantly, we also showed that the development of bNAbs
against HIV is not restricted by the germline IGHV repertoire,
which is significant for vaccine development, because it suggests
that everyone has the potential to make Abs capable of neutralizing
all strains and subtypes of HIV.
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Supplementary Table 3.2: List of all glycan components spotted onto the glycan 
arrays 
Glycan Type Glycan Name Description Linker Core Sugar Ratio 
Blood Group A 
2'F-A type 2-Sp - 
05 
GalNAca1-3[Fuca1-2]Galb1-
4[Fuca1-3]GlcNAcb-Sp Sp BSA 5 
Blood Group A 
2'F-A type 2-Sp - 
13 
GalNAca1-3[Fuca1-2]Galb1-
4[Fuca1-3]GlcNAcb-Sp Sp BSA 13 
Blood Group B 
2'F-B type 2-Sp - 
03 
Gala1-3[Fuca1-2]Galb1-4[Fuca1-
3]GlcNAcb-Sp Sp BSA 3 
Blood Group B 
2'F-B type 2-Sp - 
07 
Gala1-3[Fuca1-2]Galb1-4[Fuca1-
3]GlcNAcb-Sp Sp BSA 7 
Blood Group B 
2'F-B type 2-Sp - 
15 
Gala1-3[Fuca1-2]Galb1-4[Fuca1-
3]GlcNAcb-Sp Sp BSA 15 
Blood Group H 
2'FucLac (BG-
H5) Fuca1-2Galb1-4Glc-BSA  3 atom BSA 7 
carb-Sia 3'SLacNAc 
Sialyla2-3Galb1-4GlcNAc - BSA 
(3'SLacNAc) NA BSA 19 
carb-GlcNAc 
3'GN type1-Sp - 
04 GlcNAcb1-3Galb1-3GlcNAcb-Sp Sp BSA 4 
carb-GlcNAc 
3'GN type1-Sp - 
16 GlcNAcb1-3Galb1-3GlcNAcb-Sp Sp BSA 16 
carb-GlcNAc 
3'GN-Di-
LacNAc-Sp - 06 
GlcNAcb1-3(Galb1-4GlcNAcb1-
3)2b-Sp Sp BSA 6 
carb-GlcNAc 
3'GN-Di-
LacNAc-Sp - 14 
GlcNAcb1-3(Galb1-4GlcNAcb1-
3)2b-Sp Sp BSA 14 
carb-Sia 
3'KDNLacNAc-
Sp - 05 KDNa2-3Galb1-4GlcNAcb-Sp Sp BSA 5 
carb-Sia 
3'KDNLacNAc-
Sp - 12 KDNa2-3Galb1-4GlcNAcb-Sp Sp BSA 12 
carb-Sia 
3'-KDNLeC-Sp - 
04 KDNa2-3Galb1-3GlcNAcb-Sp Sp BSA 4 
carb-Sia 
3'-KDNLeC-Sp - 
12 KDNa2-3Galb1-3GlcNAcb-Sp Sp BSA 12 
carb-Sia 
3'S(Gc)LacNAc-
Sp - 06 Neu5Gca2-3Galb1-4GlcNAcb-Sp Sp BSA 6 
carb-Sia 
3'S(Gc)LacNAc-
Sp - 10 Neu5Gca2-3Galb1-4GlcNAcb-Sp Sp BSA 10 
carb-Sia 
3'S(Gc)LeC-Sp - 
05 Neu5Gca2-3Galb1-3GlcNAcb-Sp Sp BSA 5 
carb-Sia 
3'S(Gc)LeC-Sp - 
12 Neu5Gca2-3Galb1-3GlcNAcb-Sp Sp BSA 12 
carb-Sia 
3'S-Di-LacNAc-
Sp - 06 
Neu5Aca2-3(Galb1-4GlcNAcb1-
3)2b-Sp Sp BSA 6 
carb-Sia 
3'S-Di-LacNAc-
Sp - 13 
Neu5Aca2-3(Galb1-4GlcNAcb1-
3)2b-Sp Sp BSA 13 
carb-Sia 3'Sia-3-FL 
Siaa2-3Galb1-4(Fuca1-3)Glc -
BSA 3 atom BSA 7 
carb-Sia 
3'SLacNAc-Sp - 
05 Neu5Aca2-3Galb1-4GlcNAcb-Sp Sp BSA 5 
carb-Sia 
3'SLacNAc-Sp - 
10 Neu5Aca2-3Galb1-4GlcNAcb-Sp Sp BSA 10 
carb-Sia 3'SLDN-Sp - 05 
Neu5Aca2-3GalNAcb1-
4GlcNAcb-Sp Sp BSA 5 
carb-Sia 3'SLDN-Sp - 11 
Neu5Aca2-3GalNAcb1-
4GlcNAcb-Sp Sp BSA 11 
carb-Sia 3'SLeC-Sp - 05 Neu5Aca2-3Galb1-3GlcNAcb-Sp Sp BSA 5 
carb-Sia 3'SLeC-Sp - 12 Neu5Aca2-3Galb1-3GlcNAcb-Sp Sp BSA 12 
Lewis 3'-sulpho-LeA 
3-SO3-Galb1-3[Fuca1-
4)GlcNAc- 3 atom BSA 15 
Lewis 3'-sulpho-LeX 
3-SO3-Galb1-4[Fuca1-
3)GlcNAc- 3 atom BSA 15 
carb-Sia 6'SLac Sialyla2-6Galb1-4Glc-APD-HSA APD HSA   
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(6'Slac) 
carb-Sia 
6'S(Gc)LacNAc-
Sp - 05         
carb-Sia 
6'S(Gc)LacNAc-
Sp - ## (High) Neu5Gca2-6Galb1-4GlcNAcb-Sp Sp BSA 5 
carb-Sia 
6'S-Di-LacNAc-
Sp - 05 
Neu5Aca2-6[Galb1-4GlcNAcb1-
3)2b-Sp Sp BSA 5 
carb-Sia 
6'S-Di-LacNAc-
Sp - 13 
Neu5Aca2-6[Galb1-4GlcNAcb1-
3)2b-Sp Sp BSA 13 
carb-Sia 
6'SLacNAc-Sp - 
05 Neu5Aca2-6Galb1-4GlcNAcb-Sp Sp BSA 5 
carb-Sia 
6'SLacNAc-Sp - 
11 Neu5Aca2-6Galb1-4GlcNAcb-Sp Sp BSA 11 
carb-Sia 6'SLDN-Sp - 05 
Neu5Aca2-6GalNAcb1-
4GlcNAcb-Sp Sp BSA 5 
carb-Sia 6'SLDN-Sp - 13 
Neu5Aca2-6GalNAcb1-
4GlcNAcb-Sp Sp BSA 13 
Lewis 6'-sulpho-LeA 
6-SO3-Galb1-3[Fuca1-
4)GlcNAc- 3 atom BSA 16 
Lewis 6'-sulpho-LeX 
6-SO3-Galb1-4[Fuca1-
3)GlcNAc- 3 atom BSA 8 
carb-Sia 
9OAc3'SLacNAc
-Sp - 04 
Neu5Ac(9Ac)a2-3Galb1-
4GlcNAcb-Sp Sp BSA 4 
carb-Sia 
9OAc3'SLacNAc
-Sp - 10 
Neu5Ac(9Ac)a2-3Galb1-
4GlcNAcb-Sp Sp BSA 10 
carb-Sia 
9OAc3'SLeC-Sp 
- 05 
Neu5Ac(9Ac)a2-3Galb1-
3GlcNAcb-Sp Sp BSA 5 
carb-Sia 
9OAc3'SLeC-Sp 
- 12 
Neu5Ac(9Ac)a2-3Galb1-
3GlcNAcb-Sp Sp BSA 12 
Blood Group A 
A tetra type 1-Sp 
- 05 
GalNAca1-3[Fuca1-2]Galb1-
3GlcNAcb-Sp Sp BSA 5 
Blood Group A 
A tetra type 1-Sp 
- 15 
GalNAca1-3[Fuca1-2]Galb1-
3GlcNAcb-Sp Sp BSA 15 
Blood Group A 
A tetra type 2-Sp 
- 05 
GalNAca1-3[Fuca1-2]Galb1-
4GlcNAcb-Sp Sp BSA 5 
Blood Group A 
A tetra type 2-Sp 
- 07 
GalNAca1-3[Fuca1-2]Galb1-
4GlcNAcb-Sp Sp BSA 7 
Blood Group A 
A tetra type 2-Sp 
- 17 
GalNAca1-3[Fuca1-2]Galb1-
4GlcNAcb-Sp Sp BSA 17 
peptide-Tn 
Ac-A-Tn(Thr)-S-
G - 05 
Ac-Ala-(GalNAca)Thr-Ser-Gly-
Hex (muc4) hex BSA 5 
peptide-Tn 
Ac-A-Tn(Thr)-S-
G - 08 
Ac-Ala-(GalNAca)Thr-Ser-Gly-
Hex (muc4) hex BSA 8 
peptide-Tn 
Ac-A-Tn(Thr)-S-
G - 23 
Ac-Ala-(GalNAca)Thr-Ser-Gly-
Hex (muc4) hex BSA 23 
peptide-Tn 
Ac-G-V-Tn(Thr)-
S-A-G - 04 
Ac-Gly-Val-(GalNAca)Thr-Ser-
Ala-Gly-Hex (muc1) hex BSA 4 
peptide-Tn 
Ac-G-V-Tn(Thr)-
S-A-G - 21 
Ac-Gly-Val-(GalNAca)Thr-Ser-
Ala-Gly-Hex (muc1) hex BSA 21 
peptide-Tn 
Ac-P-Tn(Thr)-T-
G - 05 
Ac-Pro-(GalNAca)Thr-Thr-Gly-
Hex (muc2) hex BSA 5 
peptide-Tn 
Ac-P-Tn(Thr)-T-
G - 08 
Ac-Pro-(GalNAca)Thr-Thr-Gly-
Hex (muc2) hex BSA 8 
peptide-Tn 
Ac-P-Tn(Thr)-T-
G - 22 
Ac-Pro-(GalNAca)Thr-Thr-Gly-
Hex (muc2) hex BSA 22 
peptide-
GlcNAca 
Ac-S-
Ser(GlcNAca)-S-
G - 07 
AcSer-(GlcNAca)Ser-Ser-Gly-
Hex-BSA hex BSA 7 
peptide-
GlcNAca 
Ac-S-
Ser(GlcNAca)-S-
G - 24 
AcSer-(GlcNAca)Ser-Ser-Gly-
Hex-BSA hex BSA 24 
peptide-
GlcNAcb 
Ac-S-
Ser(GlcNAcB)-S-
G - 07 
AcSer-(GlcNAcb)Ser-Ser-Gly-
Hex-BSA hex BSA 7 
 195 
peptide-
GlcNAcb 
Ac-S-
Ser(GlcNAcB)-S-
G - 24 
AcSer-(GlcNAcb)Ser-Ser-Gly-
Hex-BSA hex BSA 24 
peptide Ac-S-S-S-G SerSerSerGly-BSA hex BSA 24 
peptide-TF 
Ac-S-TF(Ser)-S-
G - 04 
AcSer-(Galb1-3GalNAca)Ser-
Ser-Gly-Hex-BSA (S-TF-S) hex BSA 4 
peptide-TF 
Ac-S-TF(Ser)-S-
G - 16 
AcSer-(Galb1-3GalNAca)Ser-
Ser-Gly-Hex-BSA (S-TF-S) hex BSA 16 
peptide-TF 
Ac-S-TF(Ser)-S-
G - 28 
AcSer-(Galb1-3GalNAca)Ser-
Ser-Gly-Hex-BSA (S-TF-S) hex BSA 28 
peptide 
Ac-S-Thr-S-G - 
18 Ac-Ser-Thr-Ser-Gly-Hex  hex BSA 18 
peptide-Tn 
Ac-S-Tn(Ser)-S-
G - 04 
AcSer-(GalNAca)Ser-Ser-Gly-
Hex-BSA (STnS) hex BSA 4 
peptide-Tn 
Ac-S-Tn(Ser)-S-
G - 22 
AcSer-(GalNAca)Ser-Ser-Gly-
Hex-BSA (STnS) hex BSA 22 
peptide-Tn 
Ac-S-Tn(Ser)-S-
G - 33 
AcSer-(GalNAca)Ser-Ser-Gly-
Hex-BSA (STnS) hex BSA 33 
peptide-Tn 
Ac-S-Tn(Thr)-A-
G - 04 
Ac-Ser-(GalNAca)Thr-Ala-Gly-
Hex (muc1) hex BSA 4 
peptide-Tn 
Ac-S-Tn(Thr)-A-
G - 08 
Ac-Ser-(GalNAca)Thr-Ala-Gly-
Hex (muc1) hex BSA 8 
peptide-Tn 
Ac-S-Tn(Thr)-A-
G - 22 
Ac-Ser-(GalNAca)Thr-Ala-Gly-
Hex (muc1) hex BSA 22 
peptide-Tn 
Ac-S-Tn(Thr)-G-
G - 03 
Ac-Ser-(GalNAca)Thr-Gly-Gly-
Hex (muc4) hex BSA 3 
peptide-Tn 
Ac-S-Tn(Thr)-G-
G - 07 
Ac-Ser-(GalNAca)Thr-Gly-Gly-
Hex (muc4) hex BSA 7 
peptide-Tn 
Ac-S-Tn(Thr)-G-
G - 19 
Ac-Ser-(GalNAca)Thr-Gly-Gly-
Hex (muc4) hex BSA 19 
peptide-Tn 
Ac-S-Tn(Thr)-S-
G - 04 
AcSer-(GalNAca)Thr-Ser-Gly-
Hex-BSA (STnS) hex BSA 4 
peptide-Tn 
Ac-S-Tn(Thr)-S-
G - 24 
AcSer-(GalNAca)Thr-Ser-Gly-
Hex-BSA (STnS) hex BSA 24 
peptide-Tn 
Ac-S-Tn(Thr)-S-
G HSA-04 
AcSer-(GalNAca)Thr-Ser-Gly-
Hex-HSA (STnS) hex HSA 4 
peptide-Tn 
Ac-S-Tn(Thr)-S-
G HSA-23 
AcSer-(GalNAca)Thr-Ser-Gly-
Hex-HSA (STnS) hex HSA 23 
peptide-Tn 
Ac-S-Tn(Thr)-
Tn(Thr)-G - 05 
Ac-Ser-(GalNAca)Thr-
(GalNAca)Thr-Gly-Hex (muc2) hex BSA 5 
peptide-Tn 
Ac-S-Tn(Thr)-
Tn(Thr)-G - 09 
Ac-Ser-(GalNAca)Thr-
(GalNAca)Thr-Gly-Hex (muc2) hex BSA 9 
peptide-Tn 
Ac-S-Tn(Thr)-
Tn(Thr)-G - 22 
Ac-Ser-(GalNAca)Thr-
(GalNAca)Thr-Gly-Hex (muc2) hex BSA 22 
peptide-Tn 
Ac-S-Tn(Thr)-V-
G - 04 
Ac-Ser-(GalNAca)Thr-Val-Gly-
Hex  hex BSA 4 
peptide-Tn 
Ac-S-Tn(Thr)-V-
G - 22 
Ac-Ser-(GalNAca)Thr-Val-Gly-
Hex  hex BSA 22 
peptide-TF 
Ac-TF(Ser)-G - 
04 
Ac(Galb1-3GalNAca)Ser-Gly-
Hex-BSA hex BSA 4 
peptide-TF 
Ac-TF(Ser)-G - 
24 
Ac(Galb1-3GalNAca)Ser-Gly-
Hex-BSA hex BSA 24 
peptide-Tn 
Ac-
Tn(Ser)Tn(Ser)T
n(Ser)-G - 03 
Ac(GalNAca)Ser-(GalNAca)Ser-
(GalNAca)Ser-Gly-Hex-BSA 
(Tn3) hex BSA 3 
peptide-Tn 
Ac-Tn(Ser)-
Tn(Ser)-Tn(Ser)-
G - 16 
Ac(GalNAca)Ser-(GalNAca)Ser-
(GalNAca)Ser-Gly-Hex-BSA 
(Tn3) hex BSA 16 
peptide-Tn 
Ac-
Tn(Ser)Tn(Ser)T
n(Ser)-G - 27 
Ac(GalNAca)Ser-(GalNAca)Ser-
(GalNAca)Ser-Gly-Hex-BSA 
(Tn3) hex BSA 27 
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peptide-Tn 
Ac-Tn(Thr)-G - 
21 Ac(GalNAca)Thr-Gly-Hex-BSA hex BSA 21 
peptide-Tn 
Ac-Tn(Thr)-
Tn(Thr)-Tn(Thr)-
G - 05 
Ac-(GalNAca)Thr-
(GalNAca)Thr-(GalNAca)Thr-
Gly-Hex (muc2) hex BSA 5 
peptide-Tn 
Ac-Tn(Thr)-
Tn(Thr)-Tn(Thr)-
G - 08 
Ac-(GalNAca)Thr-
(GalNAca)Thr-(GalNAca)Thr-
Gly-Hex (muc2) hex BSA 8 
peptide-Tn 
Ac-Tn(Thr)-
Tn(Thr)-Tn(Thr)-
G - 20 
Ac-(GalNAca)Thr-
(GalNAca)Thr-(GalNAca)Thr-
Gly-Hex (muc2) hex BSA 20 
peptide-Tn 
Ac-T-Tn(Thr)-P-
G - 04 
Ac-Thr-(GalNAca)Thr-Pro-Gly-
Hex (muc2,6,7) hex BSA 4 
peptide-Tn 
Ac-T-Tn(Thr)-P-
G - 08 
Ac-Thr-(GalNAca)Thr-Pro-Gly-
Hex (muc2,6,7) hex BSA 8 
peptide-Tn 
Ac-T-Tn(Thr)-P-
G - 21 
Ac-Thr-(GalNAca)Thr-Pro-Gly-
Hex (muc2,6,7) hex BSA 21 
peptide-Tn 
Ac-V-Tn(Thr)-S-
G - 04 
Ac-Val-(GalNAca)Thr-Ser-Gly-
Hex (muc1) hex BSA 4 
peptide-Tn 
Ac-V-Tn(Thr)-S-
G - 08 
Ac-Val-(GalNAca)Thr-Ser-Gly-
Hex (muc1) hex BSA 8 
peptide-Tn 
Ac-V-Tn(Thr)-S-
G - 19 
Ac-Val-(GalNAca)Thr-Ser-Gly-
Hex (muc1) hex BSA 19 
Blood Group A Adi - 04 GalNAca1-3Galb-BSA (Adi) MEAG BSA 4 
Blood Group A Adi - 17 GalNAca1-3Galb-BSA (Adi) MEAG BSA 17 
glycoprotein AGE60 
Advanced glycation endproducts 
day 60 (AGE60) na BSA na 
Blood Group A A-LeB hexa 
GalNAca1-3(Fuca1-2)Galb1-
3(Fuca1-4)GlcNAcb1-3Galb1- (Glc) BSA 6 
glycoprotein 
Alpha-1-acid 
glycoprotein alpha1 Acid Glycoprotein na   na 
glycoprotein Alpha-fetoprotein alpha fetoprotein (AFP) na   na 
non-human-aGal alphaGal 
Gala1-3Galb1-4GlcNAc-BSA 
(alphaGal) 
14 atom 
spacer  BSA 8 
non-human 
alpha-Gal tetra - 
04 
Gala1-3Galb1-4GlcNAcb1-
3Galb1- (Glc) BSA 4 
non-human 
alpha-Gal tetra - 
17 
Gala1-3Galb1-4GlcNAcb1-
3Galb1- (Glc) BSA 17 
non-human-aGal alphaGal-6-deoxy 
Gala1-3Galb1-4(6deoxy-
GlcNAc)-HSA (alphaGal) 
3 atom 
spacer  HSA 11 
non-human Ara5 
Araa1-5Araa1-5Araa1-5Araa1-
5Araa1-BSA (Ara5) (Ara) BSA 20 
Blood Group B 
B tetra type 1-Sp 
- 04 
Gala1-3[Fuca1-2]Galb1-
3GlcNAcb-Sp Sp BSA 4 
Blood Group B 
B tetra type 1-Sp 
- 16 
Gala1-3[Fuca1-2]Galb1-
3GlcNAcb-Sp Sp BSA 16 
Blood Group B 
B tetra type 2-Sp 
- 05 
Gala1-3[Fuca1-2]Galb1-
3GlcNAcb-Sp Sp BSA 5 
Blood Group B 
B tetra type 2-Sp 
- 07 
Gala1-3[Fuca1-2]Galb1-
4GlcNAcb-Sp Sp BSA 7 
Blood Group B 
B tetra type 2-Sp 
- 20 
Gala1-3[Fuca1-2]Galb1-
4GlcNAcb-Sp Sp BSA 20 
non-human B6 di - 06 Gala1-3Galb‰ÛÒ BSA (Bdi) (Glc) BSA 6 
non-human B6 di - 16 Gala1-3Galb‰ÛÒ BSA (Bdi) (Glc) BSA 16 
non-human Bdi Gala1-3Gal‰ÛÒ BSA (Bdi) 
14 atom 
spacer  BSA 23 
Blood Group A BG-A 
GalNAca1-3(Fuca1-2)Galb•Û_ -
BSA [BG-A] 
6 atom 
spacer BSA 19 
Blood Group A BG-A1 
GalNAca1-3(Fuca1-2)Galb1-
3GlcNAcb1-3Galb1-4(Glc)-APD-
HSA (BG-A1) APD HSA 5 
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Blood Group B BG-B (Dextra) 
Gala1-3(Fuca1-2)Galb-BSA [BG-
B] from Dextra 
6 atom 
spacer BSA 13 
Blood Group H BG-H1 
Fuca1-2Galb1-3GlcNAcb1-
3Galb1-4Glcb‰ÛÒAPD-HSA 
[BG-H1]  APD- HSA 20 
Blood Group H BG-H2 
Fuca1-2Galb1-4GlcNAcb-HSA 
(BG-H2) 
unknow
n HSA 16 
control BSA Bovine serum albumin na BSA na 
control 
BSA - C5 
(Alkyne) - 10 DF-168B-175-1 C5 BSA   
control 
BSA - C5 
(Alkyne) - 23 DF-168C-16-B5 C5 BSA   
control BSA-#2   na   na 
control 
Triazole linker 
from Xuefei BSA-linker-triazole from Xuefei 
adipic 
acid BSA 43 
glycoprotein BSM 
Bovine submaxillary mucin (STn, 
STF, S-GlcNAcb1-3, ~20% of 
Sia is acetylated at 7,8, or 9) na BSM na 
glycoprotein BSM (asialo) 
Asialo-Bovine submaxillary 
mucin (aBSM, Tn, TF, 
GlcNAcb1-3GalNAc) na BSM na 
glycoprotein 
BSM 
(deacetylated) 
Deacetylated-Bovine 
submaxillary mucin na BSM na 
glycoprotein BSM (ox) 
periodate oxidized bovine 
submaxillary mucin na   na 
glycoprotein CEA carcinoembryonic antigen (CEA) na   na 
non-human Cellobiose Glcb1-4Glcb-BSA (Cellobiose) (Glc) BSA 13 
non-human Cellotriose 
Glcb1-4Glcb1-4Glcb-BSA 
(Cello3)  (Glc) BSA 13 
non-human Chito 3 
GlcNAcb1-4GlcNAcb1-
4GlcNAcb-BSA (Chito 3) 
(GlcNA
c) BSA 8 
non-human Chito 3 - 20 
GlcNAcb1-4GlcNAcb1-
4GlcNAcb-BSA (Chito 3) 
(GlcNA
c) BSA 20 
carb-Sia CT/Sda-Sp - 05 
Neu5Aca2-3[GalNAcb1-4]Galb1-
4GlcNAcb-Sp Sp BSA 5 
carb-Sia CT/Sda-Sp - 13 
Neu5Aca2-3[GalNAcb1-4]Galb1-
4GlcNAcb-Sp Sp BSA 13 
control Cy3 
Cy3-BSA (20mg/mL + BSA, 
125mg/mL total) na BSA   
control Cy5 
Cy5-BSA (30mg/mL+ BSA, 
125mg/mL total) na BSA   
Lewis DFLNH(c) 
Galb1-4GlcNAcb1-6[Fuca1-
2Galb1-3(Fuca1-4)GlcNAcb1-
3]Galb1-BSA (Glc) BSA 8 
Lewis DFLNnH 
Galb1-4(Fuca1-3)GlcNAcb1-
6[Galb1-4(Fuca1-3)GlcNAcb1-
3]Galb1-BSA (Glc) BSA 10 
Lewis DFpLNH I 
Fuca1-2Galb1-3(Fuca1-
4)GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb-BSA (Glc) BSA 9 
carb-type 2 
Di-LacNAc-Sp - 
06 (Galb1-4GlcNAcb1-3)2b-Sp Sp BSA 6 
carb-type 2 
Di-LacNAc-Sp - 
16 (Galb1-4GlcNAcb1-3)2b-Sp Sp BSA 16 
Lewis Di-LeC-Sp - 06 
Galb1-3GlcNAcb1-3Galb1-
3GlcNAcb-Sp Sp BSA 6 
Lewis Di-LeC-Sp - 16 
Galb1-3GlcNAcb1-3Galb1-
3GlcNAcb-Sp Sp BSA 16 
carb-Sia DSLNT 
Siaa2-3Galb1-3(Siaa2-
6)GlcNAcb1-3Galb1-BSA 
(DSLNT) (Glc) BSA 5.6 
glycoprotein FABP 
Fatty Acid Binding Protein 
(FABP) na   na 
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glycoprotein fetuin 
fetuin (Sia2-3LacNAc, Sia2-
6LacNAc, SiaLeC, STF) na   na 
glycoprotein fetuin (asialo) 
asialofetuin (Galb1-4GlcNAc, 
Galb1-3GlcNAc, Galb1-3GalNAc       
glycoprotein Fetuin (ox) periodate oxidized fetuin na   na 
non-human Forssman Di - 04 GalNAca1-3GalNAcb1-BSA MEAG BSA 4 
non-human Forssman Di - 21 GalNAca1-3GalNAcb1-BSA MEAG BSA 21 
non-human Forssman Di - 31 GalNAca1-3GalNAcb1-BSA MEAG BSA 31 
non-human 
Forssman Tetra-
BSA - 05 
GalNAca1-3GalNAcb1-3Gala1-
4Galb-BSA (Glc) BSA 5 
non-human 
Forssman Tetra-
BSA - 13 
GalNAca1-3GalNAcb1-3Gala1-
4Galb-BSA (Glc) BSA 13 
Lewis 
Fuc, Sia-LNnH-
APD-HSA 
Galb1-4[Fuca1-3]GlcNAcb1-
6[Neu5Aca2-3Galb1-
4GlcNAcb1-3]Galb1-APD-HSA APD HSA 12 to 15 
carb-Fuc Fuc-a - 04 Fuc-a - BSA MEAG BSA 4 
carb-Fuc Fuc-a - 22 Fuc-a - BSA MEAG BSA 22 
non-human Fuc-b - 04 Fuc-b - BSA MEAG BSA 4 
non-human Fuc-b - 22 Fuc-b - BSA MEAG BSA 22 
glycolipid Fuc-GM1a - 08 
Fuca1-2Galb1-3GalNAcb1-
4(Siaa2-3)Galb1-4 (Glc) BSA 8 
non-human G2M4 
Manb1-4(Gala1-6)Manb1-
4(Gala1-6)Manb1-4Manb1-BSA 
(G2M4) (man) BSA 7 
glycolipid GA1 - 06 
Galb1-3GalNAcb1-4Galb1-BSA 
(GA1tri or asialo-GM1) (Glc)   6 
glycolipid GA1 - 20 
Galb1-3GalNAcb1-4Galb1-BSA 
(GA1tri or asialo-GM1) (Glc) BSA 20 
glycolipid GA1di 
Galb1-3GalNAcb ‰ÛÒ HSA 
(GA1di) 
3 atom 
spacer) HSA 11 
glycolipid GA2di - 04 
GalNAcb1-4Galb - BSA (GA2di 
or asialo-GM2) MEAG BSA 4 
glycolipid GA2di - 16 
GalNAcb1-4Galb - BSA (GA2di 
or asialo-GM2) MEAG BSA 16 
glycolipid GA2di - 37 
GalNAcb1-4Galb - BSA (GA2di 
or asialo-GM2 MEAG BSA 37 
glycolipid GA2di (accurate) 
GalNAcb1-4Galb - BSA (GA2di 
or asialo-GM2) 
unknow
n BSA 28 
non-human-aGal Gal3 Gala1-3Galb1-4Gala-BSA (Gal3) (1-3Gal) BSA 7 
carb-Gal Gal-a Gal-a - BSA MEAG BSA 24 
non-human Gala1-2Gal Gala1-2Gal 3 atom BSA 13 
carb-Gal Gala1-4Galb Gala1-4Galb-CETE-BSA CETE BSA 11 
non-human-aGal Gala3-type1 Gala1-3Galb1-3GlcNAc-BSA 3 atom BSA 9 
carb-Gal Gal-b Gal-b - BSA MEAG BSA 21 
non-human Galb1-4Gal Galb1-4Gal-BSA 
3 atom 
spacer  BSA   
non-human Galb1-6Man-a Galb1-6Man-a - BSA MEAG BSA 13 
non-human-aGal Galilli Gala1-3Galb1-4Glc-BSA  3 atom BSA 21 
carb-GalNAc GalNAc-a - 04 GalNAc-a - BSA MEAG   4 
carb-GalNAc GalNAc-a - 22 GalNAc-a - BSA MEAG BSA 22 
carb-GalNAc 
GalNAca1-6Galb 
- 04 GalNAca1-6Galb-BSA MEAG   4 
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carb-GalNAc 
GalNAca1-6Galb 
- 22 GalNAca1-6Galb-BSA MEAG BSA 22 
carb-GalNAc GalNAc-b GalNAc-b - BSA MEAG BSA 21 
glycolipid Gb4 
GalNAcb1-3Gala1-4Galb1-BSA 
(Gb4 or P antigen) (Glc) BSA 9 
glycolipid 
Gb4 tetra (P1 
tetra)-Sp - 06 
GalNAcb1-3Gala1-4Galb1-
4GlcNAcb-Sp Sp BSA 6 
glycolipid 
Gb4 tetra (P1 
tetra)-Sp - 15 
GalNAcb1-3Gala1-4Galb1-
4GlcNAcb-Sp Sp BSA 15 
glycolipid Gb5/SSEA3 - 04 
Galb1-3GalNAcb1-3Gala1-
4Galb1- (Glc) BSA 4 
glycolipid Gb5/SSEA3 - 12 
Galb1-3GalNAcb1-3Gala1-
4Galb1- (Glc) BSA 12 
glycolipid GD1a-Sp - 05 
Neu5Aca2-3[Neu5Aca2-3Galb1-
3GalNAcb1-4]Galb1-4Glcb-Sp Sp BSA 5 
glycolipid GD1a-Sp - 10 
Neu5Aca2-3[Neu5Aca2-3Galb1-
3GalNAcb1-4]Galb1-4Glcb-Sp Sp BSA 10 
glycolipid GD1b 
Siaa2-8Siaa2-3(Galb1-
3GalNAcb1-4)Galb1-4-BSA (Glc) BSA 5 
glycolipid GD2-Sp - 04 
Neu5Aca2-8Neu5Aca2-
3[GalNAcb1-4]Galb1-4Glcb-Sp Sp BSA 4 
glycolipid GD2-Sp - 10 
Neu5Aca2-8Neu5Aca2-
3[GalNAcb1-4]Galb1-4Glcb-Sp Sp BSA 10 
glycolipid GD3-Sp - 04 
Neu5Aca2-8Neu5Aca2-3Galb1-
4Glcb-Sp Sp BSA 4 
glycolipid GD3-Sp - 08 
Neu5Aca2-8Neu5Aca2-3Galb1-
4Glcb-Sp Sp BSA 8 
carb-Glc Glc-a Glc-a - BSA MEAG BSA 22 
carb-Glc Glc-a - 05 Glc-a - BSA MEAG BSA 5 
carb-Glc 
Glca1-6Glca1-
4Glca1-4Glcb 
Glca1-6Glca1-4Glca1-4Glcb-
CETE-BSA CETE BSA 15 
carb-Glc Glc-b Glc-b - BSA MEAG BSA 23 
carb-GlcNAc 
GlcNAca1-4Galb 
- 03 GlcNAca1-4Galb-BSA MEAG BSA 3 
carb-GlcNAc 
GlcNAca1-4Galb 
- 20 GlcNAca1-4Galb-BSA MEAG BSA 20 
carb-GlcNAc GlcNAc-b GlcNAc-b - BSA MEAG BSA 21 
N-linked GlcNAc-Man3 
Mana1-6(GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb-BSA  
(GlcNA
c) BSA 2 
N-linked GlcNAc-Man5 
Mana1-6(Mana1-3)Mana1-
6(GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb-BSA  
(GlcNA
c) BSA 3 
Blood Group A Globo A 
GalNAca1-3(Fuca1-2)Galb1-
3GalNAcb1-3Gala1-4Galb1-BSA (Glc) BSA 9 
Blood Group H Globo H 
Fuca1-2Galb1-3GalNAcb1-
3Gala1-4Galb1-BSA (Glc) BSA 10 
glycoprotein 
glycophorin 
(asialo) asialo-glycophorin A (aGn) na Gn na 
glycoprotein Glycophorin A Glycophorin A (Gn) na Gn na 
glycolipid GM1a 
Galb1-3GalNAcb1-4(Siaa2-
3)Galb1-4(Glc)HSA  (Glc) HSA 29 
glycolipid GM2-Sp - 04 
Neu5Aca2-3[GalNAcb1-4]Galb1-
4Glcb-Sp Sp BSA 4 
glycolipid GM2-Sp - 07 
Neu5Aca2-3[GalNAcb1-4]Galb1-
4Glcb-Sp Sp BSA 7 
glycolipid GM2-Sp - 14 
Neu5Aca2-3[GalNAcb1-4]Galb1-
4Glcb-Sp Sp BSA 14 
glycolipid GM3 Sialyla2-3Galb1-4Glc-APD-HSA  APD HSA 15-Dec 
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glycolipid GM3(Gc)-Sp - 05 Neu5Gca2-3Galb1-4Glcb-Sp Sp BSA 5 
glycolipid GM3(Gc)-Sp - 14 Neu5Gca2-3Galb1-4Glcb-Sp Sp BSA 14 
glycolipid GM3-Sp - 04 Neu5Aca2-3Galb1-4Glcb-Sp Sp BSA 4 
glycolipid GM3-Sp - 11 Neu5Aca2-3Galb1-4Glcb-Sp Sp BSA 11 
carb-GlcNAc 
GNLacNAc-Sp - 
06 GlcNAcb1-3Galb1-4GlcNAcb-Sp Sp BSA 6 
carb-GlcNAc 
GNLacNAc-Sp - 
16 GlcNAcb1-3Galb1-4GlcNAcb-Sp Sp BSA 16 
glycolipid GQ2-Sp - 03 
Neu5Aca2-8Neu5Aca2-
8Neu5Aca2-8Neu5Aca2-
3[GalNAcb1-4]Galb1-4Glcb-Sp Sp BSA 3 
glycolipid GQ2-Sp - 06 
Neu5Aca2-8Neu5Aca2-
8Neu5Aca2-8Neu5Aca2-
3[GalNAcb1-4]Galb1-4Glcb-Sp Sp BSA 6 
glycolipid GT2-Sp - 03 
Neu5Aca2-8Neu5Aca2-
8Neu5Aca2-3[GalNAcb1-
4]Galb1-4Glcb-Sp Sp BSA 3 
glycolipid GT2-Sp - 08 
Neu5Aca2-8Neu5Aca2-
8Neu5Aca2-3[GalNAcb1-
4]Galb1-4Glcb-Sp Sp BSA 8 
glycolipid GT3-Sp - 03 
Neu5Aca2-8Neu5Aca2-
8Neu5Aca2-3Galb1-4Glcb-Sp Sp BSA 3 
glycolipid GT3-Sp - 07 
Neu5Aca2-8Neu5Aca2-
8Neu5Aca2-3Galb1-4Glcb-Sp Sp BSA 7 
GAG Hep-5000 
heparin polysaccharide (MW 
~5000) na BSA 1 
GAG Hep-N-acetylated 
fully N-acetylated heparin 
polysaccharide na BSA 1 
control HSA 
Human serum albumin (isolated 
from serum) na HSA na 
control HSA (recomb) 
human serum albumin 
(recombinant) na HSA na 
glycoprotein hsp90 Heat Shock Protein 90 (hsp90) na   na 
GAG Hya8 (GlcNAcb1-4GlcAb1-3)4b1- 
(GlcNA
c) BSA 3 
GAG Hya9 
(GlcAb1-3GlcNAcb1-4)4b1-
3GlcAb1- 
(GlcNA
c) BSA 3 
N-linked Hybrid-M5N4B 
GlcNAcb1-2Mana1-3[Mana1-
3(Mana1-6)Mana1-6](GlcNAcb1-
4)Manb1-4GlcNAcb1- 
(GlcNA
c) BSA 3 
carb-type 1 iLNO 
Galb1-3GlcNAcb1-3Galb1-
4GlcNAcb1-6 (Galb1-
3GlcNAcb1-3)Galb1- (Glc) BSA 6 
carb-Glc Isomaltose Glca1-6Glcb-BSA MEAG BSA 13 
glycoprotein KLH Keyhole limpet hemocyanin na KLH na 
glycoprotein KLH (oxidized) 
periodate oxidized Keyhole 
limpet hemocyanin na KLH na 
carb-type 2 LacNAc 
Galb1-4GlcNAc ‰ÛÒ BSA 
(LacNAc) 
14 atom 
spacer  BSA 22 
carb-type 2 
LacNAc 
(trimeric) 
Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb-
APE-HSA (TriLacNAc) APE HSA 8 
N-linked LacNAc-Man5 
Mana1-6(Mana1-3)Mana1-
6(Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb-BSA  
(GlcNA
c) BSA 2 
carb-type 2 LacNAc-Sp - 06 Galb1-4GlcNAcb-Sp Sp BSA 6 
carb-type 2 LacNAc-Sp - 15 Galb1-4GlcNAcb-Sp Sp BSA 15 
carb-Gal Lactose Galb1-4Glcb ‰ÛÒ BSA (Lac) 
unknow
n BSA 33 
carb-Gal Lactose-C5 - 05 Galb1-4Glcb ‰ÛÒ BSA (Lac) C5 BSA 5 
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carb-Gal Lactose-C5 - 14 Galb1-4Glcb ‰ÛÒ BSA (Lac) C5 BSA 14 
carb-GalNAc LDN-Sp - 05 GalNAcb1-4GlcNAcb-Sp Sp BSA 5 
carb-GalNAc LDN-Sp - 14 GalNAcb1-4GlcNAcb-Sp Sp BSA 14 
Lewis LeA 
Galb1-3[Fuca1-4)GlcNAcb1-
3Galb1-4Glcb- BSA  (Lea ) 
3 atom 
spacer BSA 18 
Lewis LeA-LeX 
Galb1-3(Fuca1-4)GlcNAcb1-
3Galb1-4(Fuca1-3)GlcNAcb1-
3Galb1-APD-HSA APD HSA 21 
Lewis LeB 
Fuca1-2Galb1-3[Fuca1-
4)GlcNAcb1-3Galb1-4Glcb-BSA 
(Leb ) 
3 atom 
spacer BSA 9 
Lewis LeC-Sp - 06 Galb1-3GlcNAcb-Sp Sp BSA 6 
Lewis LeC-Sp - 07 Galb1-3GlcNAcb-Sp Sp BSA 7 
Lewis LeC-Sp - 15 Galb1-3GlcNAcb-Sp Sp BSA 15 
Lewis LeX (dimeric) 
Galb1-4[Fuca1-3)GlcNAcb1-
3Galb1-4(Fuca1-3)GlcNAcb1-
3Galb1-APE-BSA  APE BSA 7 
Lewis LeX (monomeric) 
Galb1-4[Fuca1-3)GlcNAc-APD-
HSA (Lex)  APD HSA x 
Lewis LeY 
Fuca1-2Galb1-4[Fuca1-
3)GlcNAc ‰ÛÒHSA (Ley) 
unknow
n HSA 8 
carb-type 1+2 LNH - 13 
Galb1-4GlcNAcb1-6(Galb1-
3GlcNAcb1-3)Galb1-BSA (Glc) BSA 13 
carb-type 2 LNnH - 11 
Galb1-4GlcNAcb1-6(Galb1-
4GlcNAcb1-3)Galb1-BSA (Glc) BSA 11 
carb-type 2 LNnT - 04 
Galb1-4GlcNAcb1-3Galb1-BSA 
(LNnT) (Glc) BSA 4 
carb-type 2 LNnT - 14 
Galb1-4GlcNAcb1-3Galb1-BSA 
(LNnT) (Glc) BSA 14 
carb-type 1 LNT - 05 
Galb1-3GlcNAcb1-3Galb-BSA 
(LNT) (Glc) BSA 5 
carb-type 1 LNT - 21 
Galb1-3GlcNAcb1-3Galb-BSA 
(LNT) (Glc) BSA 21 
carb-GlcNAc LNT-2-Sp - 06 GlcNAcb1-3Galb1-4Glcb-Sp Sp BSA 6 
carb-GlcNAc LNT-2-Sp - 15 GlcNAcb1-3Galb1-4Glcb-Sp Sp BSA 15 
carb-type 1 LNT-Sp - 06 
Galb1-3GlcNAcb1-3Galb1-
4GlcNAcb-Sp Sp BSA 6 
carb-type 1 LNT-Sp - 15 
Galb1-3GlcNAcb1-3Galb1-
4GlcNAcb-Sp Sp BSA 15 
carb-Sia LSTa 
Siaa2-3Galb1-3GlcNAcb1-
3Galb1-BSA (LSTa) (Glc) BSA 10 
carb-Sia LSTb 
Galb1-3(Siaa2-6)GlcNAcb1-
3Galb1-BSA (LSTb) (Glc) BSA 11 
carb-Sia LSTc 
Siaa2-6Galb1-3GlcNAcb1-
3Galb1-BSA (LSTc) (Glc) BSA 7 
carb-Glc Maltopentaose 
Glca1-4Glca1-4Glca1-4Glca1-
4Glca-BSA (Malto5) (Glc) BSA 11 
carb-Glc Maltose Glca1-4Glcb-BSA (Maltose) MEAG BSA 23 
N-linked Man1 - 04 Manβ1-4GlcNAcβ1-4GlcNAcβ1- 4HB BSA 4 
N-linked Man1 - 12 Manβ1-4GlcNAcβ1-4GlcNAcβ1- 4HB BSA 12 
N-linked Man3 
Manα1-6(Manα1-3)Manβ1-
4GlcNAc -BSA (Man3) 
(GlcNA
c) BSA 5 
N-linked Man5 
Manα1-6(Manα1-3)Manα1-
6(Manα1-3)Manβ1-4GlcNAc-
BSA (Man5) 
(GlcNA
c) BSA 5 
N-linked Man6 - I 
Manα1-6(Manα1-3)Manα1-
6(Manα1-2Manα1-3)Manβ1-BSA  
(GlcNA
c) BSA 4 
N-linked Man6 - II 
Manα1-2Manα1-3Manα1-
6(Manα1-2Manα1-3)Manβ1-BSA 
(GlcNA
c) BSA 5 
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(Man6 - II) 
N-linked Man7D1 
Manα1-6(Manα1-3)Manα1-
6(Manα1-2Manα1-2Manα1-
3)Manβ1-4GlcNAc-BSA 
(GlcNA
c) BSA 10 
N-linked Man7D3 
Manα1-2Manα1-6(Manα1-
3)Manα1-6(Manα1-2Manα1-
3)Manβ1-4GlcNAc-BSA 
(GlcNA
c) BSA 8 
N-linked Man8D1D3 
Manα1-2Manα1-6(Manα1-
3)Manα1-6(Manα1-2Manα1-
2Manα1-3)Manβ1-4GlcNAc-
BSA 
(GlcNA
c) BSA 9 
N-linked Man9 
Manα1-2Manα1-6(Manα1-
2Manα1-3)Manα1-6(Manα1-
2Manα1-2Manα1-3)Manβ1-
4GlcNAc-BSA  
(GlcNA
c) BSA 5 
carb-Man Man-a Man-α - BSA MEAG BSA 20 
carb-Man Man-a - 05 Man-α - BSA MEAG BSA 5 
carb-Man Mana1-6Man-a Manα1-6Man-α - BSA MEAG BSA 15 
carb-Man 
Mana1-6Man-a - 
04 Manα1-6Man-α- BSA MEAG BSA 4 
non-human Manb4 - 04 
Manβ1-4Manβ1-4Manβ1-
4Manβ1-BSA (Manb4) (Man) BSA 14 
non-human Manb4         
carb-Man ManT 
Manα1-6[Manα1-3]Manβ-BSA 
[ManT] 
14 atom 
spacer  BSA 26 
carb-type 1 MFiLNO(1-3) 
Galb1-3GlcNAcb1-3Galb1-
4(Fuca1-3)GlcNAcb1-6 (Galb1-
3GlcNAcb1-3)Galb1- (Glc) BSA 9 
Lewis MFLNH I 
Galb1-4GlcNAcb1-6 (Fuca1-
2Galb1-3GlcNAcb1-3)Galb1- (Glc) BSA 11 
Lewis MFLNH III 
Galb1-4(Fuca1-3)GlcNAcb1-6 
(Galb1-3GlcNAcb1-3)Galb1- (Glc) BSA 14 
Lewis MSMFLNH I 
Siaa2-6Galb1-4GlcNAcb1-6 
(Fuca1-2Galb1-3GlcNAcb1-
3)Galb1- (Glc) BSA 11 
Lewis MSMFLnNH 
Galb1-4(Fuca1-3)GlcNAcb1-6 
(Siaa1-3Galb1-4GlcNAcb1-
3)Galb1- (Glc) BSA 9 
N-linked NA2 
Galb1-4GlcNAcb1-2Mana1-
6[Galb1-4GlcNAcb1-2Mana1-
3]Manb1-4GlcNAc -BSA (NA2) 
(GlcNA
c) BSA 8 
N-linked NA3 
Galb1-4GlcNAcb1-2Mana1-
6[Galb1-4GlcNAcb1-2(Galb1-
4GlcNAcb1-4)Mana1-3]Manb1-
4GlcNAc -BSA (NA3) 
(GlcNA
c) BSA 5 
N-linked NA4 
Galb1-4GlcNAcb1-2(Galb1-
4GlcNAcb1-6)Mana1-6[Galb1-
4GlcNAcb1-2(Galb1-
4GlcNAcb1-4)Mana1-3]Manb1-
4GlcNAc -BSA (NA4) 
(GlcNA
c) BSA 5 
N-linked NGA2 
GlcNAcb1-2Mana1-
6(GlcNAcb1-2Mana1-3)Manb1-
4GlcNAc -BSA (NGA2) 
(GlcNA
c) BSA 7 
N-linked NGA2B 
GlcNAcb1-2Mana1-
6(GlcNAcb1-2Mana1-
3)(GlcNAcb1-4)Manb1-4GlcNAc 
-BSA (NGA2B) 
(GlcNA
c) BSA 5 
N-linked NGA3 
GlcNAcb1-2Mana1-
6[GlcNAcb1-2(GlcNAcb1-
4)Mana1-3]Manb1-4GlcNAc -
BSA (NGA3) 
(GlcNA
c) BSA 1 
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N-linked NGA3B 
GlcNAcb1-2Mana1-
6[GlcNAcb1-2(GlcNAcb1-
4)Mana1-3](GlcNAcb1-
4)Manb1-4GlcNAc -BSA (NA3) 
(GlcNA
c) BSA 6 
N-linked NGA4 
GlcNAcb1-2(GlcNAcb1-
6)Mana1-6[GlcNAcb1-
2(GlcNAcb1-4)Mana1-3]Manb1-
4GlcNAc -BSA  
(GlcNA
c) BSA 6 
N-linked NGA4(B)2 
GlcNAcb1-2(GlcNAcb1-
4)(GlcNAcb1-6)Mana1-
6[GlcNAcb1-2Mana1-
3](GlcNAcb1-4)Manb1-4GlcNAc 
-BSA [NGA4(B)2] 
(GlcNA
c) BSA 4 
N-linked NGA5B 
GlcNAcb1-2(GlcNAcb1-
4)(GlcNAcb1-6)Mana1-
6[GlcNAcb1-2(GlcNAcb1-
4)Mana1-3](GlcNAcb1-
4)Manb1-4GlcNAc -BSA 
(NGA5B) 
(GlcNA
c) BSA 2 
glycoprotein OSM 
Ovine submaxillary mucin (94% 
STn, 4% TF, 2% Fuca1-2Galb1-
3GalNAc) na OSM na 
glycoprotein OSM (asialo) 
asialo-Ovine submaxillary mucin 
(aOSM) na OSM na 
glycoprotein OSM (ox) 
periodate oxidized ovine 
submaxillary mucin na   na 
glycoprotein ovalbumin ovalbumin (56% Man5+Man6) na   na 
glycoprotein Ovalbumin (ox) periodate oxidized ovalbumin na   na 
glycolipid P1 
Gala1-4Galb1-4GlcNAc-BSA 
(P1)   BSA 9 
control PEG-linker 
OH-(CH2)2-NH-Gly-CO-PEG7-
NH-(CO)Hept-SH-Mal-Cychex-
CO-BSA 
PEG-
linker BSA 6 
glycolipid Pk or Gb3 
Gala1-4Galb1-4Glc-HSA [Pk or 
Gb3 or CD77]   HSA 13 
carb-type 1 pLNH - 07 
Galb1-3GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-BSA 
(pLNH) (Glc) BSA 7 
carb-type 1 pLNH - 21 
Galb1-3GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-BSA 
(pLNH) (Glc) BSA 21 
glycoprotein PSA Prostate Specific Antigen (PSA)       
non-human Rha-a Rha-a ‰ÛÒ BSA MEAG BSA 18 
non-human Rha-b Rha-b - BSA MEAG BSA 21 
peptide-Tn 
R-Tn(Ser)-Tn-
hydroxyethylami
de 
BSA-linker-Tn(Ser)-
hydroxyethylamide 
adipic 
acid BSA 36 
Blood Group H Sia-LNF V 
Fuca1-2Galb1-3(Neu5Aca2-
6)GlcNAcb1-3Galb1-APD-HSA APD HSA 12 to 15 
carb-Sia Sia-LNnT 
Siaa2-3Galb1-4GlcNAcb1-
3Galb1-APD-HSA APD HSA 9 
Lewis Sialyl LeA 
Siaa2-3Galb1-3[Fuca1-
4)GlcNAcb1-3Galb1-APD-HSA 
(SLeA) APD HSA 12 
Lewis Sialyl LeX 
Sialyla2-3Galb1-4[Fuca1-
3)GlcNAc ‰ÛÒ BSA 
14 atom 
spacer  BSA 9 
glycolipid SSEA-4-Sp - 05 
Neu5Aca2-3Galb1-3GalNAcb1-
3Gala1-4Galb1-4Glcb-Sp Sp BSA 5 
glycolipid SSEA-4-Sp - 12 
Neu5Aca2-3Galb1-3GalNAcb1-
3Gala1-4Galb1-4Glcb-Sp Sp BSA 12 
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Blood Group H 
TFiLNO(1-2,1-
2,1-3) 
Fuca1-2Galb1-3GlcNAcb1-
3Galb1-4(Fuca1-3)GlcNAcb1-
6(Fuca1-2Galb1-3GlcNAcb1-
3)Galb-BSA (Glc) BSA 4 
Blood Group H 
TFiLNO(1-2,1-
2,1-4) 
Fuca1-2Galb1-3GlcNAcb1-
3Galb1-4GlcNAcb1-6[Fuca1-
2Galb1-3(Fuca1-4)GlcNAcb1-
3]Galb-BSA (Glc) BSA 6 
glycoprotein Tgl Thyroglobulin (Tgl) na   na 
non-human X3Glc3 
Xyla1-6Glcb1-4(Xyla1-6)Glcb1-
4(Xyla1-6)Glcb1-BSA  (X3Glc3) (Glc) BSA 15 
non-human Xylb4 
Xylb1-4Xylb1-4Xylb1-4Xylb1-
BSA (Xylb4) (xyl) BSA 22 
cancer-
associated 
glycopeptide 
mucins 
DTVPLPTAHG-
TF(Thr)-
SASSTG         
cancer-
associated 
glycopeptide 
mucins 
DTVPLPTAHG-
TF(Thr)-TF(Ser)-
ASSTG         
cancer-
associated 
glycopeptide 
mucins 
DTVPLPTAHGT
SASSTG         
cancer-
associated 
glycopeptide 
mucins 
DTVPLPTAHGT
-TF(Ser)-ASSTG         
cancer-
associated 
glycopeptide 
mucins 
DTVPLP-
TF(Thr)-
AHGTSASSTG        
glycoprotein gp120 gp120 glycoprotein      
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Supplementary Table 3.3: List of individuals used for the gp120 competition assay 
Patient ID (PTID) Neutralization 
CAP200 NON-BCN 
CAP206 BCN 
CAP221 NON-BCN 
CAP244 INTERMEDIATE 
CAP248 BCN 
CAP255 BCN 
CAP314 BCN 
CAP322 BCN 
 
Supplementary Table 3.4: p-values and fold-changes for glycans affected by the 
gp120 competition assay 
Type Name P-value Fold-change 
N-linked 
GlcNAc-Man3 0.005 1.6 
LacNAc-Man5 0.033 1.5 
Man7 0.044 2.9 
Man8 0.007 10.9 
Man9 0.017 2.5 
Mannose  
Man-a - 20 0.033 1.5 
Mana1-6Man-a - 15 0.030 1.4 
ManT 0.009 1.3 
G2M4 - 07 0.018 1.2 
Galb1-6Man-a - 13 0.006 1.3 
Tn-peptide 
Ac-A-Tn(Thr)-S-G - 05 & 08 0.005, 0.0177 1.7, 1.8 
Ac-P-Tn(Thr)-T-G - 05 0.004 1.7 
Ac-S-Tn(Ser)-S-G - 04 & 22 0.010, 0.015 1.8, 1.23 
Ac-S-Tn(Thr)-A-G - 04 0.004 2.1 
Ac-S-Tn(Thr)-G-G - 03 & 07 0.007, 0.008 1.6, 1.5 
Ac-S-Tn(Thr)-S-G - 04 0.023 1.6 
Ac-Tn(Ser)Tn(Ser)Tn(Ser)-G - 03 0.014 1.5 
Ac-Tn(Thr)-Tn(Thr)-Tn(Thr)-G - 08 0.022 1.2 
Ac-T-Tn(Thr)-P-G - 04 & 08 0.008, 0.05 1.8, 1.6 
Ac-V-Tn(Thr)-S-G - 04 & 08 0.014, 0.04 2.0, 1.7 
Glycolipid 
GM2-Sp - 14 0.024 2.1 
Gb4 - 09 & tetra 0.001, 0.009 1.4, 1.3 
Glycoprotein 
CEA 0.026 2.7 
fetuin (asialo) 0.034 1.2 
gp120 2.0E-06 21.4 
hsp90 0.015 1.3 
Heparin Hep-5000 0.016 2.9 
Blood Group 
BG-A1 0.007 1.7 
BG-H1 0.005 2.3 
BG-H2 0.029 2.5 
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Globo H 0.007 1.8 
Lewis Antigen Sialyl LeX 0.05 1.7 
Fucosylated 
Fuc-a 0.029 1.1 
Fuc-b  0.012 1.3 
GalNAc carbohydrate 
GalNAc-a - 04 & 22 0.006, 0.02 1.4, 1.2 
GalNAca1-6Galb - 04 0.003 1.3 
GlcNAca1-4Galb - 03 & 20 0.004, 0.03 4.4, 1.4 
GalNAc-b - 21 0.011 1.2 
GlcNAc-b - 21 0.004 1.3 
Glc carbohydrate Glc-b - 23 0.003 1.2 
GlcNAc carbohydrate 3'GN-Di-LacNAc-Sp - 06 0.05 1.2 
Type 2 carbohydrate 
LacNAc - 22 & trimeric 0.019 1.5 
LNnT - 04 0.031 2.0 
Shown are the p-values and fold-change differences between the PBS and gp120-incubated sera for 
the glycans that had p-values ≤ 0.05. Highlighted in red are the glycans that were previously 
selected in Method 1, Method 2 and/or bound by bNAbs. Highlighted in green are the glycans that 
showed an elevation in binding in the gp120-incubated sample compared to the PBS-incubated 
sample. All other glycans showed a decrease in binding in the gp120-incubated sample. 
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